

# CITATION REPORT

List of articles citing

## Breast cancer and hormone-replacement therapy in the Million Women Study

DOI: 10.1016/s0140-6736(03)14065-2  
Lancet, The, 2003, 362, 419-27.

**Source:** <https://exaly.com/paper-pdf/35486246/citation-report.pdf>

**Version:** 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| #    | Paper   | IF | Citations |
|------|---|----|-----------|
| 2302 | Paroxysmal atrial fibrillation: high frequency of embolic brain infarction in elderly autopsy patients. <b>1997</b> , 49, 1691-4                              |    | 19        |
| 2301 | Oestrogen and progestogen hormone replacement therapy for peri-menopausal and post-menopausal women: weight and body fat distribution. <b>2000</b> , CD001018 |    | 27        |
| 2300 | Epidemiologie van mammacarcinomepidemiologie. <b>2003</b> , 19, 212-218   |    |           |
| 2299 | Neues aus Medizin und Wissenschaft. <b>2003</b> , 115, III-V  |    |           |
| 2298 | [Progress in the prevention of type 2 diabetes]. <b>2003</b> , 115, 745-57  |    | 5         |
| 2297 | Estrogen therapies, lipids, and the heart disease prevention controversy. <b>2003</b> , 5, 477-82   |    | 3         |
| 2296 | [Hormone therapy in menopause. A current update]. <b>2003</b> , 44, 1500-7  |    | 3         |
| 2295 | Estrogen deficiency symptom management in breast cancer survivors in the changing context of menopausal hormone therapy. <b>2003</b> , 30, 776-88             |    | 24        |
| 2294 | Hormone replacement therapy and the breast. <b>2003</b> , 12, 251-63  |    | 4         |
| 2293 | Musculoskeletal disorders in diabetes mellitus: an update. <b>2003</b> , 17, 945-70   |    | 114       |
| 2292 | A second chance for hormone replacement therapy?. <b>2003</b> , 4, 1112-5   |    | 6         |
| 2291 | Research Highlights. <b>2003</b> , 3, 637-637   |    |           |
| 2290 | Trattamento di irsutismo e androgenizzazione in menopausa. <b>2003</b> , 4, 148-156   |    |           |
| 2289 | The Million Women Study and breast cancer. <b>2003</b> , 46, 1-6  |    | 27        |
| 2288 | Breast cancer and hormone-replacement therapy in the Million Women Study. <b>2003</b> , 46, 91-2  |    | 7         |
| 2287 | The 'Million Women' Study should not change HRT prescription. <b>2003</b> , 46, 97-8  |    | 2         |
| 2286 | The Million Women Study: no new evidence to change current opinions. <b>2003</b> , 46, 99-100   |    |           |

|      |   |    |    |     |
|------|---|----|----|-----|
| 2285 | The Million Women Study, an additional observational study with the implications and limits of an observational study. <b>2003</b> , 46, 101-2                      |    |    | 1   |
| 2284 | The Million Women Study: what is missing. <b>2003</b> , 46, 103-4   |    |    | 0   |
| 2283 | The sound of an International anti-HRT herald. <b>2003</b> , 46, 105-6  |    |    | 1   |
| 2282 | Breast cancer and HRT: general practice must not pick up the wrong pieces. <b>2003</b> , 46, 109-10   |    |    |     |
| 2281 | Differential effects of progestins on hemostasis. <b>2003</b> , 46 Suppl 1, S31-7   |    |    | 37  |
| 2280 | Classification and pharmacology of progestins. <b>2003</b> , 46 Suppl 1, S7-S16   |    |    | 373 |
| 2279 | Estrogen plus progestin use increased the risk of dementia in older postmenopausal women. <b>2003</b> , 5, 189-191  |    |    |     |
| 2278 | HT and breast cancer risk. <b>2003</b> , 80 Suppl 4, 5-9; quiz 54-5   |    |    | 4   |
| 2277 | Breast cancer and hormone-replacement therapy: the Million Women Study. <i>Lancet, The</i> , <b>2003</b> , 362, 1328; author reply 1330-1                           | 40 |    | 11  |
| 2276 | Breast cancer and hormone-replacement therapy: the Million Women Study. <i>Lancet, The</i> , <b>2003</b> , 362, 1328-9; author reply 1330-1                         | 40 |    | 19  |
| 2275 | Breast cancer and hormone-replacement therapy: the Million Women Study. <i>Lancet, The</i> , <b>2003</b> , 362, 1329; author reply 1330-1                           | 40 |    | 3   |
| 2274 | Breast cancer and hormone-replacement therapy: the Million Women Study. <i>Lancet, The</i> , <b>2003</b> , 362, 1330; author reply 1330-1                           | 40 |    | 0   |
| 2273 | Breast cancer and hormone-replacement therapy: the Million Women Study. <i>Lancet, The</i> , <b>2003</b> , 362, 1330; author reply 1330-1                           | 40 |    | 9   |
| 2272 | Breast cancer and hormone-replacement therapy: the Million Women Study. <i>Lancet, The</i> , <b>2003</b> , 362, 1330; author reply 1330-1                           | 40 |    | 7   |
| 2271 | Correspondence. <i>Lancet, The</i> , <b>2003</b> , 362, 1332  |    | 40 |     |
| 2270 | Hypoxaemia in sickle cell disease: biomarker modulation and relevance to pathophysiology. <i>Lancet, The</i> , <b>2003</b> , 362, 1450-5                            | 40 |    | 154 |
| 2269 | A million women can't be wrong. <i>Lancet, The</i> , <b>2003</b> , 362, 1455  | 40 |    | 78  |
| 2268 | Effect of ultrasound screening on the rate of first operative procedures for developmental hip dysplasia in Germany. <i>Lancet, The</i> , <b>2003</b> , 362, 1883-7 | 40 |    | 92  |

|      |  |     |
|------|--|-----|
| 2267 | What a CHARMer!. <i>Lancet, The</i> , <b>2003</b> , 362, 1887  | 40  |
| 2266 | Why the Million Women Study is important for European women. <b>2003</b> , 46, 93-4  | 2   |
| 2265 | Are herbal remedies and dietary supplements safe and effective for breast cancer patients?. <b>2003</b> , 5, 300-2   | 20  |
| 2264 | Management of Postmenopausal Osteoporosis. <b>2003</b> , 11, 673-692   | 2   |
| 2263 | Meningococcal group C vaccine in nephrotic syndrome relapse. <b>2003</b> , &NA;, 21  |     |
| 2262 | Is combined estrogen/progestogen hormone therapy worth the risk?. <b>2003</b> , 6, 177-179   | 2   |
| 2261 | Warfarin + celecoxib/rofecoxib: increased INR. <b>2003</b> , &NA;, 3   |     |
| 2260 | The study with a million women (and hopefully fewer mistakes). <b>2003</b> , 17, 359-62  | 6   |
| 2259 | Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population. <b>2003</b> , 21, 4314-21                                   | 111 |
| 2258 | Patients' understanding of risk. <b>2003</b> , 327, 693-4  | 26  |
| 2257 | Progestogens and breast cancer risk: the role of hormonal contraceptives and hormone replacement therapy. <b>2003</b> , 29, 185-7                                    | 6   |
| 2256 | Hormone therapy: the European women's perspective. <b>2003</b> , 6, 337-346  | 38  |
| 2255 | A wolf in sheep's clothing: a critical look at the ethics of drug taking. <b>2003</b> , 327, 856-8   | 20  |
| 2254 | Estrogen plus progestin use increased the risk of dementia in older postmenopausal women. <b>2003</b> , 5, 189-191   | 2   |
| 2253 | Hormone replacement therapy update: who should we be prescribing this to now?. <b>2003</b> , 15, 459-64  | 13  |
| 2252 | Estrogen and progestogen use in peri- and postmenopausal women: September 2003 position statement of The North American Menopause Society. <b>2003</b> , 10, 497-506 | 34  |
| 2251 | More breast cancer findings from the Women's Health Initiative. <b>2003</b> , 9, 97-9  | 2   |
| 2250 | Badmouthing GPs. <b>2003</b> , 179, 509-10   | 2   |

- 2249 General practice is not in crisis. **2003**, 179, 506-7; author reply 506-7
- 2248 Is general practice vocational training at risk?. **2003**, 179, 508; author reply 508
- 2247 Back to the future. **2003**, 179, 508-9; author reply 509
- 2246 "Only a GP?": is the solution to the general practice crisis intellectual?. **2003**, 179, 507; author reply 507
- 2245 The Million Women Study and breast cancer. **2003**, 9, 95, 97 5
- 2244 Menopause and Hormone Replacement Therapy. **2004**, 795-817 1
- 2243 Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer. **2004**, 164, 2253-9 81
- 2242 Epidemiological studies of UK test veterans: I. General description. **2004**, 24, 199-217 10
- 2241 Dehydroepiandrosterone increases hippocampal spine synapse density in ovariectomized female rats. **2004**, 145, 1042-5 60
- 2240 Noregestrol acetate: a progestin that deserves recognition. **2004**, 36, 257-8; author reply 259 1
- 2239 Follow-up care in breast cancer. **2004**, 4, 212-8 9
- 2238 Estrogen and Alzheimer's disease: the apolipoprotein connection. **2004**, 145, 3062-4 18
- 2237 [Postmenopausal hormone therapy]. **2004**, 129, 1689-93
- 2236 The lost promise of hormone replacement therapy and heart disease. **2004**, 4, 135-44 2
- 2235 Effects of dehydroepiandrosterone and flutamide on hippocampal CA1 spine synapse density in male and female rats: implications for the role of androgens in maintenance of hippocampal structure. **2004**, 145, 4154-61 72
- 2234 Consensus Recommendation on Hormone Therapy During the Climacterium and Postmeopause. **2004**, 64, 1024-1028 3
- 2233 Breast cancer in premenopausal women: recurrence and survival rates and relationship to hormone replacement therapy. **2004**, 7, 284-91 8
- 2232 A two-by-two factorial trial comparing oral with transdermal estrogen therapy and fenretinide with placebo on breast cancer biomarkers. **2004**, 10, 4389-97 23

|      |   |      |
|------|---|------|
| 2231 | Full house for joint RCOG/BMS menopause course. <b>2004</b> , 10, 46-7  |      |
| 2230 | Modelling the impact of detecting and treating ductal carcinoma in situ in a breast screening programme. <b>2004</b> , 11, 117-25   | 23   |
| 2229 | Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. <b>2004</b> , 291, 1701-12  | 3160 |
| 2228 | Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. <b>2004</b> , 96, 1856-65   | 407  |
| 2227 | Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. <b>2004</b> , 11, 537-51  | 313  |
| 2226 | Effect of soy protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal women: a randomized controlled trial. <b>2004</b> , 292, 65-74  | 308  |
| 2225 | Hormone therapy: making decisions in the face of uncertainty. <b>2004</b> , 164, 2308-12  | 14   |
| 2224 | Hormone replacement therapy: the way forward. <b>2004</b> , 30, 21-4  |      |
| 2223 | Post-treatment change in serum estrone predicts mammographic percent density changes in women who received combination estrogen and progestin in the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. <b>2004</b> , 22, 2842-8 | 24   |
| 2222 | Health and psychosocial status of patients with turner syndrome after transition to adulthood: the Belgian experience. <b>2004</b> , 62, 161-7  | 32   |
| 2221 | FFPRHC Guidance (April 2004). The levonorgestrel-releasing intrauterine system (LNG-IUS) in contraception and reproductive health. <b>2004</b> , 30, 99-108; quiz 109   | 48   |
| 2220 | The WHI estrogen-alone trial--do things look any better?. <b>2004</b> , 291, 1769-71  | 109  |
| 2219 | Hormone replacement therapy (HRT). <b>2004</b> , 30, 59-61  | 1    |
| 2218 | [Recommendations for estrogen and progestin replacement therapy in climacteric and postmenopause. 31. Professional Meeting of the Zurich Discussion Circle, October 2003]. <b>2004</b> , 44, 258-64   | 0    |
| 2217 | [Current debate on hormone replacement therapy]. <b>2004</b> , 44, 63-8   | 1    |
| 2216 | Model building and quantitative analysis of a tandem immuno-capturing assay as a screening tool for breast cancer. <b>2004</b> , 25, 1365-74  |      |
| 2215 | Do female sex hormones initiate breast cancer? A review of the evidence. <b>2004</b> , 7, 120-8   | 11   |
| 2214 | Where are we now with hormone replacement therapy?. <b>2004</b> , 328, 357-8  | 17   |

|      |   |    |
|------|---|----|
| 2213 | Influence of personal characteristics of individual women on sensitivity and specificity of mammography in the Million Women Study: cohort study. <b>2004</b> , 329, 477          | 82 |
| 2212 | 17Beta-estradiol/levonorgestrel transdermal system for the management of the symptomatic menopausal woman. <b>2004</b> , 5, 2559-66   | 1  |
| 2211 | Hormone replacement and breast cancer. <b>2004</b> , 15 Suppl 4, iv275-7  | 1  |
| 2210 | Hormonal exposures and breast cancer in a sample of women with systemic lupus erythematosus. <b>2004</b> , 43, 1178-81  | 18 |
| 2209 | Pharmacotherapy for sexual dysfunction in women. <b>2004</b> , 5, 1045-59   | 8  |
| 2208 | Breast cancer with different prognostic characteristics developing in Danish women using hormone replacement therapy. <b>2004</b> , 91, 644-50                                    | 41 |
| 2207 | A review of the effects of tibolone on the skeleton. <b>2004</b> , 5, 941-9   | 7  |
| 2206 | Hormone replacement therapy after surgery for stage 1 or 2 cutaneous melanoma. <b>2004</b> , 90, 770-2  | 30 |
| 2205 | Targeting oestrogen to kill the cancer but not the patient. <b>2004</b> , 90, 944-9   | 23 |
| 2204 | A longitudinal population study of climacteric symptoms and their treatment in a random sample of Swedish women. <b>2004</b> , 7, 357-65  | 8  |
| 2203 | Decision-making about hormone replacement therapy by women in England and Scotland. <b>2004</b> , 7, 41-9   | 15 |
| 2202 | Long-term effects of tibolone on the endometrium as assessed by bleeding episodes, transvaginal scan and endometrial biopsy. <b>2004</b> , 7, 261-6                               | 18 |
| 2201 | Reporting on post-menopausal hormone therapy: an analysis of gynaecologists' web pages. <b>2004</b> , 29, 211-20  | 3  |
| 2200 | The osteoporosis dilemma. <b>2004</b> , 18, 59-61   | 3  |
| 2199 | Can hypnosis reduce hot flashes in breast cancer survivors? A literature review. <b>2004</b> , 47, 29-42  | 20 |
| 2198 | The acceptability of a small intrauterine progestogen-releasing system for continuous combined hormone therapy in early postmenopausal women. <b>2004</b> , 7, 404-11             | 18 |
| 2197 | Clinical efficacy of EH0202, a Kampo formula, on the health of middle-aged women. <b>2004</b> , 32, 755-70  | 6  |
| 2196 | Measurement of aortic blood flow by magnetic resonance below and above the origin of the coronary arteries in postmenopausal hormone replacement therapy. <b>2004</b> , 6, 637-44 | 2  |

|      |   |     |
|------|---|-----|
| 2195 | Role of the nonhuman primate for research related to women's health. <b>2004</b> , 45, 212-9  | 14  |
| 2194 | Hormone replacement therapy and mammographic screening. <b>2004</b> , 10, 75, 80  |     |
| 2193 | Osteoporosis in Clinical Practice. <b>2004</b> ,  | 2   |
| 2192 | Women's needs and wants when seeing the GP in relation to menopausal issues. <b>2004</b> , 22, 118-21   | 8   |
| 2191 | Non-response to osteoporosis treatment. <b>2004</b> , 10, 76-80   | 19  |
| 2190 | Long-term safety and tolerability of continuous-combined hormone therapy in postmenopausal women: results from a seven-year randomised comparison of low and standard doses. <b>2004</b> , 10, 95-102 | 13  |
| 2189 | Endocrine disrupters and menopausal health. <b>2004</b> , 10, 54-9  | 10  |
| 2188 | Managing the menopause: BMS Council Consensus statement on HRT. <b>2004</b> , 10, 33-6  | 8   |
| 2187 | Clinical background of women prescribed tibolone or combined estrogen + progestogen therapies: a UK MediPlus study. <b>2004</b> , 7, 197-209  | 18  |
| 2186 | Red clover isoflavones and menopausal health. <b>2004</b> , 10 Suppl 1, 4-7   | 3   |
| 2185 | Red Clover Isoflavones in Practice: A Clinician's View. <b>2004</b> , 10, 7-12  | 1   |
| 2184 | HRT and breast cancer. <b>2004</b> , 7, 269-70  |     |
| 2183 | Postmenopausal hormone therapy: the pros and cons. <b>2004</b> , 34, 109-14   | 6   |
| 2182 | Hormone replacement therapy and breast cancer risk in Kyushu University Hospital: supporting the Women's Health Initiative study. <b>2004</b> , 30, 297-302   | 3   |
| 2181 | An open, randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis. <b>2004</b> , 256, 63-9                                       | 43  |
| 2180 | Rationale, design and methods of the CASHMERE study. <b>2004</b> , 18, 131-8  | 14  |
| 2179 | Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. <b>2004</b> , 19, 791-804  | 205 |
| 2178 | Skin aging and sex hormones in women -- clinical perspectives for intervention by hormone replacement therapy. <b>2004</b> , 13 Suppl 4, 36-40  | 49  |



|      |  |     |
|------|--|-----|
| 2177 | Common risk factors of breast and ovarian cancer: recent view. <b>2004</b> , 14, 721-40  | 41  |
| 2176 | Side-effects of hormone replacement therapy and influence on pattern of use among women aged 45-64 years. The Norwegian Women and Cancer (NOWAC) study 1997. <b>2004</b> , 83, 850-6                         | 19  |
| 2175 | Tibolone. <b>2004</b> , 83, 606  | 2   |
| 2174 | Decreased rates of advanced breast cancer due to mammography screening in The Netherlands. <b>2004</b> , 91, 861-7   | 131 |
| 2173 | Immune effects of surgical menopause and estrogen replacement therapy in peri-menopausal women. <b>2004</b> , 63, 31-8   | 79  |
| 2172 | Belamcanda chinensis and the thereof purified tectorigenin have selective estrogen receptor modulator activities. <b>2004</b> , 11, 392-403  | 42  |
| 2171 | Does growth hormone prevent aging in the healthy elderly with low serum insulin-like growth factor-I ?. <b>2004</b> , 125, 291-5   | 2   |
| 2170 | Selective estrogen receptor modulation: concept and consequences in cancer. <b>2004</b> , 5, 207-13  | 268 |
| 2169 | Prognostic difference of surgical treatment of exophytic versus barrel-shaped bulky cervical cancer. <b>2004</b> , 95, 77-81   | 19  |
| 2168 | The effect of Fucus vesiculosus, an edible brown seaweed, upon menstrual cycle length and hormonal status in three pre-menopausal women: a case report. <b>2004</b> , 4, 10                                  | 39  |
| 2167 | Soy isoflavone phyto-pharmaceuticals in interleukin-6 affections. Multi-purpose nutraceuticals at the crossroad of hormone replacement, anti-cancer and anti-inflammatory therapy. <b>2004</b> , 68, 1171-85 | 97  |
| 2166 | Long-term metabolic, cardiovascular and neoplastic risks with polycystic ovary syndrome. <b>2004</b> , 18, 803-12  | 35  |
| 2165 | Estrogen and combined estrogen-progestogen therapy in the menopause and breast cancer. <b>2004</b> , 13, 515-8   | 17  |
| 2164 | The million women study: a critique. <b>2004</b> , 24, 187-93  | 35  |
| 2163 | Adverse neoplastic and cardiovascular outcomes of HRT: the validity of the evidence. <b>2004</b> , 24, 203-10  | 7   |
| 2162 | Steroid receptors and cell cycle in normal mammary epithelium. <b>2004</b> , 9, 3-13   | 110 |
| 2161 | Les progrès dans la lutte contre le cancer en France et dans l'Union européenne. <b>2004</b> , 6, 229  |     |
| 2160 | Einfluss von Tibolon auf das Brustdrüsenewebe. <b>2004</b> , 2, 153  |     |

|      |  |     |
|------|--|-----|
| 2159 | [How dangerous is hormone replacement therapy (HRT) in menopause?]. <b>2004</b> , 116, 155-8   | 0   |
| 2158 | [Evidence based basis of decision making for or against a postmenopausal hormone treatment]. <b>2004</b> , 116, 461-4; discussion 504  | 1   |
| 2157 | Waarom zetten vrouwen langdurig gebruik van hormoonsuppletie voort?. <b>2004</b> , 47, 199-204   |     |
| 2156 | Women's views of optimal risk communication and decision making in general practice consultations about the menopause and hormone replacement therapy. <b>2004</b> , 53, 121-8 | 33  |
| 2155 | [Endocrinology--I]. <b>2004</b> , 99, 293-308  |     |
| 2154 | Management of hot flashes in breast cancer survivors and men with prostate cancer. <b>2004</b> , 6, 285-90   | 14  |
| 2153 | Hormone replacement therapy: review, update, and remaining questions after the Women's Health Initiative Study. <b>2004</b> , 2, 12-6  | 18  |
| 2152 | Postmenopausal osteoporosis. <b>2004</b> , 2, 101-6  | 9   |
| 2151 | [The women's health initiative and more]. <b>2004</b> , 33, 366-71   |     |
| 2150 | [What are phytoestrogens and phyto-SERMS]. <b>2004</b> , 33, 378-83  | 5   |
| 2149 | Pharmacoepidemiology and drug safety. <b>2004</b> , 13, 49-64  |     |
| 2148 | Menopausal symptoms in women with breast cancer: prevalence and treatment preferences. <b>2004</b> , 13, 769-78  | 78  |
| 2147 | Hormone replacement therapy in relation to breast carcinoma incidence rate ratios: a prospective Danish cohort study. <b>2004</b> , 100, 2328-37                               | 71  |
| 2146 | Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. <b>2004</b> , 109, 721-7                                | 189 |
| 2145 | Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer And Nutrition (EPIC). <b>2004</b> , 111, 762-71                             | 397 |
| 2144 | Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian Women and Cancer study. <b>2004</b> , 112, 130-4                                       | 113 |
| 2143 | Significance of the detection of esters of p-hydroxybenzoic acid (parabens) in human breast tumours. <b>2004</b> , 24, 1-4   | 95  |
| 2142 | Endocrine disrupters and human health: could oestrogenic chemicals in body care cosmetics adversely affect breast cancer incidence in women?. <b>2004</b> , 24, 167-76         | 111 |

|      |   |     |
|------|---|-----|
| 2141 | Three novel hormone-responsive cell lines derived from primary human breast carcinomas: functional characterization. <b>2004</b> , 199, 460-9   | 18  |
| 2140 | Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion. <b>2004</b> , 51, 55-67   | 269 |
| 2139 | Hormone replacement therapy increases breast cancer incidence and may increase breast cancer mortality in postmenopausal women. <b>2004</b> , 8, 41-42                                |     |
| 2138 | Hormone replacement therapy is not safe for breast cancer survivors. <b>2004</b> , 8, 224-226   |     |
| 2137 | Transdermal hormone therapy: gels and patches. <b>2004</b> , 7, 347-56  | 37  |
| 2136 | The Million Women Study: potential biases do not allow uncritical acceptance of the data. <b>2004</b> , 7, 3-7  | 46  |
| 2135 | WHI, WHI, WHI?. <b>2004</b> , 7, 221-4  | 5   |
| 2134 | A comparative study of breast cell proliferation during hormone replacement therapy: effects of tibolon and continuous combined estrogen-progestogen treatment. <b>2004</b> , 7, 50-8 | 45  |
| 2133 | Estrogens and women's health: a scary or a fairy tale?. <b>2004</b> , 18, 175-8   | 5   |
| 2132 | Guidelines for the hormone treatment of women in the menopausal transition and beyond. <b>2004</b> , 7, 8-11  | 33  |
| 2131 | Postmenopausal hormone therapy before and after the women's health initiative study: what consequences?. <b>2004</b> , 36, 402-13   | 38  |
| 2130 | Hormone replacement therapy – practical recommendations. <b>2004</b> , 7, 11-35   | 3   |
| 2129 | Is the elevated breast cancer risk observed in the WHI study an artifact?. <b>2004</b> , 7, 319-22  | 15  |
| 2128 | Current controversies about combined hormone therapy and the relative risks to the breast and endometrium. <b>2004</b> , 7, 229-37  |     |
| 2127 | Published results on breast cancer and hormone replacement therapy in the Million Women Study are correct. <b>2004</b> , 7, 415-6; author reply 416-7                                 | 11  |
| 2126 | Guidelines for hormone treatment of women in the menopausal transition and beyond. <b>2004</b> , 7, 333-7   | 41  |
| 2125 | Chemical reactivity as a tool to study carcinogenicity: reaction between estradiol and estrone 3,4-quinones ultimate carcinogens and guanine. <b>2004</b> , 44, 310-4                 | 17  |
| 2124 | Estrogenic and anticarcinogenic properties of kurarinone, a lavandulyl flavanone from the roots of <i>Sophora flavescens</i> . <b>2004</b> , 67, 1829-32                              | 47  |

|      |  |    |
|------|--|----|
| 2123 | Hormone replacement therapy in hypopituitarism. <b>2004</b> , 5, 1023-31   | 12 |
| 2122 | [AFSSAPS recommendations about menopause]. <b>2004</b> , 65, 179-83  | 0  |
| 2121 | Atenci3n Primaria de Salud en Europa: tendencias a principios del siglo XXI. Una reflexi3n con motivo de los XXV a3os de la Declaraci3n de Alma Ata. <b>2004</b> , 30, 245-257             | 4  |
| 2120 | 3tica y encarnizamiento m3dico con las mujeres. La terapia hormonal en la menopausia y el climaterio. <b>2004</b> , 30, 373-374  | 1  |
| 2119 | Mise au point actualis3e sur le traitement hormonal substitutif de la mhopause (THS) D3cembre 2003. <b>2004</b> , 3, 82-86   |    |
| 2118 | Challenges to environmental toxicology and epidemiology: where do we stand and which way do we go?. <b>2004</b> ,  |    |
| 2117 | Guidelines for the hormone treatment of women in the menopausal transition and beyond*1Position Statement by the Executive Committee of the International Menopause Society. <b>2004</b> , |    |
| 2116 | Immune effects of surgical menopause and estrogen replacement therapy in peri-menopausal women. <b>2004</b> ,  |    |
| 2115 | Indications for hormone therapy: the post-Women's Health Initiative era. <b>2004</b> , 33, 691-715   | 5  |
| 2114 | El beneficio del tratamiento hormonal en la posmenopausia. <b>2004</b> , 11, 528   |    |
| 2113 | Menopausia y envejecimiento en la mujer. <b>2004</b> , 51, 48-54   |    |
| 2112 | E3. Menopausal symptoms and uterine changes in postmenopausal breast cancer patients receiving tamoxifen or third generation aromatase inhibitors. <b>2004</b> , 2, 19-21                  |    |
| 2111 | E25 . The tissue-specific mechanism of action of tibolone. <b>2004</b> , 2, 72-73  |    |
| 2110 | E28. Breast tolerance, tibolone compared to other hormonal treatments. <b>2004</b> , 2, 79-80  |    |
| 2109 | Endocrine treatment and prevention of breast and gynaecological cancers. <b>2004</b> , 2, 1-14   |    |
| 2108 | Hormone replacement therapy: controversies, pros and cons. <b>2004</b> , 18, 317-32  | 39 |
| 2107 | Challenges to environmental toxicology and epidemiology: where do we stand and which way do we go?. <b>2004</b> , 151, 255-66  | 18 |
| 2106 | Should tamoxifen be used in breast cancer prevention?. <b>2004</b> , 27, 979-89  | 8  |

|      |  |     |
|------|--|-----|
| 2105 | Postmenopausal hormone therapy: impact on menopause-related symptoms, chronic disease and quality of life. <b>2004</b> , 64, 821-36  | 24  |
| 2104 | Pharmacotherapy for stress urinary incontinence : present and future options. <b>2004</b> , 64, 1503-16  | 32  |
| 2103 | Long-cycle treatment with oral contraceptives. <b>2004</b> , 64, 2447-62   | 46  |
| 2102 | The Role of Hormone Replacement Therapy and Alternative Treatments. <b>2004</b> , 3, 67-78   | 0   |
| 2101 | The Burden of Osteoporosis and the Case for Disease Management. <b>2004</b> , 12, 409-418  | 7   |
| 2100 | Prevention and Treatment of Osteoporosis in Postmenopausal Women. <b>2004</b> , 12, 19-37  | 4   |
| 2099 | New progestogens: a review of their effects in perimenopausal and postmenopausal women. <b>2004</b> , 21, 865-83   | 79  |
| 2098 | Vaginal rings for menopausal symptom relief. <b>2004</b> , 21, 757-66  | 17  |
| 2097 | Strategies for managing breast cancer risk after the menopause. <b>2004</b> , 3, 289-307   | 3   |
| 2096 | Que penser des résultats de la Women's Health Initiative (WHI) et de la Million Women Study (MWS) qui remettent en question l'usage du traitement hormonal de la ménopause ?. <b>2004</b> , 3, 79-81 |     |
| 2095 | Risques et bénéfices du THS. <b>2004</b> , 4, 49-53  |     |
| 2094 | Changes in bone mineral density during and after 3 years? use of tamoxifen or toremifene. <b>2004</b> ,  |     |
| 2093 | Towards an integrated model for breast cancer etiology: the crucial role of the number of mammary tissue-specific stem cells. <b>2005</b> , 7, 13-7  | 83  |
| 2092 | Red-clover-derived isoflavones and mammographic breast density: a double-blind, randomized, placebo-controlled trial [ISRCTN42940165]. <b>2004</b> , 6, R170-9                                       | 111 |
| 2091 | [Menopausal hormonal therapies: impact on mammographic breast density]. <b>2004</b> , 85, 1673-86  | 1   |
| 2090 | Insulin-like growth factor-I and cancer risk. <b>2004</b> , 14, 261-9  | 77  |
| 2089 | [Effects of HRT on the risks of breast cancer and cardiovascular disease: the validity of the epidemiological evidence]. <b>2004</b> , 32, 382-90  | 3   |
| 2088 | [Up-to-date clarification on the menopause hormonal substitutive treatment (HRT) December 2003]. <b>2004</b> , 32, 571-5; discussion 569-70  |     |

|      |  |    |
|------|--|----|
| 2087 | [Observational study of criteria involved in the choice of hormone replacement therapy (HRT), when initiated and subsequently adapted]. <b>2004</b> , 32, 1047-53                                    | 1  |
| 2086 | The Million Women Study: a licence to kill other investigations?. <b>2004</b> , 113, 3-5   | 8  |
| 2085 | A mammographic image analysis method to detect and measure changes in breast density. <b>2004</b> , 52, 276-82   | 26 |
| 2084 | Estrogen, inflammation and cardiovascular risk in women: a critical appraisal. <b>2004</b> , 15, 66-72   | 46 |
| 2083 | Progestogen therapies: differences in clinical effects?. <b>2004</b> , 15, 277-85  | 38 |
| 2082 | Not all progestins are the same: implications for usage. <b>2004</b> , 25, 554-7   | 54 |
| 2081 | Treating menopause in the 21st century—where do we go from here?. <b>2004</b> , 1266, 3-9  |    |
| 2080 | The Xmas present for women's health: a strike to osteoporosis prevention. <b>2004</b> , 48, 9-11   | 3  |
| 2079 | Cellular homeostasis and the breast. <b>2004</b> , 48 Suppl 1, S13-7   | 9  |
| 2078 | Changes in bone mineral density during and after 3 years' use of tamoxifen or toremifene. <b>2004</b> , 48, 321-7  | 20 |
| 2077 | Guidelines for the hormone treatment of women in the menopausal transition and beyond. Position statement by the Executive Committee of the International Menopause Society. <b>2004</b> , 48, 27-31 | 14 |
| 2076 | Where has WHI led us now?. <b>2004</b> , 48, 1-2   | 10 |
| 2075 | The turbulent seas of women's health--who is the beneficiary?. <b>2004</b> , 48, 5-7   | 3  |
| 2074 | Continuation rate of hormone replacement therapy in Hong Kong public health sector. <b>2004</b> , 49, 338-44   | 7  |
| 2073 | Postmenopausal hormone therapy and the risk of breast cancer: the view of an epidemiologist. <b>2004</b> , 49, 44-50   | 11 |
| 2072 | Local biosynthesis and metabolism of oestrogens in the human breast. <b>2004</b> , 49, 25-33   | 28 |
| 2071 | Postmenopausal hormone therapy and the risk of breast cancer. A clinician's view. <b>2004</b> , 49, 51-7   | 9  |
| 2070 | Exogenous progestagens and the human breast. <b>2004</b> , 49, 58-66   | 20 |

|      |  |     |
|------|--|-----|
| 2069 | Lessons to be learned from clinical studies on hormones and the breast. <b>2004</b> , 49, 90-6   | 5   |
| 2068 | Steroidal hormones and proliferation, differentiation and apoptosis in breast cells. <b>2004</b> , 49, 16-24   | 20  |
| 2067 | Breast cancer and HRT use. <b>2004</b> , 49, S3-4  | 4   |
| 2066 | Hormones and mammographic breast density. <b>2004</b> , 49, 67-78  | 60  |
| 2065 | Postmenopausal testosterone therapy and breast cancer risk. <b>2004</b> , 49, 267-75   | 32  |
| 2064 | Postmenopausal hormone therapy before and after breast cancer: clinical experiences. <b>2004</b> , 49, S22-31  | 7   |
| 2063 | Tissue-selective effects of tibolone on the breast. <b>2004</b> , 49, S5-S15   | 32  |
| 2062 | An evaluation of the contents and quality of menopause information on the World Wide Web. <b>2004</b> , 49, 276-82   | 32  |
| 2061 | The differential ability of the phytoestrogen genistein and of estradiol to induce uterine weight and proliferation in the rat is associated with a substance specific modulation of uterine gene expression. <b>2004</b> , 221, 21-32 | 72  |
| 2060 | Physical activity decreases cardiovascular disease risk in women: review and meta-analysis. <b>2004</b> , 26, 407-18   | 211 |
| 2059 | Availability of large-scale evidence on specific harms from systematic reviews of randomized trials. <b>2004</b> , 117, 582-9  | 52  |
| 2058 | The changing global patterns of female breast cancer incidence and mortality. <b>2004</b> , 6, 229-39  | 571 |
| 2057 | Where are we now with hormone replacement therapy?. <b>2004</b> , 12, 200-3  | 1   |
| 2056 | [Measuring the risks. In defense of a more comprehensible public health system]. <b>2004</b> , 33, 652-3   | 0   |
| 2055 | DIGESTS. <b>2004</b> , 36, 34-42   |     |
| 2054 | Estrogen and progestogen therapy in postmenopausal women. <b>2004</b> , 81, 231-41   | 6   |
| 2053 | Mammographic breast density, hormones, and growth factors during continuous combined hormone therapy. <b>2004</b> , 81, 1617-23  | 37  |
| 2052 | Cyclic changes in the mammary gland of cynomolgus macaques. <b>2004</b> , 82 Suppl 3, 1160-70  | 40  |

|      |   |    |  |     |
|------|---|----|--|-----|
| 2051 | Estrogen and progesterone therapy in postmenopausal women. <b>2004</b> , 82 Suppl 1, S70-80   |    |  | 6   |
| 2050 | [Current role of hormone replacement therapy in the prevention of postmenopausal osteoporosis: gynecologic point of view]. <b>2004</b> , 25 Suppl 5, S580-7   |    |  |     |
| 2049 | [Alternatives to hormone replacement therapy for menopause: an epidemiological evaluation]. <b>2004</b> , 33, 195-209   |    |  | 2   |
| 2048 | Relationship between monitoring parameters and perinatal outcome in severe, early intrauterine growth restriction [Relations entre la surveillance des paramètres périnataux et le pronostic périnatal dans les retards de croissance intra-utérin sévères et précoces], C.M. Bilardo, H. Wolf, R.H. Griesinger, M. Müller, F. Pineda, C. Schmitt, M. Thaler, M. Wenzel, M. Zimmermann, <i>Lancet, The</i> , <b>2004</b> , 363, 18-22 |    |  |     |
| 2047 | HABITS (traitement hormonal substitutif après cancer du sein -est-ce raisonnable ?) : étude randomisée avec interruption de l'essai [HABITS (hormonal replacement therapy after breast cancer -is it safe?): a randomised comparison: trial stopped], HABITS steering and data monitoring committees, L. Holmberg, H. Anderson, in: <i>Lancet, The</i> , <b>2004</b> , 363, 453-455. <b>2004</b> , 33, 454                            |    |  |     |
| 2046 | Dihydroartemisinin-piperaquine against multidrug-resistant <i>Plasmodium falciparum</i> malaria in Vietnam: randomised clinical trial. <i>Lancet, The</i> , <b>2004</b> , 363, 18-22  | 40 |  | 140 |
| 2045 | Statin editorial most wanted. <i>Lancet, The</i> , <b>2004</b> , 363, 22  | 40 |  | 1   |
| 2044 | HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: trial stopped. <i>Lancet, The</i> , <b>2004</b> , 363, 453-5   | 40 |  | 399 |
| 2043 | Menopausal hormone therapy after breast cancer. <i>Lancet, The</i> , <b>2004</b> , 363, 410-1   | 40 |  | 20  |
| 2042 | Laparoscopic resection of rectosigmoid carcinoma: prospective randomised trial. <i>Lancet, The</i> , <b>2004</b> , 363, 1187-92   | 40 |  | 734 |
| 2041 | Million women study most wanted in 2003. <i>Lancet, The</i> , <b>2004</b> , 363, 1192   | 40 |  | 78  |
| 2040 | Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. <b>2004</b> , 11, 11-33   |    |  | 312 |
| 2039 | It might be wise to consider adding androgen to the estrogen or estrogen-progestin regimens in the appropriate patients. <b>2004</b> , 11, 505-7  |    |  | 3   |
| 2038 | Recommendations for estrogen and progesterone use in peri- and postmenopausal women: October 2004 position statement of The North American Menopause Society. <b>2004</b> , 11, 589-600   |    |  | 94  |
| 2037 | Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. <b>2004</b> , 104, 443-51  |    |  | 158 |
| 2036 | Breast cancer incidence in postmenopausal women using testosterone in addition to usual hormone therapy. <b>2004</b> , 11, 531-5  |    |  | 92  |
| 2035 | Bibliography. Current world literature. <i>Breast</i> . <b>2004</b> , 16, 621-54  |    |  |     |
| 2034 | Sexual dysfunction in women with premature menopause. <b>2004</b> , 11, 766-77  |    |  | 74  |



|      |   |     |
|------|---|-----|
| 2033 | Hormone replacement therapy for the primary prevention of chronic diseases: recommendation statement from the Canadian Task Force on Preventive Health Care. <b>2004</b> , 170, 1535-7  | 19  |
| 2032 | Mhopause en 2004 : le « traitement hormonal substitutif » n'est plus ce qu'il fait. <b>2004</b> , 25, 806-815   | 6   |
| 2031 | Hormone Therapy: a practical guide to risk assessment for short-term symptomatic treatment of menopausal symptoms. <b>2004</b> , 46, 37-42  | 1   |
| 2030 | Changes in health-related behaviours following BRCA 1/2 genetic testing: the case of hormone replacement therapy. <b>2004</b> , 26, 1059-66   | 8   |
| 2029 | Publishing the results of the estrogen-only arm of WHI. <b>2004</b> , 7, 117-9  | 2   |
| 2028 | Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. <b>2004</b> , 15, 753-60   | 99  |
| 2027 | Views on recent trials and the future of hormonal therapy. <b>2004</b> , 47, 424-7  | 1   |
| 2026 | Mise au point actualisè sur le traitement hormonal substitutif de la mhopause (THS) d'embre 2003. <b>2004</b> , 32, 571-575   |     |
| 2025 | Non-hormonal therapy for hot flushes in postmenopausal women. <b>2004</b> ,   | 2   |
| 2024 | Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women. <b>2004</b> , 291, 2212-20   | 101 |
| 2023 | Non hormonal interventions for hot flushes in women with a history of breast cancer. <b>2004</b> ,  | 2   |
| 2022 | Sex hormones and related compounds, including hormonal contraceptives. <b>2004</b> , 27, 420-441  | 1   |
| 2021 | Hormone Replacement Therapy Appears to Be Safe After Prophylactic Adnexectomy in Premenopausal BRCA1/BRCA2 Mutation Carriers. Reaction to the 'Letter to readers' in Hereditary Cancer in Clinical Practice, 2005, 3 (2). <b>2005</b> , 3, 87 | 78  |
| 2020 | Aromatase Inhibition and Breast Cancer. <b>2005</b> , 166-180   |     |
| 2019 | Is there a role for hormone replacement therapy after breast cancer?. <b>2005</b> , 11, 140-4   | 8   |
| 2018 | Menopausal hormone therapy. <b>2005</b> , 27, 137-62  | 23  |
| 2017 | Effect of a combination of isoflavones and Actaea racemosa Linnaeus on climacteric symptoms in healthy symptomatic perimenopausal women: a 12-week randomized, placebo-controlled, double-blind study. <b>2005</b> , 12, 412-20               | 49  |
| 2016 | Activation of nitric oxide synthesis in human endothelial cells by red clover extracts. <b>2005</b> , 12, 69-77   | 35  |

2015 The bad news and the bad news. **2005**, 330, 1063

2014 The effects of progesterone, medroxyprogesterone acetate, and norethisterone on growth factor- and estradiol-treated human cancerous and noncancerous breast cells. **2005**, 12, 468-74 20

2013 Hormonal environment in the induction of breast cancer in castrated rats using dimethylbenzanthracene: influence of the presence or absence of ovarian activity and of treatment with estradiol, tibolone, and raloxifene. **2005**, 12, 601-8 3

2012 Postmenopausal hormone therapy and breast cancer: a systematic review and meta-analysis. **2005**, 12, 668-78 59

2011 Bleeding patterns during continuous estradiol with different sequential progestogens therapy. **2005**, 12, 520-5 13

2010 The new hormone therapy problem: do we solve it with long-cycle progesterone therapy?. **2005**, 12, 664-7

2009 Effects of phytoestrogens on the ovarian and pituitary phenotypes of estrogen-deficient female aromatase knockout mice. **2005**, 12, 174-85 19

2008 Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebo-controlled, double-blind study. **2005**, 12, 18-26 142

2007 The case for less-than-monthly progestogen in women on HT: is transvaginal ultrasound the key?. **2005**, 12, 110-3 5

2006 Reassessment of the cost-effectiveness of hormone replacement therapy in Sweden: results based on the Women's Health Initiative randomized controlled trial. **2005**, 21, 433-41 23

2005 Low-dose hormone therapy and bone metabolism in the context of pharmacotherapy for the postmenopausal woman. **2005**, 4, 60-66

2004 HRT and breast cancer: Is there an association?. **2005**, 16, 128-132 1

2003 Actualit  en endocrinologie de la reproduction. **2005**, 2, 198-208 1

2002 Actualit  sur la m opause. Donn s de la m decine factuelle (« evidence based medecine »). **2005**, 2, 90-101

2001 Bio-identical steroid hormone replacement: selected observations from 23 years of clinical and laboratory practice. **2005**, 1057, 506-24 15

2000 Miscellaneous hormone therapies for osteoporosis. **2005**, 3, 067-074

1999 Authors' reply. **2005**, 7, 209-210

1998 Authors' reply. **2005**, 7, 210-211

1997 Prophylactic salpingo-oophorectomy. **2005**, 7, 210-210

1996 The role of prophylactic salpingo-oophorectomy in women who carry mutations of the BRCA genes. **2005**, 7, 23-27 3

1995 New developments in HRT: low-dose therapy. **2005**, 7, 40-43

1994 Safety of vaginal oestrogen in postmenopausal women. **2005**, 7, 241-244 6

1993 Expression of p53 and markers for apoptosis in breast tissue during long-term hormone therapy in cynomolgus monkeys. **2005**, 193, 58-63 12

1992 The effect of tibolone in postmenopausal women receiving tamoxifen after surgery for breast cancer: a randomised, double-blind, placebo-controlled trial. **2005**, 112, 228-33 40

1991 Current evidence about the effect of hormone replacement therapy on the incidence of major conditions in postmenopausal women. **2005**, 112, 692-5 22

1990 The hormone replacement therapy controversy. **2005**, 112, 689-91 1

1989 Bleeding profiles and effects on the endometrium for women using a novel combination of transdermal oestradiol and natural progesterone cream as part of a continuous combined hormone replacement regime. **2005**, 112, 1402-6 14

1988 Scientific evidence changes prescribing practice--a comparison of the management of the climacteric and use of hormone replacement therapy among Swedish gynaecologists in 1996 and 2003. **2006**, 113, 15-20 14

1987 Effects of oestrogen receptor-active compounds on lipid metabolism. **2005**, 7, 471-7 8

1986 Dramatic change in prescribing of hormone replacement therapy in The Netherlands after publication of the Million Women Study: a follow-up study. **2005**, 60, 641-7 49

1985 Hormone replacement therapy: an example of McKinlay's theory on the seven stages of medical innovation. **2005**, 14, 1090-7 4

1984 Effects of testosterone on sexual function in men: results of a meta-analysis. **2005**, 63, 381-94 384

1983 Hormone use for menopausal symptoms and risk of breast cancer. A Danish cohort study. **2005**, 92, 1293-7 66

1982 An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk. **2005**, 92, 2049-58 98

1981 Mortality following development of breast cancer while using oestrogen or oestrogen plus progestin: a computer record-linkage study. **2005**, 93, 392-8 22

1980 Hormone replacement therapy in women with spinal cord injury - a survey with literature review. **2005**, 43, 67-73 3

|      |  |     |
|------|--|-----|
| 1979 | Cardiac syndrome X. <b>2005</b> , 59, 1063-9   | 26  |
| 1978 | The effect of the phytoestrogen genistein and hormone replacement therapy on homocysteine and C-reactive protein level in postmenopausal women. <b>2005</b> , 84, 474-7  | 35  |
| 1977 | Changes in attitudes, knowledge and hormone replacement therapy use: a comparative study in two random samples with 6-year interval. <b>2005</b> , 84, 395-401   | 9   |
| 1976 | Hormone replacement therapy and breast cancer risk in California. <b>2005</b> , 11, 410-5  | 18  |
| 1975 | Polymorphic catechol-O-methyltransferase gene, duration of estrogen exposure, and breast cancer risk: a nested case-control study in Taiwan. <b>2005</b> , 29, 427-32  | 21  |
| 1974 | Relaxations to oestrogen receptor subtype selective agonists in rat and mouse arteries. <b>2005</b> , 513, 101-8   | 23  |
| 1973 | How to manage osteoporosis after the menopause. <b>2005</b> , 19, 1007-19  | 18  |
| 1972 | One step forward in proving, that underarm cosmetics do not cause breast cancer. <b>2005</b> , 14, 85-6  | 5   |
| 1971 | Use of hormone replacement therapy (HRT) and survival following breast cancer diagnosis. <b>2005</b> , 14, 192-200   | 16  |
| 1970 | Breast cancer survival and the use of HRT. <b>2005</b> , 14, 178-80  | 1   |
| 1969 | Breast cancer control: signs of progress, but more work required. <b>2005</b> , 14, 429-38   | 37  |
| 1968 | La terapia hormonal sustitutiva: mandan las evidencias. <b>2005</b> , 14, 46-51  |     |
| 1967 | French hormones: progestins and therapeutic variation in France. <b>2005</b> , 60, 2609-22   | 23  |
| 1966 | Variation in the psychosocial determinants of the intention to prescribe hormone therapy prior to the release of the Women's Health Initiative trial: a survey of general practitioners and gynaecologists in France and Quebec. <b>2005</b> , 5, 31 | 22  |
| 1965 | [Non-metastatic breast cancer]. <b>2005</b> , 142, 355-66  |     |
| 1964 | Detection of DNA strand breaks and oxidized DNA bases at the single-cell level resulting from exposure to estradiol and hydroxylated metabolites. <b>2005</b> , 45, 397-404  | 44  |
| 1963 | Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. <b>2005</b> , 114, 448-54   | 269 |
| 1962 | Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. <b>2005</b> , 103, 2241-51  | 172 |

|      |  |    |
|------|--|----|
| 1961 | Alzheimer's disease, estrogens, and clinical trials: a case study in drug development for complex disorders. <b>2005</b> , 66, 53-77   | 5  |
| 1960 | Influence of estrus status on urinary chemical parameters related to urolithiasis. <b>2005</b> , 33, 476-80  | 16 |
| 1959 | Prevention of bone loss by phloridzin, an apple polyphenol, in ovariectomized rats under inflammation conditions. <b>2005</b> , 77, 311-8  | 60 |
| 1958 | Schlagen Frauenherzen wirklich anders?. <b>2005</b> , 30, 353-355  |    |
| 1957 | Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. <b>2005</b> , 16, 15-25  | 56 |
| 1956 | Safety profile of raloxifene as used in general practice in England: results of a prescription-event monitoring study. <b>2005</b> , 16, 490-500                                   | 11 |
| 1955 | Performance of four clinical screening tools to select peri- and early postmenopausal women for dual X-ray absorptiometry. <b>2005</b> , 16, 764-72                                | 27 |
| 1954 | Axial BMD, change in BMD and bone turnover do not predict breast cancer incidence in early postmenopausal women. <b>2005</b> , 16, 1627-32   | 17 |
| 1953 | Sex steroid regulation of angiogenesis in breast tissue. <b>2005</b> , 8, 127-36   | 18 |
| 1952 | [Role of hormone-replacement therapy for prevention of coronary artery disease in women]. <b>2005</b> , 94 Suppl 3, III/74-8   | 1  |
| 1951 | A practical guide to the management of menopausal symptoms in breast cancer patients. <b>2005</b> , 13, 573-8  | 14 |
| 1950 | Quantitative histomorphometric analysis of gonadal steroid receptor distribution in the normal human endometrium through the menstrual cycle. <b>2005</b> , 123, 463-74            | 28 |
| 1949 | Kombinierte Hormonersatztherapie mit 1 mg ðtradiol und 2 mg Drospirenon. <b>2005</b> , 3, 55-59  |    |
| 1948 | Möglichkeiten der hormonellen Substitution bei gynðologischen Malignomen. <b>2005</b> , 3, 97-106  |    |
| 1947 | Randomized trial comparing low-dose hormone replacement therapy and HRT plus 1alpha-OH-vitamin D3 (alfacalcidol) for treatment of postmenopausal bone loss. <b>2006</b> , 24, 11-5 | 17 |
| 1946 | Osteoporotic distal radius curettageâfilling with an injectable calcium phosphate cement. A cadaveric study. <b>2005</b> , 15, 1-6   | 14 |
| 1945 | MammakarzinomâStandards der Versorgung heute und morgen. <b>2005</b> , 11, 265-272   | 1  |
| 1944 | The effects of remifemin on subjective symptoms of menopause. <b>2005</b> , 22, 148-54   | 40 |

|      |   |     |
|------|---|-----|
| 1943 | Safety, tolerability, and pharmacokinetics of single ascending doses of synthetic genistein (Bonistein) in healthy volunteers. <b>2005</b> , 22, 65-78                        | 28  |
| 1942 | The epidemiology of breast cancer. <b>2005</b> , 1, 24-28   | 4   |
| 1941 | Factors modifying the association between hormone-replacement therapy and breast cancer risk. <b>2005</b> , 20, 699-711   | 51  |
| 1940 | Previous oral contraceptive use and breast cancer risk according to hormone replacement therapy use among postmenopausal women. <b>2005</b> , 16, 537-44                      | 11  |
| 1939 | Use of menopausal hormones in the United States, 1992 through June, 2003. <b>2005</b> , 14, 171-6   | 46  |
| 1938 | Brown kelp modulates endocrine hormones in female sprague-dawley rats and in human luteinized granulosa cells. <b>2005</b> , 135, 296-300                                     | 16  |
| 1937 | Hormone replacement therapy and breast cancer: estimate of risk. <b>2005</b> , 331, 347-9   | 9   |
| 1936 | Helping women make the right HRT choice. <b>2005</b> , 16, 73-78  | 2   |
| 1935 | The aromatase inhibitors in early breast cancer: who, when, and why?. <b>2005</b> , 183, 24-7   | 11  |
| 1934 | Gynecology and the Older Patient. 1447-1458   |     |
| 1933 | Breast Cancer in the Elderly. 1531-1540   |     |
| 1932 | INCORPORACIÓN Y CUMPLIMIENTO DE LA TERAPIA DE REEMPLAZO HORMONAL DEL CLIMATERIO FEMENINO ANTES Y DESPUÉS DEL ESTUDIO DEL WHI: REVISIÓN DE LA EVIDENCIA. <b>2005</b> , 70, 186 |     |
| 1931 | Aromatase inhibitors for breast cancer prevention. <b>2005</b> , 23, 1636-43  | 160 |
| 1930 | Differential regulation of estrogen receptor (ER)alpha and ERbeta in primate mammary gland. <b>2005</b> , 90, 435-44  | 69  |
| 1929 | Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review. <b>2005</b> , 11, 3711-28  | 17  |
| 1928 | Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). <b>2005</b> , 97, 755-65     | 355 |
| 1927 | Effect of statins on the mortality of patients with ischaemic heart disease: population based cohort study with nested case-control analysis. <b>2006</b> , 92, 752-8         | 31  |
| 1926 | The effect of estradiol valerate and dienogest combination on serum homocysteine levels in postmenopausal women: a clinical trial. <b>2005</b> , 21, 185-8                    | 0   |

|      |   |     |
|------|---|-----|
| 1925 | Lifelong endocrine fluctuations and related cognitive disorders. <b>2005</b> , 11, 4229-52  | 42  |
| 1924 | Hormone replacement therapy and arterial blood pressure in postmenopausal women with hypertension. <b>2005</b> , 14, 38-44  | 12  |
| 1923 | Where are we with postmenopausal hormone therapy in 2005?. <b>2005</b> , 21, 248-56   | 4   |
| 1922 | Non-steroidal subtype selective estrogens. <b>2005</b> , 12, 1077-136   | 57  |
| 1921 | Estrogen or antiprogestin treatment induces complete regression of pulmonary and axillary metastases in an experimental model of breast cancer progression. <b>2005</b> , 26, 1055-63 | 26  |
| 1920 | Managing the menopause: British Menopause Society Council consensus statement on hormone replacement therapy. <b>2005</b> , 11, 152-6   | 8   |
| 1919 | Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. <b>2005</b> , 23, 6919-30   | 177 |
| 1918 | Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. <b>2005</b> , 12, 1071-82                        | 375 |
| 1917 | Hormones and menopause: pro. <b>2005</b> , 60, 261-8  | 3   |
| 1916 | Progestins and recurrence in breast cancer survivors. <b>2005</b> , 97, 471-2   | 10  |
| 1915 | Performance of floating absolute risks. <b>2005</b> , 162, 487-90   | 4   |
| 1914 | Fertility in female cancer survivors: pathophysiology, preservation and the role of ovarian reserve testing. <b>2005</b> , 11, 69-89  | 129 |
| 1913 | Awareness of risk of osteoporosis may cause uncertainty and worry in menopausal women. <b>2005</b> , 33, 203-7  | 28  |
| 1912 | Sex hormones and related compounds, including hormonal contraceptives. <b>2005</b> , 480-504  |     |
| 1911 | Alternatives to estrogen to manage hot flushes. <b>2005</b> , 20, 13-21   | 6   |
| 1910 | Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients. <b>2005</b> , 16, 70-4   | 41  |
| 1909 | Patterns of hormone replacement therapy in a population-based cohort of postmenopausal German women. Changes after HERS II and WHI. <b>2005</b> , 113, 529-33                         | 13  |
| 1908 | [Women's Health in Austria]. <b>2005</b> , 127, 333-7   | 1   |

|      |  |     |
|------|--|-----|
| 1907 | Breast cancer: the role of hormone therapy. <b>2005</b> , 23, 167-71   | 6   |
| 1906 | Dose-dependent changes of the ratio of apoptosis to proliferation by norethisterone and medroxyprogesterone acetate in human breast epithelial cells. <b>2005</b> , 37, 468-73                                       | 12  |
| 1905 | Breast cancer risk with postmenopausal hormonal treatment. <b>2005</b> , 11, 545-60  | 132 |
| 1904 | Pharmacologic treatment options for hypoactive sexual desire disorder. <b>2005</b> , 1, 263-77   | 4   |
| 1903 | Progesterone but not estradiol 17beta potentiates local GH secretions by hormone-dependent breast cancer explants. An in vitro study. <b>2005</b> , 113, 127-32  | 5   |
| 1902 | Does hormone replacement therapy have a future?. <b>2005</b> , 1, 5-8  |     |
| 1901 | Revealing progesterone's role in uterine and mammary gland biology: insights from the mouse. <b>2005</b> , 23, 22-37   | 69  |
| 1900 | Dietary phyto-oestrogens: molecular mechanisms, bioavailability and importance to menopausal health. <b>2005</b> , 18, 183-201   | 15  |
| 1899 | Breast cancer and sex steroids: critical review of epidemiological, experimental and clinical investigations on etiopathogenesis, chemoprevention and endocrine treatment of breast cancer. <b>2005</b> , 20, 343-60 | 36  |
| 1898 | The need for tissue selective menopausal agents. <b>2005</b> , 21 Suppl 1, 22-7  | 3   |
| 1897 | Intrauterine levonorgestrel delivered by a frameless system, combined with systemic estrogen: acceptability and endometrial safety after 3 years of use in peri- and postmenopausal women. <b>2005</b> , 20, 336-42  | 11  |
| 1896 | Treatment of menopausal symptoms post-Women's Health Initiative: refinement of existing treatments and development of new therapies. <b>2005</b> , 10, 619-41  | 1   |
| 1895 | Hormone replacement therapy and breast density changes. <b>2005</b> , 8, 185-92  | 18  |
| 1894 | What about breast cancer and cardiovascular disease risks with the best treatments during the climacterium and beyond. <b>2005</b> , 20, 301-4   | 1   |
| 1893 | The rise and fall of menopausal hormone therapy. <b>2005</b> , 26, 115-40  | 56  |
| 1892 | Menopausal hormone therapy and risk of breast cancer: a meta-analysis of epidemiological studies and randomized controlled trials. <b>2005</b> , 11, 561-73  | 66  |
| 1891 | Pharmacology of different progestogens: the special case of drospirenone. <b>2005</b> , 8 Suppl 3, 4-12  | 86  |
| 1890 | Urinary hydroxyestrogens and breast cancer risk among postmenopausal women: a prospective study. <b>2005</b> , 14, 2137-42   | 38  |



|      |   |     |
|------|---|-----|
| 1889 | Cytochrome P-450 1A1 gene polymorphisms and risk of breast cancer: a HuGE review. <b>2005</b> , 161, 901-15   | 102 |
| 1888 | Pegvisomant: current and possible future indications. <b>2005</b> , 2, 525-532  |     |
| 1887 | Hard work never hurt anyone: or did it? A review of occupational associations with soft tissue musculoskeletal disorders of the neck and upper limb. <b>2005</b> , 64, 1391-6   | 70  |
| 1886 | Plasma sex hormone concentrations and subsequent risk of breast cancer among women using postmenopausal hormones. <b>2005</b> , 97, 595-602   | 71  |
| 1885 | Environmental influences in cancer aetiology. <b>2005</b> , 15, 56-114  | 10  |
| 1884 | Current patient perceptions on the menopause: a South African perspective. <b>2005</b> , 8, 327-32  | 5   |
| 1883 | Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women. <b>2005</b> , 14, 1724-31  | 71  |
| 1882 | Dose and duration of hormone use: understanding the effects of combined menopausal hormones on breast cancer better, 1976-2004. <b>2005</b> , 59, 1078-9  |     |
| 1881 | Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate. <b>2005</b> , 65, 8487-96   | 55  |
| 1880 | Epidemiology and prevention of breast cancer. <b>2005</b> , 14, 768-72  | 43  |
| 1879 | Breast cancer incidence, case-fatality and breast cancer mortality in Danish women using hormone replacement therapy--a prospective observational study. <b>2005</b> , 34, 931-5  | 12  |
| 1878 | Increased extracellular local levels of estradiol in normal breast in vivo during the luteal phase of the menstrual cycle. <b>2005</b> , 187, 103-8   | 23  |
| 1877 | Positive correlation between estradiol and vascular endothelial growth factor but not fibroblast growth factor-2 in normal human breast tissue in vivo. <b>2005</b> , 11, 8036-41   | 49  |
| 1876 | Medroxyprogesterone acetate induces cell proliferation through up-regulation of cyclin D1 expression via phosphatidylinositol 3-kinase/Akt/nuclear factor-kappaB cascade in human breast cancer cells. <b>2005</b> , 146, 4917-25 | 69  |
| 1875 | Comparative genomic hybridization of human breast epithelial cells transformed by estrogen and its metabolites. <b>2005</b> , 26, 691   | 1   |
| 1874 | Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis. <b>2005</b> , 330, 1059-63   | 95  |
| 1873 | Menopausal complaints, oestrogens, and heart disease risk: an explanation for discrepant findings on the benefits of post-menopausal hormone therapy. <b>2005</b> , 26, 1358-61   | 42  |
| 1872 | 'Tib the balance': the search for the optimal hormone replacement therapy. <b>2005</b> , 26, 1345-6   | 3   |

|      |  |    |     |
|------|--|----|-----|
| 1871 | Current status of hormone therapy and breast cancer. <b>2005</b> , 11, 541-3   |    | 10  |
| 1870 | Osteoporosis therapy: an example of putting evidence-based medicine into clinical practice. <b>2005</b> , 98, 403-13   |    | 14  |
| 1869 | Endometrial cancer and hormone-replacement therapy in the Million Women Study. <i>Lancet, The</i> , <b>2005</b> , 365, 1543-51   | 40 | 498 |
| 1868 | Treatment of menopausal symptoms: what shall we do now?. <i>Lancet, The</i> , <b>2005</b> , 366, 409-21  | 40 | 98  |
| 1867 | Breast cancer. <i>Lancet, The</i> , <b>2005</b> , 365, 1727-41   | 40 | 346 |
| 1866 | [Actions of a 19-norprogesterone derivative on mammary gland: nomegestrol acetate]. <b>2005</b> , 34, 69-84  |    | 5   |
| 1865 | [Will publication of the French study E3N change prescription practices for hormone replacement therapy in menopausal women?]. <b>2005</b> , 34, 101-4   |    | 0   |
| 1864 | [Methodology of the inquiry MISSION (menopause, breast cancer risk, morbidity and prevalence)]. <b>2005</b> , 34, 658-65   |    | 4   |
| 1863 | [Risk factors and risk reduction of breast cancer]. <b>2005</b> , 21, 175-80   |    | 16  |
| 1862 | [Osteoporosis and hormone replacement therapy]. <b>2005</b> , 34, 379-84   |    | 1   |
| 1861 | Management of menopausal symptoms in patients with breast cancer: an evidence-based approach. <b>2005</b> , 6, 687-95  |    | 63  |
| 1860 | Ovulation induction and cancer risk. <b>2005</b> , 83, 261-74; quiz 525-6  |    | 84  |
| 1859 | Postmenopausal hormone therapy: critical reappraisal and a unified hypothesis. <b>2005</b> , 83, 558-66  |    | 85  |
| 1858 | Hormone therapy use among postmenopausal French women before the publication of the Women's Health Initiative study: duration of use and factors associated with discontinuation. <b>2005</b> , 83, 1771-9 |    | 12  |
| 1857 | Effect of 17 beta-estradiol, progesterone, synthetic progestins, tibolone, and tibolone metabolites on vascular endothelial growth factor mRNA in breast cancer cells. <b>2005</b> , 84, 485-91            |    | 22  |
| 1856 | A critique of the Women's Health Initiative hormone therapy study. <b>2005</b> , 84, 1589-601  |    | 48  |
| 1855 | Viewing the pyramid--through a glass, darkly?. <b>2005</b> , 3, 240-2  |    | 0   |
| 1854 | [Not Available]. <b>2005</b> , 1, 81-3   |    |     |

1853 [Not Available]. **2005**, 1, 84-5

1852 Progestins and estrogens and Alzheimer's disease. **2005**, 93, 305-8 19

1851 Nociones de epidemiología en dermatología. **2005**, 39, 1-10

1850 [Update on menopause treatments, after recent controversies]. **2005**, 66, 30-2

1849 Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. **2005**, 23, 7804-10 339

1848 UK women doctors' use of hormone replacement therapy: 10-year follow up. **2005**, 8, 154-61 6

1847 Vasomotor symptoms decrease in women with breast cancer randomized to treatment with applied relaxation or electro-acupuncture: a preliminary study. **2005**, 8, 243-50 88

1846 Clinical effects of tibolone in postmenopausal women after 5 years of tamoxifen therapy for breast cancer. **2005**, 8, 342-51 12

1845 The Million Women Study--is it believable?. **2005**, 8, 210-3 7

1844 Menopausal hormone therapies: their effect on mammographic density and breast cancer risk. **2005**, 21 Suppl 1, 12-6 19

1843 ESHRE guideline for the diagnosis and treatment of endometriosis. **2005**, 20, 2698-704 1065

1842 Effect of nomegestrol acetate on estrogen biosynthesis and transformation in MCF-7 and T47-D breast cancer cells. **2005**, 93, 1-13 22

1841 Phytoestrogens derived from red clover: an alternative to estrogen replacement therapy?. **2005**, 94, 499-518 183

1840 Comparison of the efficacy and tolerability of a new once-a-week matrixial estradiol transdermal system (Estrapatch 40 and Estrapatch 60) with a twice week system. **2005**, 93, 309-18 4

1839 Progestins and progesterone in hormone replacement therapy and the risk of breast cancer. **2005**, 96, 95-108 111

1838 Hormonal aspects in the causation of human breast cancer: epidemiological hypotheses reviewed, with special reference to nutritional status and first pregnancy. **2005**, 97, 451-8 22

1837 Pregnancy, progesterone and progestins in relation to breast cancer risk. **2005**, 97, 441-50 31

1836 Postmenopausal hormone therapy and cancer risk. **2005**, 1279, 133-140 1

|      |   |     |
|------|---|-----|
| 1835 | Nitric oxide in postmenopausal women taking three different HRT regimens. <b>2005</b> , 50, 52-7  | 9   |
| 1834 | Applied relaxation and oral estradiol treatment of vasomotor symptoms in postmenopausal women. <b>2005</b> , 51, 154-62   | 41  |
| 1833 | Presentations of endometrial activity after curative radiotherapy for cervical cancer. <b>2005</b> , 51, 172-6  | 5   |
| 1832 | . <b>2005</b> , 50, 66-67   | 1   |
| 1831 | Continuous combined parenteral estrogen substitution and intrauterine progestogen delivery: the ideal HST combination?. <b>2005</b> , 51, 207-14                          | 14  |
| 1830 | Morphometric evaluation of effects of two sex steroids on mammary gland of female rats. <b>2005</b> , 51, 370-9   | 14  |
| 1829 | Cimicifuga racemosa dried ethanolic extract in menopausal disorders: a double-blind placebo-controlled clinical trial. <b>2005</b> , 51, 397-404                          | 99  |
| 1828 | Women's views of the climacteric at the time of low menopausal hormone use, Estonia 1998. <b>2005</b> , 51, 413-25  | 6   |
| 1827 | Soy isoflavones, body composition, and physical performance. <b>2005</b> , 52, 102-10   | 20  |
| 1826 | Justification for the use of HRT in the long-term prevention of osteoporosis. <b>2005</b> , 51, 113-26  | 42  |
| 1825 | Hormone replacement therapy in Germany: determinants and possible health-related outcomes. Results of National Health Surveys from 1984 to 1999. <b>2005</b> , 52, 223-34 | 12  |
| 1824 | Women's health after WHI. <b>2005</b> , 51, 1-3   | 6   |
| 1823 | Guidelines for hormone treatment of women in the menopausal transition and beyond. <b>2005</b> , 51, 15-20  | 11  |
| 1822 | Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group. <b>2005</b> , 51, 21-8                               | 102 |
| 1821 | The woman patient after WHI. <b>2005</b> , 51, 29-37  | 6   |
| 1820 | Menopause and HRT--the state of the art in Europe. <b>2005</b> , 51, 40-7   | 6   |
| 1819 | Postmenopausal hormone therapy and breast cancer: what is the problem?. <b>2005</b> , 51, 75-82   | 7   |
| 1818 | Breast cancer risk in the WHI study: the problem of obesity. <b>2005</b> , 51, 83-97  | 42  |

|      |  |     |
|------|--|-----|
| 1817 | Appropriate use of hormones should alleviate concerns of cardiovascular and breast cancer risk. <b>2005</b> , 51, 98-109   | 7   |
| 1816 | Gynecologists' attitudes towards hormone therapy in the post "Women's Health Initiative" study era. <b>2005</b> , 52, 18-25  | 22  |
| 1815 | Use of hormone replacement therapy in the Hong Kong public health sector after the Women's Health Initiative trial. <b>2005</b> , 52, 277-85   | 12  |
| 1814 | Treatment adherence in the Estonian postmenopausal hormone therapy (EPHT) trial [ISRCTN35338757]. <b>2005</b> , 52, 286-95   | 14  |
| 1813 | Estimated numbers of postmenopausal women treated by hormone therapy in France. <b>2005</b> , 52, 296-305  | 23  |
| 1812 | New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits. <b>2005</b> , 52, 1-10 | 56  |
| 1811 | Endometrial cancer--surprising reports. <b>2005</b> , 51, 329-33   | 2   |
| 1810 | Changes in women's attitudes towards and use of hormone therapy after HERS and WHI. <b>2005</b> , 52, 11-7   | 61  |
| 1809 | Prophylaxis approach to a-symptomatic post-menopausal women: breast cancer. <b>2005</b> , 52 Suppl 1, S23-31   | 12  |
| 1808 | Pulsed estradiol exposure has a limited ability to induce uterine proliferation in ovariectomised female Wistar rats. <b>2005</b> , 230, 7-15  | 11  |
| 1807 | Synthetic progestins used in HRT have different glucocorticoid agonist properties. <b>2005</b> , 242, 23-32  | 110 |
| 1806 | The possible role of female sex hormones in milk from pregnant cows in the development of breast, ovarian and corpus uteri cancers. <b>2005</b> , 65, 1028-37  | 116 |
| 1805 | [Acceptability of continuous combined versus cyclical HRT: a French multicentric randomized clinical study]. <b>2005</b> , 33, 498-504   | 1   |
| 1804 | [HRT: abandon? Menopausal hormone replacement: future]. <b>2005</b> , 33, 847-50   |     |
| 1803 | Evidence-based hormone replacement therapy for the well woman at menopause. <b>2005</b> , 15, 244-250  |     |
| 1802 | A randomised double-blind controlled trial of oral soy supplements versus placebo for treatment of menopausal symptoms in patients with early breast cancer. <b>2005</b> , 41, 708-14                | 81  |
| 1801 | HRT and breast cancer: impact on population risk and incidence. <b>2005</b> , 41, 1775-81  | 21  |
| 1800 | Hormone replacement therapy (HRT) and endometrial morphology under consideration of the different molecular pathways in endometrial carcinogenesis. <b>2005</b> , 122, 4-12                          | 13  |

|      |   |     |
|------|---|-----|
| 1799 | The influence of hormone replacement therapy on the pathology of breast cancer. <b>2005</b> , 31, 467-72  | 19  |
| 1798 | Intervention thresholds for osteoporosis in the UK. <b>2005</b> , 36, 22-32   | 94  |
| 1797 | Integration of progesterone receptor mediated rapid signaling and nuclear actions in breast cancer cell models: role of mitogen-activated protein kinases and cell cycle regulators. <b>2005</b> , 70, 418-26 | 73  |
| 1796 | Black cohosh: just another phytoestrogen?. <b>2005</b> , 16, 214-21   | 37  |
| 1795 | The phytoestrogen biochaninA weakens acute cardiac allograft rejection without affecting the reproductive system. <b>2005</b> , 15, 45-53   | 1   |
| 1794 | Endometrial cancer and HRT. <b>2005</b> , 5, 51-56  | 5   |
| 1793 | Estrogen with and without progestin: benefits and risks of short-term use. <b>2005</b> , 118 Suppl 12B, 79-87   | 17  |
| 1792 | [Substitutive hormonal treatment guidelines and risk of endometrial cancer. Data from the Million Women Study]. <b>2005</b> , 125, 374-5  |     |
| 1791 | Long term hormone therapy for perimenopausal and postmenopausal women. <b>2005</b> , CD004143   | 57  |
| 1790 | [Adventures and misadventures of solitary sailors on the sea of uncertainty]. <b>2005</b> , 35, 95-8  | 7   |
| 1789 | Therapy for menopausal symptoms during and after treatment for breast cancer : safety considerations. <b>2005</b> , 28, 1085-100  | 25  |
| 1788 | The 17alpha and 17beta isomers of estradiol both induce rapid spine synapse formation in the CA1 hippocampal subfield of ovariectomized female rats. <b>2005</b> , 146, 287-93                                | 191 |
| 1787 | Notions d'pidmiologie utiles en dermatologie. <b>2005</b> , 2, 119-131  |     |
| 1786 | Unravelling the confusion about HRT in women. <b>2005</b> , 2, 287-291  | 2   |
| 1785 | The role of mammographic density in evaluating changes in breast cancer risk. <b>2005</b> , 21 Suppl 1, 1-5   | 58  |
| 1784 | Comparison of the in vitro estrogenic activities of compounds from hops ( <i>Humulus lupulus</i> ) and red clover ( <i>Trifolium pratense</i> ). <b>2005</b> , 53, 6246-53                                    | 99  |
| 1783 | Anti-resorptive therapy for the prevention of postmenopausal osteoporosis : when should treatment begin?. <b>2005</b> , 4, 263-77   | 8   |
| 1782 | Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. <b>2005</b> , 26, 423-38   | 245 |

|      |  |     |
|------|--|-----|
| 1781 | Premature ovarian failure. <b>2005</b> , 11, 391-410   | 424 |
| 1780 | Hormone replacement therapy and false positive recall in the Million Women Study: patterns of use, hormonal constituents and consistency of effect. <b>2006</b> , 8, R8                              | 24  |
| 1779 | The progestational and androgenic properties of medroxyprogesterone acetate: gene regulatory overlap with dihydrotestosterone in breast cancer cells. <b>2005</b> , 7, R1036-50                      | 55  |
| 1778 | XRCC1 and XPD genetic polymorphisms, smoking and breast cancer risk in a Finnish case-control study. <b>2005</b> , 7, R987-97  | 50  |
| 1777 | Antisense oligonucleotides targeting the progesterone receptor inhibit hormone-independent breast cancer growth in mice. <b>2005</b> , 7, R1111-21   | 18  |
| 1776 | Menopausal hormone therapy after breast cancer. <b>2005</b> , 7, 168-70  | 5   |
| 1775 | Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case-control study. <b>2006</b> , 8, R11              | 81  |
| 1774 | Serotonergic agents as an alternative to hormonal therapy for the treatment of menopausal vasomotor symptoms. <b>2006</b> , 5, 83-7  | 27  |
| 1773 | Cancer du sein. <b>2006</b> ,  |     |
| 1772 | Breast Cancer and Molecular Medicine. <b>2006</b> ,  | 2   |
| 1771 | Chemical modification modulates estrogenic activity, oxidative reactivity, and metabolic stability in 4'-F-DMA, a new benzothiophene selective estrogen receptor modulator. <b>2006</b> , 19, 779-87 | 24  |
| 1770 | Breast Cancer. <b>2006</b> ,   | 2   |
| 1769 | Development and characterization of biphenylsulfonamides as novel inhibitors of bone resorption. <b>2006</b> , 49, 7487-92   | 15  |
| 1768 | The European Menopause Survey 2005: women's perceptions on the menopause and postmenopausal hormone therapy. <b>2006</b> , 22, 369-75  | 73  |
| 1767 | Hormone therapy: maximizing the benefits. <b>2006</b> , 22, 160-2  | 4   |
| 1766 | Male hormonal contraception: a safe option?. <b>2006</b> , 1, 25-32  |     |
| 1765 | The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits--an attempt to interpret the Women's Health Initiative results. <b>2006</b> , 22, 303-17                          | 20  |
| 1764 | The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. <b>2006</b> , 24, 3576-82                                      | 166 |

|      |   |     |
|------|---|-----|
| 1763 | Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. <b>2006</b> , 7, 910-8  | 218 |
| 1762 | Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. <b>2006</b> , 295, 2057-71   | 469 |
| 1761 | Treatment for menopausal symptoms. <b>2006</b> , 34, 31-37  |     |
| 1760 | HRT and breast cancer. <b>2006</b> , 3, 15-17   | 2   |
| 1759 | Risk factors and epidemiology of breast cancer. <b>2006</b> , 3, 8-14   | 15  |
| 1758 | Treatment for menopausal symptoms. <b>2006</b> , 3, 217-223   |     |
| 1757 | Hormone replacement therapy. <b>2006</b> , 33, 953-63   | 5   |
| 1756 | Current status of combined hormone replacement therapy in clinical practice. <b>2006</b> , 6 Suppl 2, S51-7   | 9   |
| 1755 | Assessing drug risks and benefits: lessons from postmenopausal hormone therapy studies. <b>2006</b> , 6 Suppl 2, S65-70   | 1   |
| 1754 | Environmental oestrogens, cosmetics and breast cancer. <b>2006</b> , 20, 121-43   | 142 |
| 1753 | Regulation of endocrine-disrupting chemicals: critical overview and deficiencies in toxicology and risk assessment for human health. <b>2006</b> , 20, 145-65   | 75  |
| 1752 | [Perception and communication of medical risk which implications for preoperative anaesthetic consultations?]. <b>2006</b> , 25, 50-62  | 6   |
| 1751 | Digitized assessment of mammographic breast density in patients who received low-dose intrauterine levonorgestrel in continuous combination with oral estradiol valerate: a pilot study. <b>2006</b> , 85, 989-95 | 25  |
| 1750 | Histological and immunohistochemical evaluation of postmenopausal endometrium after 3 weeks of treatment with tibolone, estrogen only, or estrogen plus progestagen. <b>2006</b> , 86, 352-61                     | 18  |
| 1749 | Estrogen and progestogen therapy in postmenopausal women. <b>2006</b> , 86, S75-88  | 3   |
| 1748 | [Is the clinical profile of women treated with tibolone similar to that of women receiving a classical estrogen-progestogen therapy? Data from a nationwide survey in France]. <b>2006</b> , 34, 224-32           | 2   |
| 1747 | Two-view mammography at the incident round has improved the rate of screen-detected breast cancer in Wales. <b>2006</b> , 61, 478-82  | 3   |
| 1746 | Endometrial cancer risk was lower in women who used continuous combined HRT than in non-users. <b>2006</b> , 8, 68-69   |     |



|      |   |     |
|------|---|-----|
| 1745 | Hormone replacement therapy is more prevalent among Jewish BRCA1/2 mutation carriers. <b>2006</b> , 42, 650-5   | 11  |
| 1744 | Optimising endocrine approaches for the chemoprevention of breast cancer beyond the Study of Tamoxifen and Raloxifene (STAR) trial. <b>2006</b> , 42, 2909-13                 | 37  |
| 1743 | Attitudes of Italian gynaecologists towards prophylactic oophorectomy at hysterectomy for non-malignant conditions. <b>2006</b> , 124, 82-7                                   | 7   |
| 1742 | The thoughts of physicians regarding the need to start hormone replacement therapy in breast cancer survivors. <b>2006</b> , 124, 207-11                                      | 11  |
| 1741 | Bone turnover in young hypoestrogenic women on hormonal therapy. <b>2006</b> , 124, 204-6   | 5   |
| 1740 | The thoughts of breast cancer survivors regarding the need for starting hormone replacement therapy. <b>2006</b> , 124, 250-3   | 10  |
| 1739 | Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS)--a systematic enquiry and overview. <b>2006</b> , 125, 9-28                                       | 105 |
| 1738 | The effect of progesterone, testosterone and synthetic progestogens on growth factor- and estradiol-treated human cancerous and benign breast cells. <b>2006</b> , 129, 77-83 | 31  |
| 1737 | Gynaecological oncology perspective on management of the menopause. <b>2006</b> , 32, 892-7   | 14  |
| 1736 | Comparison of a transdermal continuous combined and an interrupted progestogen HRT. <b>2006</b> , 53, 19-26   | 0   |
| 1735 | Evaluation of mammographic density and (99m)Tc-sestamibi scintimammographic uptake in postmenopausal women on hormone replacement therapy. <b>2006</b> , 53, 97-106           | 4   |
| 1734 | Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy. <b>2006</b> , 53, 191-200   | 23  |
| 1733 | Use of hormones in the menopausal transition period in the Netherlands between 1993 and 1997. <b>2006</b> , 53, 462-75  | 11  |
| 1732 | Personal use of hormone therapy by postmenopausal women doctors and male doctors' wives in Italy after the publication of WHI trial. <b>2006</b> , 54, 181-92                 | 12  |
| 1731 | HRT use in 2001 and 2004 in The Netherlands--a world of difference. <b>2006</b> , 54, 193-7   | 29  |
| 1730 | Tibolone and its metabolites inhibit invasion of human mammary carcinoma cells in vitro. <b>2006</b> , 54, 229-37   | 6   |
| 1729 | Fracture reducing potential of hormone replacement therapy on a population level. <b>2006</b> , 54, 285-93  | 13  |
| 1728 | Results from the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]. <b>2006</b> , 55, 162-73   | 43  |

|      |  |     |
|------|--|-----|
| 1727 | Latin American position on the current status of hormone therapy during the menopausal transition and thereafter. <b>2006</b> , 55, 5-13   | 4   |
| 1726 | Response to plasma concentrations of levo-norgestrel in patients with an intra-uterine progestogen delivery system: Do they have any significance? <b>2006</b> , 55, 96-97                       |     |
| 1725 | Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. <b>2006</b> , 55, 103-15  | 177 |
| 1724 | Progestin inhibition of cell death in human breast cancer cell lines. <b>2006</b> , 98, 218-27   | 33  |
| 1723 | Characterization of the stimulatory effect of medroxyprogesterone acetate and chlormadinone acetate on growth factor treated normal human breast epithelial cells. <b>2006</b> , 98, 174-8       | 11  |
| 1722 | Anti-estrogenic activities of Ginkgo biloba extracts. <b>2006</b> , 100, 167-76  | 42  |
| 1721 | Steroid receptor coactivator 2 is essential for progesterone-dependent uterine function and mammary morphogenesis: insights from the mouse--implications for the human. <b>2006</b> , 102, 22-31 | 19  |
| 1720 | Metabolism of exogenous sex steroids and effect on brain functions with a focus on tibolone. <b>2006</b> , 102, 195-204  | 15  |
| 1719 | [Identification and management of hereditary breast-ovarian cancers (2004 update)]. <b>2006</b> , 54, 230-50   | 8   |
| 1718 | Obesity and cancer. <b>2006</b> , 16, 1-7  | 51  |
| 1717 | Lack of aromatisation of the 3-keto-4-ene metabolite of tibolone to an estrogenic derivative. <b>2006</b> , 71, 639-46   | 6   |
| 1716 | The role of xenoestrogenic compounds in the development of breast cancer. <b>2006</b> , 27, 447-54   | 15  |
| 1715 | Breast cancer. <b>2006</b> , 1, 187-210  | 2   |
| 1714 | "Are My Bones Normal Doctor?" The Role of Technology in Understanding and Communicating Health Risks for Midlife Women. <b>2006</b> , 11, 1-16   | 5   |
| 1713 | . <b>2006</b> ,  | 21  |
| 1712 | Familial Breast Cancer, Prevention, Risk Factors and Genetics [Highlights from the San Antonio Breast Cancer Symposium (SABCS) Poster Presentations. <b>2006</b> , 1, 103-106                    |     |
| 1711 | [Breast histologic changes in female rats treated with sex steroids]. <b>2006</b> , 52, 369-74   | 5   |
| 1710 | Selective estrogen receptor modulators (SERMS). <b>2006</b> , 50, 720-34   | 18  |

|      |  |     |
|------|--|-----|
| 1709 | Lifetime reproductive and anthropometric risk factors for breast cancer in postmenopausal women. <b>2005</b> , 24, 17-35   | 81  |
| 1708 | Hormonal effects on the mammary gland of postmenopausal nonhuman primates. <b>2005</b> , 24, 59-70   | 16  |
| 1707 | A prospective study of female hormone use and breast cancer among black women. <b>2006</b> , 166, 760-5  | 23  |
| 1706 | The prenylflavonoid isoxanthohumol from hops ( <i>Humulus lupulus</i> L.) is activated into the potent phytoestrogen 8-prenylnaringenin in vitro and in the human intestine. <b>2006</b> , 136, 1862-7 | 174 |
| 1705 | Raloxifene reduces fractures in postmenopausal women with osteoporosis. <b>2006</b> , 443, 48-54   | 19  |
| 1704 | Use of the Foreign Studies: Transposition of the Results, Prediction of the Therapeutic Effects in the French Population, Modelling of the Public Health Interest. <b>2006</b> , 61, 491-9             | 2   |
| 1703 | [Not Available]. <b>2006</b> , 61, 481-9   | 2   |
| 1702 | Estradiol and phytoestrogens differently influence the rodent postmenopausal mammary gland. <b>2006</b> , 13, 72-9   | 17  |
| 1701 | Hormone therapy and breast cancer risk: trumping fear with facts. <b>2006</b> , 13, 160-3  | 7   |
| 1700 | Morphologic changes induced by oral long-term treatment with 8-prenylnaringenin in the uterus, vagina, and mammary gland of castrated rats. <b>2006</b> , 13, 669-77                                   | 25  |
| 1699 | Breast cancer risk in postmenopausal women using estrogen-only therapy. <b>2006</b> , 108, 1354-60   | 109 |
| 1698 | Notions d'pidmiologie utiles en dermatologie. <b>2006</b> , 1, 1-9   |     |
| 1697 | Hormones and breast cancer: should practice be changed?. <b>2006</b> , 108, 1352-3   | 4   |
| 1696 | The role of phytochemicals in menopause: a new actor on the scene of alternative treatment options. <b>2006</b> , 13, 724-6  |     |
| 1695 | Bibliography. Current world literature. Gynecologic cancer. <b>2006</b> , 18, 76-81  |     |
| 1694 | Premature ovarian failure. <b>2006</b> , 18, 418-26  | 40  |
| 1693 | Hormone therapy and breast cancer: what factors modify the association?. <b>2006</b> , 13, 178-84  | 13  |
| 1692 | Effects of tibolone on estrogen biosynthesis in the mammary tissue of postmenopausal monkeys. <b>2006</b> , 13, 232-40   | 11  |

|      |  |     |
|------|--|-----|
| 1691 | Attempt to reduce the progestogen component in hormone therapy. <b>2006</b> , 13, 538; author reply 538  | 0   |
| 1690 | The selective estrogen receptor-beta agonist biochanin A shows vasculoprotective effects without uterotrophic activity. <b>2006</b> , 13, 489-99   | 25  |
| 1689 | Efficacy and safety of a special extract of <i>Rheum rhaponticum</i> (ERr 731) in perimenopausal women with climacteric complaints: a 12-week randomized, double-blind, placebo-controlled trial. <b>2006</b> , 13, 744-59 | 44  |
| 1688 | American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of menopause. <b>2006</b> , 12, 315-37  | 54  |
| 1687 | Breast cancer risk associated with different HRT formulations: a register-based case-control study. <b>2006</b> , 6, 13  | 13  |
| 1686 | Estimation of time-dependent rate ratios in case-control studies: comparison of two approaches for exposure assessment. <b>2006</b> , 15, 304-16   | 5   |
| 1685 | Influence of hormone replacement therapy on the accuracy of screening mammography. <b>2006</b> , 12, 154-8   | 7   |
| 1684 | Effects of hormone replacement therapy regimens on mammographic breast density: the role of progestins. <b>2006</b> , 32, 305-8  | 21  |
| 1683 | Prophylactic salpingo-oophorectomy in 51 women with familial breast-ovarian cancer: importance of fallopian tube dysplasia. <b>2006</b> , 16, 183-8  | 24  |
| 1682 | Endocrine Treatment and Prevention of Breast and Gynecological Cancers Vth International Symposium of the Flemish Gynecological Oncology Group, January 26-28, 2006. <b>2006</b> , 16 Suppl 2, 479-91                      | 2   |
| 1681 | Exogenous steroids for menopausal symptoms and breast/endometrial cancer risk. <b>2006</b> , 16 Suppl 2, 494-6   | 6   |
| 1680 | Effects of 17beta-estradiol, progesterone, synthetic progestins, tibolone, and raloxifene on vascular endothelial growth factor and Thrombospondin-1 messenger RNA in breast cancer cells. <b>2006</b> , 16 Suppl 2, 560-3 | 14  |
| 1679 | The risk of breast, endometrial and ovarian cancer in users of hormonal preparations. <b>2006</b> , 98, 288-96   | 34  |
| 1678 | Pharmacokinetics and systemic endocrine effects of the phyto-oestrogen 8-prenylnaringenin after single oral doses to postmenopausal women. <b>2006</b> , 62, 288-96  | 81  |
| 1677 | Breast cancer, oestrogens and environmental pollutants: a re-evaluation from a mixture perspective. <b>2006</b> , 29, 193-8  | 48  |
| 1676 | Hormone replacement therapy and cataract: a population-based case-control study. <b>2006</b> , 20, 417-22  | 24  |
| 1675 | Clinical management of BRCA1 and BRCA2 mutation carriers. <b>2006</b> , 25, 5825-31  | 69  |
| 1674 | Ovarian cancer. <b>2006</b> , 60, 159-79   | 159 |

|      |   |     |
|------|---|-----|
| 1673 | Menopause: a review on the role of oxygen stress and favorable effects of dietary antioxidants. <b>2006</b> , 42, 289-306                                   | 95  |
| 1672 | Hormone replacement therapy in breast cancer survivors. <b>2006</b> , 1092, 349-60  | 8   |
| 1671 | An alternative approach to the menopause. <b>2006</b> , 8, 96-102   | 2   |
| 1670 | Complementary therapies in menopause management. <b>2006</b> , 17, 50-56  |     |
| 1669 | Population-based mammography screening and breast cancer incidence in New South Wales, Australia. <b>2006</b> , 17, 153-60                                  | 15  |
| 1668 | Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women. <b>2006</b> , 24, 314-8                               | 69  |
| 1667 | Estradiol increases VEGF in human breast studied by whole-tissue culture. <b>2006</b> , 325, 245-51   | 28  |
| 1666 | Early breast cancer. <b>2006</b> , 11, 108-19   | 17  |
| 1665 | Traitement hormonal de la mñopause et cancer du sein: quâ€n est-il rllement?. <b>2006</b> , 8, 206-210   |     |
| 1664 | Lifestyle interventions to prevent osteoporotic fractures: a systematic review. <b>2006</b> , 17, 20-8  | 40  |
| 1663 | At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis. <b>2006</b> , 17, 1459-71 | 103 |
| 1662 | Effect of clinical trial publicity on HRT prescribing in Ireland. <b>2006</b> , 62, 307-10  | 33  |
| 1661 | Hot flushes in breast cancer patients. <b>2006</b> , 57, 63-77  | 50  |
| 1660 | Estrogenic effects of a methanol extract of the fruit of Brenania brieyi de Wild (Rubiaceae). <b>2006</b> , 61, 86-89                                       | 1   |
| 1659 | Menopause hormonal therapy from the urologist's perspective. <b>2006</b> , 7, 1-3   | 5   |
| 1658 | Opvliegers. <b>2006</b> , 49, 951-956   |     |
| 1657 | HRT: have we changed?. <b>2006</b> , 175, 58-61   |     |
| 1656 | [Models of disease in the developed world]. <b>2006</b> , 20 Suppl 1, 2-9   | 2   |

|      |  |     |
|------|--|-----|
| 1655 | The effect of lifestyle factors on gynaecological cancer. <b>2006</b> , 20, 227-51   | 52  |
| 1654 | Menopause: evidence-based practice. <b>2006</b> , 20, 799-839  | 44  |
| 1653 | Loyalties in clinical research on drugs: the case of hormone replacement therapy. <b>2006</b> , 63, 540-51   | 6   |
| 1652 | Health professionals, their medical interventions and uncertainty: a study focusing on women at midlife. <b>2006</b> , 62, 1078-90   | 24  |
| 1651 | Drug delivery systems for hormone therapy. <b>2006</b> , 112, 1-14   | 57  |
| 1650 | Remarkable change in age-specific breast cancer incidence in the Swiss canton of Geneva and its possible relation with the use of hormone replacement therapy. <b>2006</b> , 6, 78   | 25  |
| 1649 | Hormone-replacement therapy influences gene expression profiles and is associated with breast-cancer prognosis: a cohort study. <b>2006</b> , 4, 16  | 40  |
| 1648 | Hypnosis in cancer care. <b>2006</b> , 23, 47-57   | 8   |
| 1647 | Epidemiology and the causes of breast cancer. <b>2006</b> , 118, 2373-8  | 87  |
| 1646 | Cancer risk among patients with multiple sclerosis: a population-based register study. <b>2006</b> , 118, 979-84   | 99  |
| 1645 | Postmenopausal hormone therapy and breast cancer risk: the Multiethnic Cohort. <b>2006</b> , 118, 1285-91  | 49  |
| 1644 | Obesity, hormone therapy, estrogen metabolism and risk of postmenopausal breast cancer. <b>2006</b> , 118, 1292-301  | 33  |
| 1643 | Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. <b>2006</b> , 118, 1481-95 | 273 |
| 1642 | Estradiol and its metabolites 4-hydroxyestradiol and 2-hydroxyestradiol induce mutations in human breast epithelial cells. <b>2006</b> , 118, 1862-8   | 95  |
| 1641 | Development in incidence of breast cancer in non-screened Danish women, 1973-2002--a population-based study. <b>2006</b> , 118, 2366-9   | 10  |
| 1640 | Use of hormone therapy and risk of breast cancer detected at screening and between mammographic screens. <b>2006</b> , 118, 3112-7   | 29  |
| 1639 | Differential response to phytoestrogens in endocrine sensitive and resistant breast cancer cells in vitro. <b>2006</b> , 119, 515-21   | 37  |
| 1638 | Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women. <b>2006</b> , 166, 1483-9  | 106 |

|      |   |     |
|------|---|-----|
| 1637 | Unopposed estrogen therapy and the risk of invasive breast cancer. <b>2006</b> , 166, 1027-32   | 167 |
| 1636 | [The benefits and risks of hormonal replacement therapy--an update]. <b>2006</b> , 46, 166-73   | 0   |
| 1635 | [Hormone replacement therapy for internal risk patients]. <b>2006</b> , 46, 174-90  | 5   |
| 1634 | Screening for breast cancer. <b>2006</b> , 332, 499-500   | 4   |
| 1633 | The association of oestrogen receptor alpha-haplotypes with cardiovascular risk factors in the British Women's Heart and Health Study. <b>2006</b> , 27, 1597-604                                   | 28  |
| 1632 | HRT, osteoporosis and regulatory authorities Quis custodiet ipsos custodes?. <b>2006</b> , 21, 1668-71  | 23  |
| 1631 | Current breast cancer risks of hormone replacement therapy in postmenopausal women. <b>2006</b> , 7, 2455-63  | 6   |
| 1630 | Mehr Risiken als Nutzen? - Hormonersatztherapie in der Menopause. <b>2006</b> , 35, 24-27   |     |
| 1629 | The growth inhibitory activity of the Cimicifuga racemosa extract Ze 450 is mediated through estrogen and progesterone receptors-independent pathways. <b>2006</b> , 72, 317-23                     | 16  |
| 1628 | Effects of long-term treatment with resveratrol and subcutaneous and oral estradiol administration on the pituitary-thyroid-axis. <b>2006</b> , 114, 82-90  | 19  |
| 1627 | Serum lipoprotein(a) dynamics before/after menopause and long-term effects of hormone replacement therapy on lipoprotein(a) levels in middle-aged and older Japanese women. <b>2006</b> , 38, 581-6 | 31  |
| 1626 | Clinical evaluation of women presenting with low libido and determination of whether androgen therapy might be appropriate. <b>2006</b> , 24, 86-96   |     |
| 1625 | Influence of menopausal status and use of hormone replacement therapy on radiation dose from mammography in routine breast screening. <b>2006</b> , 79, 597-602                                     | 0   |
| 1624 | Tibolone and breast cancer. <b>2006</b> , 82, 658-62  | 5   |
| 1623 | Combined effects of physical activity, dietary isoflavones and 17beta-estradiol on movement drive, body weight and bone mineral density in ovariectomized female rats. <b>2006</b> , 72, 484-7      | 35  |
| 1622 | Endometrial safety, overall safety and tolerability of transdermal continuous combined hormone replacement therapy over 96 weeks: a randomized open-label study. <b>2006</b> , 9, 368-79            | 13  |
| 1621 | Addressing the soy and breast cancer relationship: review, commentary, and workshop proceedings. <b>2006</b> , 98, 1275-84  | 232 |
| 1620 | Estrogen receptors: molecular interactions, virtual screening and future prospects. <b>2006</b> , 6, 217-43   | 27  |

|      |  |     |
|------|--|-----|
| 1619 | Medicolegal pitfalls of prescribing hormone replacement therapy. <b>2006</b> , 12, 34-5  | 1   |
| 1618 | Reducing the problems of the progestogen. <b>2006</b> , 9, 241-3   | 3   |
| 1617 | A study of women on long-term hormone replacement therapy and their attitude to suggested cessation. <b>2006</b> , 9, 459-63                                       | 14  |
| 1616 | Is HRT justified for symptom management in women at higher risk of developing breast cancer?. <b>2006</b> , 9, 404-15  | 12  |
| 1615 | Risk communication in consultations about hormone therapy in the menopause: concordance in risk assessment and framing due to the context. <b>2006</b> , 9, 347-54 | 7   |
| 1614 | Screening in women's health, with emphasis on fetal Down's syndrome, breast cancer and osteoporosis. <b>2006</b> , 12, 499-512                                     | 7   |
| 1613 | Hormone replacement therapy and mortality in 52- to 70-year-old women: the Kuopio Osteoporosis Risk Factor and Prevention Study. <b>2006</b> , 154, 101-7          | 16  |
| 1612 | Risk of brain tumors associated with exposure to exogenous female sex hormones. <b>2006</b> , 164, 629-36  | 118 |
| 1611 | The agreement between self-reported cervical smear abnormalities and screening programme records. <b>2006</b> , 13, 72-5   | 11  |
| 1610 | Meta- and pooled analyses of the cytochrome P-450 1B1 Val432Leu polymorphism and breast cancer: a HuGE-GSEC review. <b>2007</b> , 165, 115-25                      | 68  |
| 1609 | Brittle bones: ageing or threat of disease exploring women's cultural models of osteoporosis. <b>2006</b> , 34, 320-6  | 22  |
| 1608 | Hormone replacement therapy and acute myocardial infarction: a large observational study exploring the influence of age. <b>2006</b> , 35, 731-8                   | 12  |
| 1607 | Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. <b>2006</b> , 295, 1647-57            | 410 |
| 1606 | Hyperprolactinaemia as an adverse effect in regulatory and clinical toxicology: role in breast and prostate cancer. <b>2006</b> , 25, 395-404                      | 32  |
| 1605 | Dehydroepiandrosterone sulfate is neuroprotective when administered either before or after injury in a focal cortical cold lesion model. <b>2006</b> , 147, 683-6  | 28  |
| 1604 | Effect of tibolone therapy on lipids and coagulation indices. <b>2006</b> , 44, 1498-9   | 4   |
| 1603 | Sexuality and the menopause. <b>2006</b> , 12, 149-52  | 15  |
| 1602 | Mammographic density: a hormonally responsive risk factor for breast cancer. <b>2006</b> , 12, 186-93  | 55  |



|      |  |     |
|------|--|-----|
| 1601 | Removing organs "just in case"--is prophylactic removal of the ovaries a good thing?. <b>2006</b> , 60, 186-7  | 6   |
| 1600 | Effects of long-term treatment with resveratrol and subcutaneous and oral estradiol administration on pituitary function in rats. <b>2006</b> , 189, 77-88                                   | 32  |
| 1599 | Use of oral conjugated estrogen alone and risk of breast cancer. <b>2007</b> , 165, 524-9  | 21  |
| 1598 | Subject Index to Volume 1. <b>2006</b> , 2, 3-7  | 2   |
| 1597 | Hormone Replacement Therapy in Rheumatoid Arthritis. <b>2006</b> , 2, 251-260  | 2   |
| 1596 | Oestrogen-A Protective Factor in Schizophrenia?. <b>2006</b> , 2, 339-352  | 7   |
| 1595 | TReP-132 is a novel progesterone receptor coactivator required for the inhibition of breast cancer cell growth and enhancement of differentiation by progesterone. <b>2006</b> , 26, 7632-44 | 25  |
| 1594 | Factors associated with the use of complementary medicine and non-pharmacological interventions in symptomatic menopausal women. <b>2006</b> , 9, 336-46                                     | 72  |
| 1593 | Are possible risk factors for differentiated thyroid cancer of prognostic importance?. <b>2006</b> , 16, 659-66  | 3   |
| 1592 | The influence of premenopausal hormones on severity of climacteric symptoms and use of HRT. <b>2006</b> , 9, 135-45  | 8   |
| 1591 | Breast cancer in postmenopausal women with and without hormone replacement therapy: preliminary results of the MISSION study. <b>2006</b> , 22, 423-31                                       | 9   |
| 1590 | Web chatter before and after the Women's Health Initiative results: a content analysis of on-line menopause message boards. <b>2006</b> , 11, 133-47   | 15  |
| 1589 | Pills, Power, People: Sociological Understandings of the Pharmaceutical Industry. <b>2006</b> , 40, 297-314  | 60  |
| 1588 | Exercise for vasomotor menopausal symptoms. <b>2006</b> ,  | 2   |
| 1587 | New progestagens for contraceptive use. <b>2006</b> , 12, 169-78   | 235 |
| 1586 | Risk factors for the incidence of endometrial cancer according to the aggressiveness of disease. <b>2006</b> , 164, 56-62  | 37  |
| 1585 | Mammographic density as a surrogate marker for the effects of hormone therapy on risk of breast cancer. <b>2006</b> , 15, 961-6  | 59  |
| 1584 | Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. <b>2007</b> , 99, 1152-61                             | 318 |

|      |   |      |
|------|---|------|
| 1583 | Exercise for vasomotor menopausal symptoms. <b>2007</b> , CD006108  | 27   |
| 1582 | Effect of tibolone on breast cancer cell proliferation in postmenopausal ER+ patients: results from STEM trial. <b>2007</b> , 13, 4185-90   | 17   |
| 1581 | Low-dose tamoxifen for combination hormone replacement therapy users. <b>2007</b> , 25, 4162-4  | 3    |
| 1580 | Improved survival rate for women with interval breast cancer - results from the breast cancer screening programme in MalmöSweden 1976-1999. <b>2007</b> , 14, 138-43  | 28   |
| 1579 | A prospective study of postmenopausal hormone use and ovarian cancer risk. <b>2007</b> , 96, 151-6  | 73   |
| 1578 | Hormone replacement therapy, body mass, and the risk of colorectal cancer among postmenopausal women from Germany. <b>2007</b> , 97, 1486-92  | 22   |
| 1577 | Oral progestagens before menopause and breast cancer risk. <b>2007</b> , 96, 841-4  | 26   |
| 1576 | Gender differences in colorectal cancer: implications for age at initiation of screening. <b>2007</b> , 96, 828-31  | 152  |
| 1575 | Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis. <b>2007</b> , 23, 398-403                 | 18   |
| 1574 | Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. <b>2007</b> , 4, e297   | 1900 |
| 1573 | 'Feeling hot, hot, hot': is there a role for exercise in the management of vasomotor and other menopausal symptoms?. <b>2007</b> , 33, 143-5  | 3    |
| 1572 | Hormone therapy and breast cancer risk. <b>2007</b> , 10 Suppl 2, 54-61   | 24   |
| 1571 | False alarm: postmenopausal hormone therapy and ovarian cancer. <b>2007</b> , 10, 466-9, discussion 469-70  | 7    |
| 1570 | Recent epidemiological evidence relevant to the clinical management of the menopause. <b>2007</b> , 10 Suppl 2, 2-15  | 22   |
| 1569 | Low dose of transdermal estradiol gel for treatment of symptomatic postmenopausal women: a randomized controlled trial. <b>2007</b> , 109, 588-96   | 49   |
| 1568 | Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation. <b>2007</b> , 29, 45-60 | 33   |
| 1567 | Das klimakterische Syndrom der Patientin mit Mammakarzinom: Risiken und Nutzen der Behandlungsoptionen. <b>2007</b> , 67, R53-R72   |      |
| 1566 | Weniger Hormonersatztherapie, weniger Brustkrebs in Deutschland?. <b>2007</b> , 67, 1217-1221   | 6    |

1565 Update Hormonersatz: Bioidentische Hormongaben sind risikoarm. **2007**, 5, 16-21

1564 Risk of malignancy in patients with schizophrenia or bipolar disorder: nested case-control study. **2007**, 64, 1368-76 115

1563 Activation of estrogen receptor-mediated gene transcription by the equine estrogen metabolite, 4-methoxyequilenin, in human breast cancer cells. **2007**, 148, 4793-802 13

1562 Phosphorylation-dependent antagonism of sumoylation derepresses progesterone receptor action in breast cancer cells. **2007**, 21, 2890-906 92

1561 Effect of premature menopause on sexuality. **2007**, 3, 455-74 9

1560 Sleep and menopause. **2007**, 3, 99-106 8

1559 Successful Translation Research with Selective Oestrogen Receptor Modulators to Treat and Prevent Breast Cancer. **2007**, 67, 443-450

1558 [The influence of published studies and position papers on the prescription of peri- and post-menopausal hormone therapy]. **2007**, 69, 379-84 2

1557 Menopausal hormone therapy for vasomotor symptoms: balancing the risks and benefits with ultra-low doses of estrogen. **2007**, 16, 2005-20 11

1556 Modifiable risk factors for breast cancer recurrence: what can we tell survivors?. **2007**, 16, 177-90 26

1555 A comparison of different methods for including 'age at menopause' in analyses of the association between hormone replacement therapy use and breast cancer. **2007**, 33, 11-6 10

1554 Age and menopausal effects of hormonal birth control and hormone replacement therapy in relation to breast cancer risk. **2007**, 165, 1187-98 37

1553 Transdermal natural progesterone cream for postmenopausal women: inconsistent data and complex pharmacokinetics. **2007**, 27, 655-9 12

1552 Tamoxifen or raloxifene for breast cancer chemoprevention: a tale of two choices--point. **2007**, 16, 2207-9 16

1551 Regional changes in hormone therapy use and breast cancer incidence in California from 2001 to 2004. **2007**, 25, 3437-9 55

1550 Risk of breast cancer after exposure to fertility drugs: results from a large Danish cohort study. **2007**, 16, 1400-7 64

1549 The effect of mammographic screening and hormone replacement therapy use on breast cancer incidence in England and Wales. **2007**, 16, 2257-61 34

1548 Changes in practice since the publication in 2007 of further results from the Women's Health Initiative and the Million Women Study. **2007**, 13, 141-3 4

|      |   |     |
|------|---|-----|
| 1547 | Continuous combined hormone replacement therapy relieves climacteric symptoms and improves health-related quality of life in early postmenopausal women. <b>2007</b> , 13, 116-23   | 14  |
| 1546 | Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Src-dependent sustained activation of Erk1/2 mitogen-activated protein kinase in breast cancer cells. <b>2007</b> , 27, 466-80 | 173 |
| 1545 | Hormones and breast cancer: what's the story?. <b>2007</b> , 16, 1697-9   | 0   |
| 1544 | The position of the Regulatory Authorities. <b>2007</b> , 10 Suppl 2, 121-4   |     |
| 1543 | Hormone replacement therapy and female malignancy: what has the Million Women Study added to our knowledge?. <b>2007</b> , 33, 237-43   |     |
| 1542 | Neutral effect of ultra-low-dose continuous combined estradiol and norethisterone acetate on mammographic breast density. <b>2007</b> , 10, 249-56  | 25  |
| 1541 | Testosterone addition during menopausal hormone therapy: effects on mammographic breast density. <b>2007</b> , 10, 155-63   | 29  |
| 1540 | Postmenopausal hormone therapy and changes in mammographic density. <b>2007</b> , 25, 1323-8  | 30  |
| 1539 | Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. <b>2007</b> , 99, 272-82   | 437 |
| 1538 | Hormone replacement therapy and cancers: the biological roles of estrogen and progestin in tumorigenesis are different between the endometrium and breast. <b>2007</b> , 212, 1-12  | 36  |
| 1537 | Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women: a randomized trial. <b>2007</b> , 146, 839-47   | 216 |
| 1536 | Comparative pathology of mammary gland cancers in domestic and wild animals. <b>2007</b> , 28, 7-21   | 72  |
| 1535 | Oral intake of soy isoflavone aglycone improves the aged skin of adult women. <b>2007</b> , 53, 57-62   | 49  |
| 1534 | Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. <b>2007</b> , 147, W163-94  | 765 |
| 1533 | Opinion of the Scientific Panel on contaminants in the food chain (CONTAM) related to hormone residues in bovine meat and meat products. <b>2007</b> , 5, 510   | 7   |
| 1532 | Decline in use of hormone therapy among postmenopausal women in the United Kingdom. <b>2007</b> , 14, 462-7   | 30  |
| 1531 | Women's health during mid-life survey: the use of complementary and alternative medicine by symptomatic women transitioning through menopause in Sydney. <b>2007</b> , 14, 397-403  | 65  |
| 1530 | Levonorgestrel-releasing intrauterine system as an adjunct to estrogen for the treatment of menopausal symptoms--a review. <b>2007</b> , 14, 550-4  | 3   |

|      |   |      |
|------|---|------|
| 1529 | Options for hormone therapy in women who have had a hysterectomy. <b>2007</b> , 14, 592-7; quiz 598-9   | 15   |
| 1528 | An isopropanolic extract of black cohosh does not increase mammographic breast density or breast cell proliferation in postmenopausal women. <b>2007</b> , 14, 89-96  | 40   |
| 1527 | Testosterone inhibits estrogen/progestogen-induced breast cell proliferation in postmenopausal women. <b>2007</b> , 14, 183-90  | 81   |
| 1526 | Effect of ultra-low-dose transdermal estradiol on breast density in postmenopausal women. <b>2007</b> , 14, 391-6   | 15   |
| 1525 | Preferential prescribing of tibolone and combined estrogen plus progestogen therapy in postmenopausal women. <b>2007</b> , 14, 518-27   | 7    |
| 1524 | Tamoxifen or aromatase inhibitors in breast cancer: efficacy and safety. <b>2007</b> , 107, 240-56  | 1    |
| 1523 | Estrogen affects post-menopausal women differently than estrogen plus progestin replacement therapy. <b>2007</b> , 22, 1769-77  | 44   |
| 1522 | Should testosterone be added to estrogen-progestin therapy for breast protection?. <b>2007</b> , 14, 159-62   | 4    |
| 1521 | Why epidemiologists cannot afford to ignore poverty. <b>2007</b> , 18, 658-63   | 114  |
| 1520 | Flexible estrogen receptor modulators: synthesis, biochemistry and molecular modeling studies for 3-benzyl-4,6-diarylhex-3-ene and 3,4,6-triarylhex-3-ene derivatives. <b>2007</b> , 3, 135-55  | 5    |
| 1519 | Historical Perspectives in Postmenopausal Hormone Therapy: Defining the Right Dose and Duration. <b>2007</b> , 82, 219-226  | 3    |
| 1518 | Mhopause. <b>2007</b> , 2, 1-20   | 6    |
| 1517 | Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. <b>2007</b> , 18, 805-35  | 1174 |
| 1516 | Linkage of progestin and epidermal growth factor signaling: phosphorylation of progesterone receptors mediates transcriptional hypersensitivity and increased ligand-independent breast cancer cell growth. <b>2007</b> , 72, 188-201 | 71   |
| 1515 | Test-retest reliability of self-reported reproductive and lifestyle data in the context of a German case-control study on breast cancer and postmenopausal hormone therapy. <b>2007</b> , 17, 993-8                                   | 30   |
| 1514 | Are low doses of enoxaparin with aspirin sufficient to guarantee good gestational outcome in women with heterozygote factor V Leiden mutation?. <b>2007</b> , 130, 138-40   |      |
| 1513 | Pharmacological doses of the natural phyto-SERM DT56a (Femarelle) have no effect on MCF-7 human breast cancer cell-line. <b>2007</b> , 130, 140-1   | 6    |
| 1512 | The multitude and diversity of environmental carcinogens. <b>2007</b> , 105, 414-29   | 167  |

|      |   |     |
|------|---|-----|
| 1511 | Tibolone histology of the endometrium and breast endpoints study: design of the trial and endometrial histology at baseline in postmenopausal women. <b>2007</b> , 88, 866-78               | 16  |
| 1510 | Safety of testosterone treatment in postmenopausal women. <b>2007</b> , 88, 1-17  | 92  |
| 1509 | Therapeutic options for the management of hot flashes in breast cancer survivors: an evidence-based review. <b>2007</b> , 29, 230-41  | 85  |
| 1508 | The influence of HRT on technical recall in the UK Breast Screening Programme: are pain, compression force, and compressed breast thickness contributing factors?. <b>2007</b> , 62, 439-46 | 3   |
| 1507 | Observation versus intervention in the evaluation of drugs: the story of hormone replacement therapy. <b>2007</b> , 330, 347-55   | 2   |
| 1506 | The effects of sex steroid replacement therapy on an expanded panel of IGF-related peptides. <b>2007</b> , 17, 210-9  | 5   |
| 1505 | [Hormone replacement therapy in postmenopausal women: all the treatments are not the same]. <b>2007</b> , 35, 388-97  | 6   |
| 1504 | [Hormone replacement therapy in postmenopausal women: all the treatments are not the same. Do all the patients have the same characteristics?]. <b>2007</b> , 35, 502-3                     | 0   |
| 1503 | Lifestyle-related factors and environmental agents causing cancer: an overview. <b>2007</b> , 61, 640-58  | 195 |
| 1502 | The bone-protective effect of the phytoestrogen genistein is mediated via ER alpha-dependent mechanisms and strongly enhanced by physical activity. <b>2007</b> , 40, 1529-35               | 68  |
| 1501 | Novel perspectives for progesterone in hormone replacement therapy, with special reference to the nervous system. <b>2007</b> , 28, 387-439   | 138 |
| 1500 | A prospective, randomized, double-blind, placebo-controlled study on the influence of a hormone replacement therapy on skin aging in postmenopausal women. <b>2007</b> , 10, 320-34         | 59  |
| 1499 | Effects of the chemically synthesized flavanone 7-(O-prenyl)naringenin-4'-acetate on the estrogen signaling pathway in vivo and in vitro. <b>2007</b> , 107, 114-9                          | 11  |
| 1498 | Progesterone regulates catechol-O-methyl transferase gene expression in breast cancer cells: distinct effect of progesterone receptor isoforms. <b>2007</b> , 107, 253-61                   | 21  |
| 1497 | Activation of estrogen receptor-beta by a special extract of Rheum raphonticum (ERr 731), its aglycones and structurally related compounds. <b>2007</b> , 107, 191-201                      | 39  |
| 1496 | Asparagus racemosus--ethnopharmacological evaluation and conservation needs. <b>2007</b> , 110, 1-15  | 120 |
| 1495 | [Breast cancer: reasons for the continuous increase in incidence]. <b>2007</b> , 36, 312-4  |     |
| 1494 | Attitudes towards the menopause and hormone therapy over the turn of the century. <b>2007</b> , 56, 12-20   | 14  |

|      |  |    |     |
|------|--|----|-----|
| 1493 | The attitude of gynecologists in S̃o Paulo, Brazil 3 years after the Women’s Health Initiative study. <b>2007</b> , 56, 129-41   |    | 25  |
| 1492 | Efficacy on menopausal neurovegetative symptoms and some plasma lipids blood levels of an herbal product containing isoflavones and other plant extracts. <b>2007</b> , 56, 249-56   |    | 20  |
| 1491 | Differential effects of progestogens, by type and regimen, on estrogen-metabolizing enzymes in human breast cancer cells. <b>2007</b> , 56, 142-52   |    | 23  |
| 1490 | Ethanollic extracts of black cohosh ( <i>Actaea racemosa</i> ) inhibit growth and oestradiol synthesis from oestrone sulphate in breast cancer cells. <b>2007</b> , 56, 359-67   |    | 23  |
| 1489 | Use of hormone replacement therapy (HRT) among women aged 45-64 years in the German EPIC-cohorts. <b>2007</b> , 56, 436-46   |    | 8   |
| 1488 | Endometrial safety after 5 years of continuous combined transdermal estrogen and intrauterine levonorgestrel delivery for postmenopausal hormone substitution. <b>2007</b> , 57, 205-9   |    | 18  |
| 1487 | The problems with some epidemiological studies. <b>2007</b> , 57, 11-5   |    | 2   |
| 1486 | Do journals have a publication bias?. <b>2007</b> , 57, 16-9   |    | 1   |
| 1485 | Androgens and the breast. <b>2007</b> , 57, 47-9   |    | 19  |
| 1484 | Effects of black cohosh on estrogen biosynthesis in normal breast tissue in vitro. <b>2007</b> , 57, 382-91  |    | 19  |
| 1483 | Effects of tibolone and raloxifene on health-related quality of life and sexual function. <b>2007</b> , 58, 164-73   |    | 15  |
| 1482 | Hormone therapy use and prescription durations of menopausal women in Taiwan: a 5 years’ National Cohort study. <b>2007</b> , 58, 259-68   |    | 14  |
| 1481 | Good agreement between physician and self-reported hormone therapy data in a case-control study. <b>2007</b> , 60, 1280-7  |    | 17  |
| 1480 | Ovarian cancer and hormone replacement therapy in the Million Women Study. <i>Lancet, The</i> , <b>2007</b> , 369, 1703-10   | 40 | 342 |
| 1479 | Ovarian cancer and HRT in the Million Women Study. <i>Lancet, The</i> , <b>2007</b> , 369, 1667-8  | 40 | 6   |
| 1478 | Hypopituitarism. <i>Lancet, The</i> , <b>2007</b> , 369, 1461-1470   | 40 | 270 |
| 1477 | Clinical update: new treatments for hot flushes. <i>Lancet, The</i> , <b>2007</b> , 369, 2062-4  | 40 | 23  |
| 1476 | Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. <i>Lancet, The</i> , <b>2007</b> , 370, 1609-21 | 40 | 340 |

|      |  |     |
|------|--|-----|
| 1475 | Effects of tibolone on the breast of postmenopausal women. <b>2007</b> , 46, 121-6   | 9   |
| 1474 | Standard and low-dose hormone therapy for postmenopausal women--focus on the breast. <b>2007</b> , 46, 127-34  | 20  |
| 1473 | [Not Available]. <b>2007</b> , 3 Suppl 1, S26-32   | 2   |
| 1472 | Premature ovarian failure. <b>2007</b> , 68, 196-202   | 86  |
| 1471 | The protective side of progesterone. <b>2007</b> , 9, 402  | 1   |
| 1470 | Recent breast cancer trends among Asian/Pacific Islander, Hispanic, and African-American women in the US: changes by tumor subtype. <b>2007</b> , 9, R90   | 64  |
| 1469 | Breast cancer risk-assessment models. <b>2007</b> , 9, 213   | 90  |
| 1468 | Decline in breast cancer incidence due to removal of promoter: combination estrogen plus progestin. <b>2007</b> , 9, 108   | 21  |
| 1467 | Clinical Trials in Osteoporosis. <b>2007</b> ,   | 8   |
| 1466 | Variations on hormone replacement therapy: an answer to the 'one dose fits all' Women's Health Initiative study. <b>2007</b> , 23, 665-71  | 10  |
| 1465 | Differential effects of various progestogens on metabolic risk factors for breast cancer. <b>2007</b> , 23 Suppl 1, 22-31  | 3   |
| 1464 | The truth about hormone replacement therapy and breast cancer. <b>2007</b> , 2, 25-29  | 1   |
| 1463 | IMS updated recommendations on postmenopausal hormone therapy. <b>2007</b> , 10, 181-94  | 130 |
| 1462 | Can 19-nortestosterone derivatives be aromatized in the liver of adult humans? Are there clinical implications?. <b>2007</b> , 10, 344-53  | 19  |
| 1461 | Recent advances in the medical management of breast cancer: highlights from the 29th San Antonio Breast Cancer Conference San Antonio, TX, USA, 14-17 December 2007. <b>2007</b> , 8, 1179-88                          |     |
| 1460 | Estrogen and tibolone metabolite levels in blood and breast tissue of postmenopausal women recently diagnosed with early-stage breast cancer and treated with tibolone or placebo for 14 days. <b>2007</b> , 14, 151-9 | 6   |
| 1459 | Effects of acupuncture, applied relaxation, estrogens and placebo on hot flushes in postmenopausal women: an analysis of two prospective, parallel, randomized studies. <b>2007</b> , 10, 38-45                        | 42  |
| 1458 | Menopause: developing a rational treatment plan. <b>2007</b> , 23, 682-91  | 3   |



|      |   |     |
|------|---|-----|
| 1457 | Perceived risk of osteoporosis: restricted physical activities? Qualitative interview study with women in their sixties. <b>2007</b> , 25, 160-5  | 31  |
| 1456 | Breast cancer incidence and hormone replacement therapy: results from the MISSION study, prospective phase. <b>2007</b> , 23, 391-7   | 35  |
| 1455 | The HRT misuse and osteoporosis epidemic: a possible future scenario. <b>2007</b> , 10, 273-5   | 16  |
| 1454 | Italian position statement on hormone replacement therapy following the National Conference on Menopause and Hormone Replacement Therapy, Villa Tuscolana, Frascati (Rome), May 8-9, 2007. <b>2007</b> , 23, 436-44 | 5   |
| 1453 | Women's attitudes to hormone replacement therapy, alternative therapy and sexual health: a web-based survey. <b>2007</b> , 13, 79-83  | 48  |
| 1452 | Black cohosh does not exert an estrogenic effect on the breast. <b>2007</b> , 59, 269-77  | 30  |
| 1451 | New hormonal therapies and regimens in the postmenopause: routes of administration and timing of initiation. <b>2007</b> , 10, 358-70   | 14  |
| 1450 | Progestins and breast cancer. <b>2007</b> , 23 Suppl 1, 32-41   | 27  |
| 1449 | Evaluation of the phytoestrogenic activity of <i>Cyclopia genistoides</i> (honeybush) methanol extracts and relevant polyphenols. <b>2007</b> , 55, 4371-81   | 25  |
| 1448 | Hormonal replacement therapy (HRT) in postmenopause: a reappraisal. <b>2007</b> , 68, 241-50  | 13  |
| 1447 | Historical perspectives in postmenopausal hormone therapy: defining the right dose and duration. <b>2007</b> , 82, 219-26   | 7   |
| 1446 | Malicia sanitaria y prevención cuaternaria. <b>2007</b> , 104, 93-96  | 1   |
| 1445 | Long-term effects of ovulation-stimulating drugs on cancer risk. <b>2007</b> , 15, 38-44  | 54  |
| 1444 | Phytoestrogens for vasomotor menopausal symptoms. <b>2007</b> , CD001395  | 85  |
| 1443 | Breast response to menopausal hormone therapy--aspects on proliferation, apoptosis and mammographic density. <b>2007</b> , 39, 28-41  | 37  |
| 1442 | Tibolone: Selective Tissue Estrogen Activity Regulator Utilization in Postmenopausal Women. <b>2007</b> , 847-852   |     |
| 1441 | Microbial and dietary factors are associated with the equol producer phenotype in healthy postmenopausal women. <b>2007</b> , 137, 2242-6   | 101 |
| 1440 | Raloxifene. <b>2007</b> , 103-121   | 4   |

|      |  |     |
|------|--|-----|
| 1439 | Effects of chronic genistein treatment in mammary gland, uterus, and vagina. <b>2007</b> , 115 Suppl 1, 62-8   | 51  |
| 1438 | Management of women at increased risk for hereditary breast cancer. <b>2006</b> , 27, 51-67  | 13  |
| 1437 | HRT: a reappraisal of the risks and benefits. <b>2007</b> , 186, 643-6   | 19  |
| 1436 | Progesterone-action in the murine uterus and mammary gland requires steroid receptor coactivator 2: relevance to the human. <b>2007</b> , 12, 3640-7   | 11  |
| 1435 | Assessing the mammary gland of nonhuman primates: effects of endogenous hormones and exogenous hormonal agents and growth factors. <b>2007</b> , 80, 126-46  | 34  |
| 1434 | Increased expression of fatty acid synthase and progesterone receptor in early steps of human mammary carcinogenesis. <b>2007</b> , 120, 224-9   | 41  |
| 1433 | Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. <b>2007</b> , 120, 885-91 | 236 |
| 1432 | Different types of postmenopausal hormone therapy and mammographic density in Norwegian women. <b>2007</b> , 120, 880-4  | 21  |
| 1431 | Breast tumours following combined hormone replacement therapy express favourable prognostic factors. <b>2007</b> , 120, 2202-7   | 39  |
| 1430 | Hormone replacement therapy and breast cancer in former users of oral contraceptives--The Norwegian Women and Cancer study. <b>2007</b> , 121, 645-8   | 23  |
| 1429 | Bioavailability and urinary excretion of isoflavones in humans: effects of soy-based supplements formulation and equol production. <b>2007</b> , 43, 1488-94   | 37  |
| 1428 | Differences in menopausal hormone therapy use among women in Germany between 1998 and 2003. <b>2007</b> , 7, 19  | 26  |
| 1427 | The Women's international study of long-duration oestrogen after menopause (WISDOM): a randomised controlled trial. <b>2007</b> , 7, 2   | 31  |
| 1426 | The aged breast. <b>2007</b> , 211, 232-40   | 25  |
| 1425 | Prospective study of grapefruit intake and risk of breast cancer in postmenopausal women: the Multiethnic Cohort Study. <b>2007</b> , 97, 440-5  | 27  |
| 1424 | Beyond raloxifene for the prevention of osteoporosis and breast cancer. <b>2007</b> , 150, 3-4   | 12  |
| 1423 | Tibolone therapy in breast cancer survivors: a retrospective study. <b>2007</b> , 33, 68-73  | 1   |
| 1422 | Women's conception of the menopausal transition--a qualitative study. <b>2007</b> , 16, 509-17   | 23  |

|      |  |      |
|------|--|------|
| 1421 | Is hormone replacement therapy-related breast cancer more favorable? A case-control study. <b>2007</b> , 13, 496-500   | 6    |
| 1420 | Cost-effectiveness analysis of a quality-controlled mammography screening program from the Swiss statutory health-care perspective: quantitative assessment of the most influential factors. <b>2007</b> , 10, 42-53 | 11   |
| 1419 | Hormone replacement therapy use and variations in the risk of breast cancer. <b>2008</b> , 115, 169-75; discussion 175   | 64   |
| 1418 | The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer. <b>2007</b> , 61, 2051-63  | 118  |
| 1417 | Safety of tibolone in the treatment of vasomotor symptoms in breast cancer patients--design and baseline data 'LIBERATE' trial. <b>2007</b> , 16 Suppl 2, S182-9   | 12   |
| 1416 | Progesterone: therapeutic opportunities for neuroprotection and myelin repair. <b>2007</b> , 116, 77-106   | 198  |
| 1415 | Estrogenic effects of the ethyl-acetate extract of the stem bark of <i>Erythrina lysistemon</i> Hutch (Fabaceae). <b>2007</b> , 14, 222-6  | 9    |
| 1414 | Hormone replacement therapy. <b>2007</b> , 35, 529-532   | 2    |
| 1413 | Management of menopausal symptoms: the risks and benefits. <b>2007</b> , 18, 24-41   | 0    |
| 1412 | Estrogen receptors: how do they signal and what are their targets. <b>2007</b> , 87, 905-31  | 1266 |
| 1411 | Biotechnology of flavonoids and other phenylpropanoid-derived natural products. Part I: Chemical diversity, impacts on plant biology and human health. <b>2007</b> , 2, 1214-34                                      | 318  |
| 1410 | Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapy. <b>2007</b> , 196, 342.e1-9   | 29   |
| 1409 | Non-hormonal therapy of post-menopausal vasomotor symptoms: a structured evidence-based review. <b>2007</b> , 276, 463-9   | 73   |
| 1408 | Impact of recent studies on attitudes and use of hormone therapy among Scandinavian gynaecologists. <b>2007</b> , 86, 1490-5   | 13   |
| 1407 | Black cohosh and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized trial. <b>2007</b> , 24, 448-61   | 45   |
| 1406 | Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005. <b>2007</b> , 63, 843-9  | 69   |
| 1405 | Molecular analysis of human endometrium: short-term tibolone signaling differs significantly from estrogen and estrogen + progestagen signaling. <b>2007</b> , 85, 471-80  | 15   |
| 1404 | Do Finnish women using hormone replacement therapy need more information about risks. <b>2007</b> , 29, 635-40   | 12   |

|      |  |     |
|------|--|-----|
| 1403 | SERMs for the treatment and prevention of breast cancer. <b>2007</b> , 8, 229-39   | 63  |
| 1402 | Mucinous cystadenocarcinoma of the pancreas developing during hormone replacement therapy. <b>2007</b> , 52, 1326-8  | 12  |
| 1401 | Progesterone, progestins, pregnancy and breast cancer risk. <b>2007</b> , 103, 373-4   |     |
| 1400 | Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. <b>2008</b> , 107, 103-11                                      | 417 |
| 1399 | The discovery and mechanism of action of letrozole. <b>2007</b> , 105 Suppl 1, 7-17  | 135 |
| 1398 | Declines in breast cancer after the WHI: apparent impact of hormone therapy. <b>2007</b> , 18, 847-52  | 35  |
| 1397 | Cancers du sein. <b>2007</b> , 9, 593-644  | 13  |
| 1396 | Vrais et faux bñfices et risques des traitements hormonaux de la mhopause. <b>2007</b> , 2, 168-174  |     |
| 1395 | Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. <b>2008</b> , 107, 427-30   | 100 |
| 1394 | Breast cancer: a candidate gene approach across the estrogen metabolic pathway. <b>2008</b> , 108, 137-49  | 68  |
| 1393 | Differential effect of hormone therapy on E1S-sulfatase activity in non-malignant and cancerous breast cells in vitro. <b>2008</b> , 108, 363-74   | 10  |
| 1392 | Variations in breast cancer incidence per decade of life (Goiñbia, GO, Brazil): 16-year analysis. <b>2008</b> , 19, 681-7  | 12  |
| 1391 | Prvention des Mammakarzinoms. <b>2008</b> , 41, 490-499  |     |
| 1390 | Postmenopausale Hormontherapie und Mammakarzinomrisiko. <b>2008</b> , 41, 865-873  | 1   |
| 1389 | Trends in HRT and anti-osteoporosis medication prescribing in a European population after the WHI study. <b>2008</b> , 19, 1047-54   | 36  |
| 1388 | Effects of ginkgo biloba on in vitro osteoblast cells and ovariectomized rat osteoclast cells. <b>2008</b> , 31, 216-24  | 18  |
| 1387 | Rationale for low-dose systemic hormone replacement therapy and review of estradiol 0.5 mg/NETA 0.1 mg. <b>2008</b> , 25, 525-51   | 10  |
| 1386 | No increase of breast cancer incidence in Japanese women who received hormone replacement therapy: overview of a case-control study of breast cancer risk in Japan. <b>2008</b> , 13, 8-11 | 16  |

1385 Psychopharmaka in der Frauenheilkunde. **2008**, 6, 234-240

1384 Effects of raloxifene and hormone replacement therapy on serum Th2 and Th3 type cytokine concentrations in healthy postmenopausal women: a randomised controlled trial. **2008**, 277, 489-93 12

1383 The effect of clomiphene citrate on osteoporosis in ovariectomized rats. **2008**, 278, 107-14 9

1382 Impact of hormone replacement therapy on the histologic subtype of breast cancer. **2008**, 278, 443-9 4

1381 Hormone replacement therapy use and plasma levels of sex hormones in the Norwegian Women and Cancer postgenome cohort - a cross-sectional analysis. **2008**, 8, 1 45

1380 Study Protocol: effects of acupuncture on hot flushes in perimenopausal and postmenopausal women - a multicenter randomized clinical trial. **2008**, 9, 70 4

1379 Early life events and conditions and breast cancer risk: from epidemiology to etiology. **2008**, 122, 481-5 89

1378 HMG-CoA reductase expression in breast cancer is associated with a less aggressive phenotype and influenced by anthropometric factors. **2008**, 123, 1146-53 48

1377 Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy. **2008**, 123, 933-41 119

1376 When to promote, and when to avoid, a population perspective. **2008**, 45, 763-84 24

1375 Treatment of climacteric symptoms in Finland prior to the controversial reports on hormone therapy. **2008**, 87, 682-6 8

1374 OPG and sRANKL serum concentrations in osteopenic, postmenopausal women after 2-year genistein administration. **2008**, 23, 715-20 54

1373 Effects of lasofoxifene on the uterus, vagina, and breast in ovariectomized cynomolgus monkeys (*Macaca fascicularis*). **2008**, 199, 158.e1-8 11

1372 Hormone therapy, dilemmas, medical decisions. **2008**, 36, 73-88, 4 3

1371 Effects of genistein aglycone in osteoporotic, ovariectomized rats: a comparison with alendronate, raloxifene and oestradiol. **2008**, 155, 896-905 68

1370 Complexities in the estimation of overdiagnosis in breast cancer screening. **2008**, 99, 1176-8 61

1369 Differential impact of conventional and low-dose oral hormone therapy, tibolone and raloxifene on mammographic breast density, assessed by an automated quantitative method. **2008**, 115, 773-9 19

1368 Commentary on 'Hormone replacement therapy use and variations in the risk of breast cancer'. **2008**, 115, 918

|      |   |     |
|------|---|-----|
| 1367 | JSSM Guidelines for erectile dysfunction. <b>2008</b> , 15, 564-76  | 8   |
| 1366 | “The horror of this living decay” Women’s negotiation and resistance of medical discourses around menopause and midlife. <b>2008</b> , 31, 293-299                              | 25  |
| 1365 | Increased risk of second cancer among patients with ovarian borderline tumors. <b>2008</b> , 109, 210-4   | 12  |
| 1364 | Experiences of a long-term randomized controlled prevention trial in a maiden environment: Estonian Postmenopausal Hormone Therapy trial. <b>2008</b> , 8, 51                   |     |
| 1363 | Comparative actions of progesterone, medroxyprogesterone acetate, drospirenone and nesterone on breast cancer cell migration and invasion. <b>2008</b> , 8, 166                 | 28  |
| 1362 | Baja masa ñea y factores ginecolñgicos asociados en mujeres climatñficas. <b>2008</b> , 17, 35-43   |     |
| 1361 | Sexual counseling in elderly couples. <b>2008</b> , 5, 2027-43  | 33  |
| 1360 | Reclaiming Embodiment within Critical Psychology: A Material-Discursive Analysis of the Menopausal Body. <b>2008</b> , 2, 1781-1798   | 16  |
| 1359 | Vaginal Drug Delivery. 809-878  | 11  |
| 1358 | Guñas de prñtica clñica en la osteoporosis posmenopñsica, glucocorticoidea y del varñ. Sociedad Española de Investigaciñ ñea y del Metabolismo Mineral. <b>2008</b> , 208, 1-24 | 38  |
| 1357 | Pharmacological therapy for female sexual dysfunction: has progress been made?. <b>2008</b> , 68, 259-64  | 15  |
| 1356 | Exogenous and endogenous hormones and breast cancer. <b>2008</b> , 22, 573-85   | 58  |
| 1355 | Late effects of chronic graft-versus-host disease. <b>2008</b> , 21, 309-31   | 19  |
| 1354 | Treating hot flushes in menopausal women with homeopathic treatment--results of an observational study. <b>2008</b> , 97, 10-5  | 25  |
| 1353 | Menopausal hormone therapy in relation to breast cancer characteristics and prognosis: a cohort study. <b>2008</b> , 10, R78  | 35  |
| 1352 | Assessing risk for breast cancer. <b>2008</b> , 10 Suppl 4, S13   | 10  |
| 1351 | Breast cancer tumor growth estimated through mammography screening data. <b>2008</b> , 10, R41  | 115 |
| 1350 | Breast Cancer 2nd edition. <b>2008</b> ,  | 1   |

|      |  |     |
|------|--|-----|
| 1349 | Effects of hormone therapy on estrogen synthesis from E1S in the mammary gland of postmenopausal women. <b>2008</b> , 59, 163-73   | 2   |
| 1348 | Does a short cessation of HRT decrease mammographic density?. <b>2008</b> , 59, 315-22   | 5   |
| 1347 | What is the optimal policy for osteoporosis management?. <b>2008</b> , 60, 3-9   | 1   |
| 1346 | Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women. <b>2008</b> , 60, 92-107  | 39  |
| 1345 | Risks of hormone therapy in the 50-59 year age group. <b>2008</b> , 60, 59-64  | 13  |
| 1344 | The Hot Flush Beliefs Scale: a tool for assessing thoughts and beliefs associated with the experience of menopausal hot flushes and night sweats. <b>2008</b> , 60, 158-69                                   | 45  |
| 1343 | Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review. <b>2008</b> , 60, 185-201  | 76  |
| 1342 | Effects of tibolone and conventional HRT on the expression of estrogen and progesterone receptors in the breast. <b>2008</b> , 61, 345-9   | 3   |
| 1341 | Postmenopausal hormone drugs and breast and colon cancer: Nordic countries 1995-2005. <b>2008</b> , 61, 299-304  | 31  |
| 1340 | Classification and pharmacology of progestins. <b>2008</b> , 61, 171-80  | 141 |
| 1339 | Effects of intravaginal dehydroepiandrosterone on vaginal histomorphology, sex steroid receptor expression and cell proliferation in the rat. <b>2008</b> , 109, 67-80                                       | 11  |
| 1338 | Differing transcriptional responses to pulsed or continuous estradiol exposure in human umbilical vein endothelial cells. <b>2008</b> , 111, 41-9  | 5   |
| 1337 | Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women. <b>2008</b> , 111, 178-94   | 79  |
| 1336 | Do oestrogens induce chromosome specific aneuploidy in vitro, similar to the pattern of aneuploidy seen in breast cancer?. <b>2008</b> , 651, 46-55  | 15  |
| 1335 | Challenges to defining a role for progesterone in breast cancer. <b>2008</b> , 73, 914-21  | 47  |
| 1334 | Progesterone and breast cancer. <b>2008</b> , 4, 151-62  | 49  |
| 1333 | Cost effectiveness of hormone therapy in women at high risks of fracture in Sweden, the US and the UK--results based on the Women's Health Initiative randomised controlled trial. <b>2008</b> , 42, 294-306 | 23  |
| 1332 | Estrogen and progestogen therapy in postmenopausal women. <b>2008</b> , 90, S88-102  | 21  |

|      |  |     |
|------|--|-----|
| 1331 | Hormone replacement therapy and the risk of breast cancer. <b>2008</b> , 44, 2344-9  | 36  |
| 1330 | [Against medicalizing the postmenopause with HRT]. <b>2008</b> , 36, 104-9   | 1   |
| 1329 | [Hormone replacement therapy: the pros]. <b>2008</b> , 36, 98-103  | 1   |
| 1328 | [The risk of getting breast cancer after hormonal replacement therapy for menopause is stopped]. <b>2008</b> , 36, 1067-9  |     |
| 1327 | [Hormonal carcinogenesis in women: from mechanisms to prevention]. <b>2008</b> , 331, 104-13   | 5   |
| 1326 | Are the progestins responsible for breast cancer risk during hormone therapy in the postmenopause? Experimental vs. clinical data. <b>2008</b> , 109, 11-5                                   | 30  |
| 1325 | Efecto de diosgenina sobre la proteína C reactiva y homocisteína en pacientes menopáusicas. <b>2008</b> , 35, 120-125  |     |
| 1324 | Cancer incidence in women with Turner syndrome in Great Britain: a national cohort study. <b>2008</b> , 9, 239-46  | 140 |
| 1323 | [Did the decrease in use of menopausal hormone therapy induce a decrease in the incidence of breast cancer in France (and elsewhere)?]. <b>2008</b> , 56, 297-301                            | 10  |
| 1322 | Perils of Progestins: Increased Breast Cancer Risk Associated with Postmenopausal Hormone Replacement Therapy. <b>2008</b> , 19, 123-126   |     |
| 1321 | Type and Duration of Exogenous Hormone Use Affects Breast Cancer Histology. <b>2008</b> , 19, 23-25  |     |
| 1320 | Did the decrease in use of menopausal hormone therapy induce a decrease in the incidence of breast cancer in France (and elsewhere)? <b>2008</b> , 56, e8-e12                                | 1   |
| 1319 | Breast density in women with premature ovarian failure using hormone therapy. <b>2008</b> , 24, 40-3   | 14  |
| 1318 | Cluster analysis of genetic and epidemiological data in molecular epidemiology. <b>2008</b> , 71, 835-44   | 4   |
| 1317 | Tibolone: the way to beat many a postmenopausal ailments. <b>2008</b> , 9, 1039-47   | 4   |
| 1316 | Associations between serum testosterone levels, cell proliferation and progesterone receptor content in normal and malignant breast tissue in postmenopausal women. <b>2008</b> , 24, 405-10 | 8   |
| 1315 | Problematic detoxification of estrogen quinones by NAD(P)H-dependent quinone oxidoreductase and glutathione-S-transferase. <b>2008</b> , 21, 1324-9  | 26  |
| 1314 | Women's sexual function and dysfunction: current uncertainties, future directions. <b>2008</b> , 20, 466-78  | 60  |



|      |   |    |
|------|---|----|
| 1313 | The rise of raloxifene and the fall of invasive breast cancer. <b>2008</b> , 100, 831-3   | 10 |
| 1312 | Life prevalence of hormone replacement therapy and profile of users have not changed among women with self-reported menopause in the last two decades in Porto, Portugal. <b>2008</b> , 11, 26-31 |    |
| 1311 | Commentary: Hormone therapy and breast cancer incidence: did epidemiologists miss an effect on national trends?. <b>2008</b> , 37, 638-40   | 1  |
| 1310 | Breast Cancer. <b>2008</b> ,  | 3  |
| 1309 | Are the benefits of low-dose estrogens really proven?. <b>2008</b> , 11, 438  |    |
| 1308 | Oral contraceptives, postmenopausal hormones, and risk of asynchronous bilateral breast cancer: the WECARE Study Group. <b>2008</b> , 26, 1411-8  | 12 |
| 1307 | Menopausal hormone therapy and breast cancer risk in the NIH-AARP Diet and Health Study Cohort. <b>2008</b> , 17, 3150-60   | 63 |
| 1306 | Pilot study: absorption and efficacy of multiple hormones delivered in a single cream applied to the mucous membranes of the labia and vagina. <b>2008</b> , 66, 111-8                            | 11 |
| 1305 | The 38th David A. Karnofsky lecture: the paradoxical actions of estrogen in breast cancer--survival or death?. <b>2008</b> , 26, 3073-82  | 87 |
| 1304 | Impact of estrogen deprivation on gene expression profiles of normal postmenopausal breast tissue in vivo. <b>2008</b> , 17, 855-63   | 9  |
| 1303 | The Year in Basic Science: update of estrogen plus progestin therapy for menopausal hormone replacement implicating stem cells in the increased breast cancer risk. <b>2008</b> , 22, 2743-50     | 25 |
| 1302 | Ovarian failure following cancer treatment: current management and quality of life. <b>2008</b> , 23, 2506-12   | 37 |
| 1301 | Reforming NHS dentistry. <b>2008</b> , 336, 1202-3  | 5  |
| 1300 | Smoking cessation in primary care. <b>2008</b> , 336, 1200-1  | 0  |
| 1299 | Type of hormone replacement therapy and risk of venous thromboembolism. <b>2008</b> , 336, 1203-4   | 3  |
| 1298 | Survival after extremely preterm birth. <b>2008</b> , 336, 1199-200   |    |
| 1297 | Increasing drug resistant tuberculosis in the UK. <b>2008</b> , 336, 1201-2   | 4  |
| 1296 | What caused the decline in US breast cancer incidence?. <b>2008</b> , 5, 314-5  | 6  |

|      |   |     |
|------|---|-----|
| 1295 | [Recommendations for hormone treatment with estrogen and progesterone in the climacteric and postmenopausal periods. 37th Workshop of the Zurich Discussion Group , September 2006]. <b>2008</b> , 48, 38-46                            | 0   |
| 1294 | Climacteric Complaints after Breast Cancer - Is HRT an Option?. <b>2008</b> , 3, 204-209  | 1   |
| 1293 | Methodology and challenges to recruitment to a randomized, double-blind, placebo-controlled trial of oral DHEA in postmenopausal women. <b>2008</b> , 17, 1559-65   | 6   |
| 1292 | The women's health initiative: lessons learned. <b>2008</b> , 29, 131-50  | 57  |
| 1291 | Estrogen Receptors as Therapeutic Targets in Breast Cancer. <b>2008</b> , 127-199   | 7   |
| 1290 | Long-term follow-up of acupuncture and hormone therapy on hot flushes in women with breast cancer: a prospective, randomized, controlled multicenter trial. <b>2008</b> , 11, 166-74  | 72  |
| 1289 | Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer. <b>2008</b> , 19, 1669-80   | 78  |
| 1288 | Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. <b>2008</b> , 167, 1207-16  | 111 |
| 1287 | Principles of Molecular Oncology. <b>2008</b> ,   | 1   |
| 1286 | The World Health Organization defines hormone replacement therapy as carcinogenic: is this plausible?. <b>2008</b> , 24, 129-32   | 6   |
| 1285 | Ultra-low-dose continuous combined estradiol and norethisterone acetate: improved bleeding profile in postmenopausal women. <b>2008</b> , 11, 63-73   | 18  |
| 1284 | Updated practical recommendations for hormone replacement therapy in the peri- and postmenopause. <b>2008</b> , 11, 108-23  | 65  |
| 1283 | Vaginal drug administration in the hospital setting. <b>2008</b> , 65, 254-9  | 5   |
| 1282 | Adverse effects of prolactin in rodents and humans: breast and prostate cancer. <b>2008</b> , 22, 20-7  | 61  |
| 1281 | Separate and joint effects of alcohol and smoking on the risks of cirrhosis and gallbladder disease in middle-aged women. <b>2009</b> , 169, 153-60   | 28  |
| 1280 | Hormone therapy and the rise and perhaps fall of US breast cancer incidence rates: critical reflections. <b>2008</b> , 37, 627-37   | 32  |
| 1279 | Causation, bias and confounding: a hitchhiker's guide to the epidemiological galaxy Part 2. Principles of causality in epidemiological research: confounding, effect modification and strength of association. <b>2008</b> , 34, 185-90 | 21  |
| 1278 | FOUR AUTHORS REPLY. <b>2008</b> , 168, 1213-1214  | 2   |

|      |  |     |
|------|--|-----|
| 1277 | Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. <b>2008</b> , 100, 475-82   | 215 |
| 1276 | Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial. <b>2008</b> , 100, 563-71                               | 46  |
| 1275 | Using mammographic density to improve breast cancer screening outcomes. <b>2008</b> , 17, 2818-24  | 35  |
| 1274 | Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. <b>2008</b> , 167, 1407-15             | 111 |
| 1273 | Does menopausal hormone therapy initiate new breast cancers or promote the growth of existing ones?. <b>2008</b> , 4, 207-10                                       | 12  |
| 1272 | HRT and breast cancer: recent findings in the context of the evidence to date. <b>2008</b> , 4, 427-31   | 5   |
| 1271 | The effects of tibolone in older postmenopausal women. <b>2008</b> , 359, 697-708  | 308 |
| 1270 | Progestins in hormone replacement therapies reactivate cancer stem cells in women with preexisting breast cancers: a hypothesis. <b>2008</b> , 93, 3295-8          | 86  |
| 1269 | Relationship between body mass index and length of hospital stay for gallbladder disease. <b>2008</b> , 30, 161-6  | 14  |
| 1268 | Menopause hormone replacement therapy and cancer risk: an Italian record linkage investigation. <b>2008</b> , 19, 150-5  | 50  |
| 1267 | Rheumatoid arthritis: a female challenge. <b>2008</b> , 4, 195-201   | 18  |
| 1266 | Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. <b>2008</b> , 100, 1361-7  | 152 |
| 1265 | Prevalence and opinions of hormone therapy prior to the Women's Health Initiative: a multinational survey on four continents. <b>2008</b> , 17, 1151-66            | 15  |
| 1264 | Estrogens, progestins, and risk of breast cancer. <b>2007</b> , 127-50   | 9   |
| 1263 | Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study. <b>2008</b> , 337, a386      | 53  |
| 1262 | Comparative effects of oral conjugated equine estrogens and micronized 17beta-estradiol on breast proliferation: a retrospective analysis. <b>2008</b> , 15, 890-8 | 13  |
| 1261 | Effects of dietary equol administration on the mammary gland in ovariectomized Sprague-Dawley rats. <b>2008</b> , 15, 340-5  | 13  |
| 1260 | Data analysis methods and the reliability of analytic epidemiologic research. <b>2008</b> , 19, 785-8; discussion 789-93   | 7   |

|      |  |     |
|------|--|-----|
| 1259 | Postmenopausal hormone therapy and the risk of breast cancer: a contrary thought. <b>2008</b> , 15, 393-400  | 9   |
| 1258 | A long-term user of cosmetic cream containing estrogen developed breast cancer and endometrial hyperplasia. <b>2008</b> , 15, 1191-2                     | 6   |
| 1257 | Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. <b>2008</b> , 15, 584-602    | 146 |
| 1256 | Breast cancer and hormonal therapy. <b>2008</b> , 51, 592-606  | 16  |
| 1255 | . <b>2008</b> ,  | 14  |
| 1254 | Breast. 190-213  |     |
| 1253 | HORMONAS FEMENINAS Y CÁNCER DE MAMA: ESTADO DE LA POLÍTICA Y EVIDENCIAS EN 2008. ¿QUE RESPONDER A LAS PACIENTES?. <b>2008</b> , 14,                      | 0   |
| 1252 | Role of androgens, progestins and tibolone in the treatment of menopausal symptoms: a review of the clinical evidence. <b>2008</b> , 3, 1-8              | 16  |
| 1251 | Evolving issues in the clinical and managed care settings on the management of menopause following the women's health initiative. <b>2008</b> , 14, 7-13 | 13  |
| 1250 | Steroid receptor coactivator 2: an essential coregulator of progestin-induced uterine and mammary morphogenesis. <b>2007</b> , 55-76                     | 3   |
| 1249 | Mars and Venus: does gender matter in ageing?. <b>2008</b> , 188, 271-3  | 2   |
| 1248 | Definitions and controversies. 1-8   |     |
| 1247 | Breast disease. 73-84  |     |
| 1246 | Cancer genetics and reproduction. 13-22  |     |
| 1245 | Azathioprine and Steroids. <b>2008</b> , 220-233   | 2   |
| 1244 | The Beginning of a Decline in Breast Cancer Incidence in Italy?. <b>2008</b> , 94, 293-296   | 3   |
| 1243 | Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. <b>2008</b> , 188, 641-4                  | 106 |
| 1242 | Estrogen, NFkappaB, and the heat shock response. <b>2008</b> , 14, 517-27  | 76  |

|      |  |     |
|------|--|-----|
| 1241 | Regulation of Gene Expression by Hop-Derived 8-Prenylaringenin. <b>2009</b> , 725-734  |     |
| 1240 | Global Journal of Health Science, Vol. 1, No. 2, October 2009, all in one file.. <b>2009</b> , 1,  |     |
| 1239 | Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update. <b>2010</b> , 1, 11-20                            | 15  |
| 1238 | HRT, contraceptives and other drugs affecting the endometrium. 43-54   |     |
| 1237 | Hormone Therapies and Menopause: Where Do We Stand in the Post-WHI Era?. <b>2009</b> , 127-144   |     |
| 1236 | Progesterone action in human tissues: regulation by progesterone receptor (PR) isoform expression, nuclear positioning and coregulator expression. <b>2009</b> , 7, e009 | 112 |
| 1235 | Raloxifene: mechanism of action, effects on bone tissue, and applicability in clinical traumatology practice. <b>2009</b> , 3, 14-21                                     | 44  |
| 1234 | Breast Cancer: Knowledge and Perceptions of Chinese Women in Hong Kong. <b>2009</b> , 1,   | 9   |
| 1233 | Hormone replacement therapy: the risks and benefits of treatment. <b>2009</b> , 39, 324-6  | 6   |
| 1232 | The benefits of oestrogen following menopause: why hormone replacement therapy should be offered to postmenopausal women. <b>2009</b> , 190, 321-5                       | 32  |
| 1231 | Drospirenone in HRT?. <b>2009</b> , 47, 41-4   | 2   |
| 1230 | Cost-effectiveness of hormone therapy in the United States. <b>2009</b> , 18, 1669-77  | 19  |
| 1229 | Chinese medicinal herbs in relieving perimenopausal depression: a randomized, controlled trial. <b>2009</b> , 15, 93-100   | 8   |
| 1228 | Expression of the androgen receptor and syndecan-1 in breast tissue during different hormonal treatments in cynomolgus monkeys. <b>2009</b> , 12, 72-9                   | 6   |
| 1227 | Cimicifuga racemosa treatment and health related quality of life in post-menopausal Spanish women. <b>2009</b> , 25, 21-6  | 19  |
| 1226 | Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks?. <b>2009</b> , 27, 5138-43   | 99  |
| 1225 | Breast cancer after use of estrogen plus progestin in postmenopausal women. <b>2009</b> , 360, 573-87  | 345 |
| 1224 | Progesterone inhibits activation-induced deaminase by binding to the promoter. <b>2009</b> , 183, 1238-44  | 42  |

|      |   |     |
|------|---|-----|
| 1223 | Estradiol increases IL-8 secretion of normal human breast tissue and breast cancer in vivo. <b>2009</b> , 182, 371-8  | 63  |
| 1222 | Breast density and outcome of mammography screening: a cohort study. <b>2009</b> , 100, 1205-8  | 78  |
| 1221 | Lignans and breast cancer risk in pre- and post-menopausal women: meta-analyses of observational studies. <b>2009</b> , 100, 1492-8   | 62  |
| 1220 | Reproductive history, hormonal factors and the incidence of hip and knee replacement for osteoarthritis in middle-aged women. <b>2009</b> , 68, 1165-70   | 39  |
| 1219 | Towards a functional classification of pathogenic FOXL2 mutations using transactivation reporter systems. <b>2009</b> , 18, 3324-33   | 37  |
| 1218 | Third consensus on medical treatment of metastatic breast cancer. <b>2009</b> , 20, 1771-85   | 139 |
| 1217 | Hormone replacement therapy (HRT) or etidronate for osteoporosis in postmenopausal asthmatics on glucocorticoids: a randomised factorial trial. <b>2009</b> , 54, 21-5  | 3   |
| 1216 | Reproductive history and pancreatic cancer incidence and mortality in a cohort of postmenopausal women. <b>2009</b> , 18, 1457-60   | 14  |
| 1215 | Hormone replacement therapy and cardiovascular disease revisited. <b>2009</b> , 15, 55-7  | 17  |
| 1214 | [Complications of hormonal contraception with estrogen and gestagens in the climacteric and in the postmenopausal period. 39th Congress of the "Zurich Discussion Group", October 2007]. <b>2009</b> , 49, 45-51  |     |
| 1213 | Trends in hormone therapy and breast cancer incidence - results from the German Network of Cancer Registries. <b>2009</b> , 76, 90-7  | 38  |
| 1212 | Endometrium protection and acceptability of nasally administered continuously combined hormone therapy: a multicentre, multinational, double-blind trial in post-menopausal women evaluating three regimens of 17beta-estradiol and norethisterone when compared with an orally administered 17beta-estradiol/norethisterone regimen. <b>2009</b> , 21, 1739-47 | 5   |
| 1211 | Marketing disease: is osteoporosis an example of 'disease mongering'?. <b>2009</b> , 18, 1064-7   | 0   |
| 1210 | Long term hormone therapy for perimenopausal and postmenopausal women. <b>2009</b> , CD004143   | 46  |
| 1209 | Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. <b>2009</b> , 113, 65-73  | 134 |
| 1208 | Pharmacotherapy for women's sexual dysfunction. <b>2009</b> , 10, 1631-48   | 18  |
| 1207 | Equol but not genistein improves early metaphyseal fracture healing in osteoporotic rats. <b>2009</b> , 75, 459-65  | 22  |
| 1206 | Finally! A model for progesterone receptor action in normal human breast. <b>2009</b> , 150, 2988-90  | 12  |

|      |   |    |
|------|---|----|
| 1205 | The bioidentical hormone debate: are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than commonly used synthetic versions in hormone replacement therapy?. <b>2009</b> , 121, 73-85 | 35 |
| 1204 | Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer. <b>2009</b> , 9, 481-99   | 95 |
| 1203 | Implementation of digital mammography in a population-based breast cancer screening program: effect of screening round on recall rate and cancer detection. <b>2009</b> , 252, 31-9   | 38 |
| 1202 | LIBERATE-Studie: Hormonersatztherapie mit Tibolon erhht das Rezidivrisiko bei Mammakarzinompatientinnen. <b>2009</b> , 69, 199-201   | 1  |
| 1201 | [Metabolism of nitric oxide (NO) and arginine: significance for male health]. <b>2009</b> , 40, 235-41  | 3  |
| 1200 | Cost-effectiveness of hormone replacement therapy for menopausal symptoms in the UK. <b>2009</b> , 15, 19-25  | 8  |
| 1199 | Images, femininity and cancer: an analysis of an international patient education programme. <b>2009</b> , 13, 67-85   | 3  |
| 1198 | Vascular effects of estrogen and progestins and risk of coronary artery disease: importance of timing of estrogen treatment. <b>2009</b> , 60, 308-17   | 9  |
| 1197 | Infiltrating duct carcinoma within a fibroadenoma. <b>2009</b> , 46, 244-6  | 8  |
| 1196 | Recent changes in breast cancer incidence in Spain, 1980-2004. <b>2009</b> , 101, 1584-91   | 77 |
| 1195 | Enterocolic fistula associated with a gastrointestinal stromal tumor. <b>2009</b> , 46, 246-7   | 4  |
| 1194 | Efficacy, safety, and tolerability of low-dose hormone therapy in managing menopausal symptoms. <b>2009</b> , 22, 563-73  | 15 |
| 1193 | State of the Evidence: The Connection Between Breast Cancer and the Environment. <b>2009</b> , 15, 43-78  | 53 |
| 1192 | Effect of chronic estradiol administration on vimentin and GFAP immunohistochemistry within the inner ear. <b>2009</b> , 35, 201-8  | 4  |
| 1191 | Breast cancer epidemiology according to recognized breast cancer risk factors in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Cohort. <b>2009</b> , 9, 84                                       | 80 |
| 1190 | The incidence of invasive breast cancer among women prescribed testosterone for low libido. <b>2009</b> , 6, 1850-6   | 35 |
| 1189 | Genistein supplements might not induce clitoral modifications in postmenopausal women: a prospective, pilot study. <b>2009</b> , 6, 3132-8  | 5  |
| 1188 | Gabapentin for the treatment of hot flashes in women with natural or tamoxifen-induced menopause: a systematic review and meta-analysis. <b>2009</b> , 31, 221-35   | 38 |

|      |  |    |
|------|--|----|
| 1187 | Cancer issues. <b>2009</b> , 23, 87-107  | 9  |
| 1186 | Alternative treatments for the menopause. <b>2009</b> , 23, 151-61   | 23 |
| 1185 | Menopause and menopause transition. Preface and introduction. <b>2009</b> , 23, 1-6  | 2  |
| 1184 | [Changes in the use of hormone replacement therapy after an educational intervention aimed at women and prescribers]. <b>2009</b> , 23, 100-3  | 5  |
| 1183 | [Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration]. <b>2009</b> , 23, 158  | 78 |
| 1182 | S3 The changes in breast cancer incidence: A result of recent changes in hormone use by postmenopausal women?. <b>2009</b> , 18, S1-S2   | 15 |
| 1181 | S4 Did we learn more about adjuvant chemotherapy? The dark side of data from clinical trials. <b>2009</b> , 18, S2   |    |
| 1180 | S5 Aiming at the target: In the crosshairs or the crossfire?. <b>2009</b> , 18, S2-S3  | 1  |
| 1179 | Estrogen/isoflavone interactions in cynomolgus macaques ( <i>Macaca fascicularis</i> ). <b>2009</b> , 71, 722-31   | 22 |
| 1178 | Postmenopausal hormone therapy and prevalent round screening mammography. <b>2009</b> , 124, 1490-1  | 1  |
| 1177 | A population-based cohort study on the use of hormone treatment and endometrial cancer in southern Sweden. <b>2009</b> , 125, 421-5  | 9  |
| 1176 | +331G/A variant in the progesterone receptor gene, postmenopausal hormone use and risk of breast cancer. <b>2009</b> , 125, 1685-91  | 10 |
| 1175 | Influence of ferutinin on bone metabolism in ovariectomized rats. I: role in preventing osteoporosis. <b>2009</b> , 27, 538-45   | 36 |
| 1174 | CYP2C19*17 is associated with decreased breast cancer risk. <b>2009</b> , 115, 391-6   | 51 |
| 1173 | Reversal of antiprogestin resistance and progesterone receptor isoform ratio in acquired resistant mammary carcinomas. <b>2009</b> , 116, 449-60   | 25 |
| 1172 | Tamoxifen induces regression of estradiol-induced mammary cancer in the ACI.COP-Ept2 rat model. <b>2009</b> , 117, 517-24  | 15 |
| 1171 | Tamoxifen and ICI 182,780 increase Bcl-2 levels and inhibit growth of breast carcinoma cells by modulating PI3K/AKT, ERK and IGF-1R pathways independent of ERalpha. <b>2009</b> , 118, 605-21 | 21 |
| 1170 | Sustained lower rates of HRT prescribing and breast cancer incidence in Australia since 2003. <b>2009</b> , 117, 671-3   | 24 |



|      |  |     |
|------|--|-----|
| 1169 | Reduction in hormone replacement therapy use and declining breast cancer incidence in the Belgian province of Limburg. <b>2009</b> , 118, 425-32                 | 24  |
| 1168 | The efficacy of sertraline for controlling hot flashes in women with or at high risk of developing breast cancer. <b>2009</b> , 118, 369-75                      | 20  |
| 1167 | Genistein effects on quantitative ultrasound parameters and bone mineral density in osteopenic postmenopausal women. <b>2009</b> , 20, 1947-54                   | 28  |
| 1166 | Estimating the effect of current, previous and never use of drugs in studies based on prescription registries. <b>2009</b> , 18, 147-53                          | 8   |
| 1165 | Evaluation of a group cognitive behavioural intervention for women suffering from menopausal symptoms following breast cancer treatment. <b>2009</b> , 18, 560-3 | 67  |
| 1164 | Informing women about hormone replacement therapy: the consensus conference statement. <b>2009</b> , 9, 14   | 16  |
| 1163 | No evidence for variation in colorectal cancer risk associated with different types of postmenopausal hormone therapy. <b>2009</b> , 86, 416-24                  | 43  |
| 1162 | Reproductive factors and specific histological types of breast cancer: prospective study and meta-analysis. <b>2009</b> , 100, 538-44                            | 51  |
| 1161 | Effects of estrogen on genioglossal muscle contractile properties and fiber-type distribution in chronic intermittent hypoxia rats. <b>2009</b> , 117, 685-90    | 24  |
| 1160 | Evidence-based review of therapies at the menopause. <b>2009</b> , 7, 112-23   | 28  |
| 1159 | The replacement of the replacement in menopause: hormone therapy, controversies, truth and risk. <b>2009</b> , 16, 212-22  | 5   |
| 1158 | Breast cancer incidence after hormonal infertility treatment in Sweden: a cohort study. <b>2009</b> , 200, 72.e1-7   | 35  |
| 1157 | Is the recent fall in incidence of post-menopausal breast cancer in UK related to changes in use of hormone replacement therapy?. <b>2009</b> , 45, 1649-53      | 68  |
| 1156 | Trends in hip fracture epidemiology in Australia: possible impact of bisphosphonates and hormone replacement therapy. <b>2009</b> , 45, 246-53                   | 62  |
| 1155 | Cardiovascular risk in menopausal women and prevalent related co-morbid conditions: facing the post-Women's Health Initiative era. <b>2009</b> , 92, 1171-1186   | 104 |
| 1154 | [Breast density: a major parameter to follow during hormone replacement therapy]. <b>2009</b> , 37, 657-60   | 1   |
| 1153 | Estrogen and progesterone interactive effects in postconfluent MCF-7 cell culture. <b>2009</b> , 74, 410-8   | 13  |
| 1152 | Progesterin stimulation of manganese superoxide dismutase and invasive properties in T47D human breast cancer cells. <b>2009</b> , 117, 23-30                    | 22  |

|      |  |     |
|------|--|-----|
| 1151 | Effect of testosterone on E1S-sulfatase activity in non-malignant and cancerous breast cells in vitro. <b>2009</b> , 117, 168-75                                       | 6   |
| 1150 | Effects of the special extract ERr 731 from Rheum rhaponticum on estrogen-regulated targets in the uterotrophy model of ovariectomized rats. <b>2009</b> , 117, 176-84 | 12  |
| 1149 | Progestogen use in women approaching the menopause and breast cancer risk. <b>2009</b> , 62, 338-42  | 10  |
| 1148 | Progestins in HRT: sufferance or desire?. <b>2009</b> , 62, 371-5  | 8   |
| 1147 | Tibolone in postmenopausal women with systemic lupus erythematosus: a pilot study. <b>2009</b> , 62, 311-6   | 13  |
| 1146 | Exercise to reduce vasomotor and other menopausal symptoms: a review. <b>2009</b> , 63, 176-80   | 76  |
| 1145 | Patterns of hormone therapy use in the Norwegian Women and Cancer study (NOWAC) 1996-2005. <b>2009</b> , 63, 220-6   | 13  |
| 1144 | Menopause: knowledge, attitude and practice among Italian women. <b>2009</b> , 63, 246-52  | 33  |
| 1143 | Hormonal contraceptive regimens in the perimenopause. <b>2009</b> , 63, 204-12   | 21  |
| 1142 | The incidence of breast cancer and changes in the use of hormone replacement therapy: a review of the evidence. <b>2009</b> , 64, 80-5                                 | 48  |
| 1141 | Progestational effects of dydrogesterone in vitro, in vivo and on the human endometrium. <b>2009</b> , 65 Suppl 1, S3-11   | 40  |
| 1140 | Signaling inputs to progesterone receptor gene regulation and promoter selectivity. <b>2009</b> , 308, 47-52   | 51  |
| 1139 | The cost-effectiveness of hormone therapy in younger and older postmenopausal women. <b>2009</b> , 122, 42-52.e2   | 55  |
| 1138 | Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women. <b>2009</b> , 122, 1016-1022.e1   | 117 |
| 1137 | Structural modulation of oxidative metabolism in design of improved benzothiophene selective estrogen receptor modulators. <b>2009</b> , 37, 161-9                     | 14  |
| 1136 | Hormone replacement therapy: a 2008 perspective. <b>2009</b> , 19, 13-18   | 5   |
| 1135 | Prevention and treatment of osteoporosis in women: an update. <b>2009</b> , 19, 157-163  | 2   |
| 1134 | Cancer Prevention II. <b>2009</b> ,  | 1   |

|      |  |     |
|------|--|-----|
| 1133 | Androgens and the breast. <b>2009</b> , 11, 212  | 115 |
| 1132 | Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit?. <b>2009</b> , 11, 206  | 173 |
| 1131 | Menopause and Aging. <b>2009</b> , 325-355   | 6   |
| 1130 | Breast Cancer. <b>2009</b> , 659-686   | 1   |
| 1129 | Le traitement hormonal de la mēopause : aprē sept ans de polmiques. <b>2009</b> , 1, 31-37   |     |
| 1128 | Estrogens as first-choice therapy for osteoporosis prevention and treatment in women under 60. <b>2009</b> , 12, 206-9   | 16  |
| 1127 | Socioeconomic factors in menopausal women's use of hormone replacement therapy. <b>2009</b> , 21, 99-110   | 1   |
| 1126 | Hormone replacement therapy after breast cancer: attitudes of women eligible in a randomized trial. <b>2009</b> , 12, 478-89   | 2   |
| 1125 | Risk of gynecological cancers in users of estradiol/dydrogesterone or other HRT preparations. <b>2009</b> , 12, 514-24   | 35  |
| 1124 | Progestagen component in combined hormone replacement therapy in postmenopausal women and breast cancer risk: a debated clinical issue. <b>2009</b> , 25, 807-15                         | 21  |
| 1123 | Is HRT still indicated for the primary prevention of osteoporosis?. <b>2009</b> , 25, 629-33   | 1   |
| 1122 | Postmenopausal hormone therapy with estradiol and norethisterone acetate and mammographic density: findings from a cross-sectional study among Norwegian women. <b>2009</b> , 12, 248-58 | 15  |
| 1121 | Gynaecological uses of a new class of steroids: the selective progesterone receptor modulators. <b>2009</b> , 25, 67-73  | 12  |
| 1120 | Parenteral administration of progestins for hormonal replacement therapy. <b>2009</b> , 14, 88-96  | 14  |
| 1119 | Characteristics and recent evolution of menopausal hormone therapy use in a cohort of Swedish women. <b>2009</b> , 12, 410-8   | 6   |
| 1118 | Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. <b>2009</b> , 10, 135-46                           | 236 |
| 1117 | Tibolone: the risk is too high. <b>2009</b> , 10, 103-4  | 3   |
| 1116 | ¿Sabemos quē causa el cāncer de mama? Influencia actual de los diferentes factores de riesgo. <b>2009</b> , 52, 595-608  | 1   |

|      |   |    |
|------|---|----|
| 1115 | Current alternative and complementary therapies used in menopause. <b>2009</b> , 25, 166-74   | 39 |
| 1114 | [Physiopathological mechanism of hot flushes-perspiration induced by androgen deprivation in prostate carcinoma]. <b>2009</b> , 33, 235-41  |    |
| 1113 | Hormone Therapy and the Risk of Breast Cancer in BRCA1 Mutation Carriers: Eisen A, Lubinski J, Gronwald J, et al (Sunnybrook Regional Cancer Ctr, Toronto, Ontario, Canada; Pomeranian Med Univ, Szczecin, Poland; et al) J Natl Cancer Inst 100:1361-1367, 2008. <b>2009</b> , 20, 101-102 |    |
| 1112 | The Acupuncture on Hot Flushes Among Menopausal Women (ACUFLASH) study, a randomized controlled trial. <b>2009</b> , 16, 484-93   | 97 |
| 1111 | Replacing hormone therapy--is the decline in prescribing sustained, and are nonhormonal drugs substituted?. <b>2009</b> , 16, 329-35  | 6  |
| 1110 | Low-dose transdermal estradiol induces breast density and heterogeneity changes comparable to those of raloxifene. <b>2009</b> , 16, 785-91   | 8  |
| 1109 | Trends in hormone therapy use before and after publication of the Women's Health Initiative trial: 10 years of follow-up. <b>2009</b> , 16, 1061-4  | 34 |
| 1108 | Vasomotor symptoms usually reappear after cessation of postmenopausal hormone therapy: a Swedish population-based study. <b>2009</b> , 16, 1213-7   | 7  |
| 1107 | Postmenopausal estrogen-containing hormone therapy and the risk of breast cancer. <b>2009</b> , 113, 74-80  | 50 |
| 1106 | Hormone replacement therapy: real concerns and false alarms. <b>2009</b> , 15, 93-104   | 22 |
| 1105 | Hormone therapy: rigour and responsibility in knowledge translation. <b>2009</b> , 31, 13-5, 16-9   | 1  |
| 1104 | Hormone Therapy and Breast Cancer. <b>2009</b> , 31, S19-S26  | 1  |
| 1103 | Systematic Review: Comparative Effectiveness of Medications to Reduce Risk for Primary Breast Cancer. <b>2009</b> , 151, 703  | 53 |
| 1102 | Endocrine and Metabolic Effects of Chronic Graft versus Host Disease. 289-301   |    |
| 1101 | Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women. <b>2009</b> , 16, 30-6  | 88 |
| 1100 | Hormonothérapie : Rigueur et responsabilité en matière d'application des connaissances. <b>2009</b> , 31, 16-19   |    |
| 1099 | Cancer du sein (I). Épidémiologie, facteurs de risque, imagerie. <b>2009</b> , 4, 1-30  |    |
| 1098 | Glucose transporters in sex steroid hormone related cancer. <b>2009</b> , 7, 534-48   | 21 |

|      |  |     |
|------|--|-----|
| 1097 | Prevalence of symptoms in relation to androgen concentrations in women using estrogen plus progestogen and women using estrogen alone. <b>2009</b> , 16, 149-55                    | 1   |
| 1096 | Effect of isoflavone extracts from Glycine max on human endothelial cell damage and on nitric oxide production. <b>2009</b> , 16, 539-44   | 9   |
| 1095 | Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. <b>2009</b> , 16, 907-22                                      | 137 |
| 1094 | Mhopause. <b>2010</b> , 7, 1-19  | 1   |
| 1093 | Role of hormone therapy in the management of menopause. <b>2010</b> , 115, 839-855   | 59  |
| 1092 | Use of a multibotanical (Nutrafem) for the relief of menopausal vasomotor symptoms: a double-blind, placebo-controlled study. <b>2010</b> , 17, 303-8                              | 9   |
| 1091 | Effects of acupuncture on hot flashes in perimenopausal and postmenopausal women--a multicenter randomized clinical trial. <b>2010</b> , 17, 269-80                                | 70  |
| 1090 | The role of oestrogen in the pathogenesis of obesity, type 2 diabetes, breast cancer and prostate disease. <b>2010</b> , 19, 256-71  | 34  |
| 1089 | The Acupuncture on Hot Flashes Among Menopausal Women study: observational follow-up results at 6 and 12 months. <b>2010</b> , 17, 262-8   | 34  |
| 1088 | Hormone replacement therapy for women previously treated for endometrial cancer. <b>2010</b> ,   |     |
| 1087 | Hormone replacement therapy for women with type 1 diabetes mellitus. <b>2010</b> ,   |     |
| 1086 | A principal stratification approach to assess the differences in prognosis between cancers caused by hormone replacement therapy and by other factors. <b>2010</b> , 6, Article 20 | 2   |
| 1085 | Breast cancer risk reduction. <b>2010</b> , 8, 1112-46   | 21  |
| 1084 | Vaginal Drug Delivery. <b>2010</b> , 1   |     |
| 1083 | Decline in prolonged hormone replacement therapy in women aged 45 years or more, and impact of a centralised database tool. <b>2010</b> , 14, 31-35                                |     |
| 1082 | Hormone replacement therapy and breast disease. <b>2010</b> , 12, 155-163  | 1   |
| 1081 | Current options in the treatment of menopausal symptoms. <b>2010</b> , 21, 13-26   |     |
| 1080 | Inflammatory responses improve with milk ribonuclease-enriched lactoferrin supplementation in postmenopausal women. <b>2010</b> , 59, 971-8  | 25  |

|      |   |    |
|------|---|----|
| 1079 | Hormontherapie in der Peri- und Postmenopause. <b>2010</b> , 43, 318-323  |    |
| 1078 | Population screening for osteoporosis risk: a randomised control trial of medication use and fracture risk. <b>2010</b> , 21, 561-8   | 35 |
| 1077 | Hormontherapie in der Peri- und Postmenopause und Malignomrisiko. <b>2010</b> , 8, 13-16  |    |
| 1076 | The role of sex steroid receptors on lipogenesis in breast and prostate carcinogenesis: a viewpoint. <b>2010</b> , 1, 63-70   | 11 |
| 1075 | 2-Methoxyestradiol inhibits progesterone-dependent tissue factor expression and activity in breast cancer cells. <b>2010</b> , 1, 117-26  | 7  |
| 1074 | Partisan perspectives in the medical literature: a study of high frequency editorialists favoring hormone replacement therapy. <b>2010</b> , 25, 914-9                              | 16 |
| 1073 | How to judge the association of postmenopausal hormone therapy and the risk of breast cancer. <b>2010</b> , 4, 290-3  | 2  |
| 1072 | Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women. <b>2010</b> , 119, 463-74          | 64 |
| 1071 | Changing pattern of age-specific breast cancer incidence in the Swiss canton of Geneva. <b>2010</b> , 120, 519-23   | 17 |
| 1070 | Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women. <b>2010</b> , 120, 727-36                     | 55 |
| 1069 | Postmenopausal estrogen monotherapy-associated breast cancer risk is modified by CYP17A1_-34_T>C polymorphism. <b>2010</b> , 120, 737-44  | 16 |
| 1068 | Reductions in use of hormone replacement therapy: effects on Swedish breast cancer incidence trends only seen after several years. <b>2010</b> , 121, 679-83                        | 34 |
| 1067 | Breast cancer risk assessment in a mammography screening program and participation in the IBIS-II chemoprevention trial. <b>2010</b> , 121, 101-10                                  | 24 |
| 1066 | Recording of hormone therapy and breast density in breast screening programs: summary and recommendations of the International Cancer Screening Network. <b>2010</b> , 124, 793-800 | 5  |
| 1065 | The impact of changes in hormone therapy on breast cancer incidence in the US population. <b>2010</b> , 21, 83-90   | 32 |
| 1064 | Screening mammography intervals among postmenopausal hormone therapy users and nonusers. <b>2010</b> , 21, 147-52   | 4  |
| 1063 | DNA methylation changes in a human cell model of breast cancer progression. <b>2010</b> , 688, 28-35  | 25 |
| 1062 | An investigation of breast cancer risk factors in Cyprus: a case control study. <b>2010</b> , 10, 447   | 50 |

|      |   |     |
|------|---|-----|
| 1061 | Role of endogenous and exogenous female sex hormones in arthritis and osteoporosis development in B10.Q-ncf1 <sup>*/*</sup> mice with collagen-induced chronic arthritis. <b>2010</b> , 11, 284             | 8   |
| 1060 | Skin and brain age together: The role of hormones in the ageing process. <b>2010</b> , 45, 801-13   | 72  |
| 1059 | Anovulation with or without PCO, hyperandrogenaemia and hyperinsulinaemia as promoters of endometrial and breast cancer. <b>2010</b> , 24, 19-27  | 26  |
| 1058 | The pros and cons of phytoestrogens. <b>2010</b> , 31, 400-19   | 456 |
| 1057 | Effects of Korean red ginseng on sexual arousal in menopausal women: placebo-controlled, double-blind crossover clinical study. <b>2010</b> , 7, 1469-77  | 54  |
| 1056 | A case-control study on hormone therapy as a risk factor for breast cancer in Finland: Intrauterine system carries a risk as well. <b>2010</b> , 126, 483-9   | 71  |
| 1055 | Polymorphisms in genes of the steroid receptor superfamily modify postmenopausal breast cancer risk associated with menopausal hormone therapy. <b>2010</b> , 126, 2935-46                                  | 25  |
| 1054 | Do the dose or route of administration of norethisterone acetate as a part of hormone therapy play a role in risk of breast cancer: national-wide case-control study from Finland. <b>2010</b> , 127, 185-9 | 10  |
| 1053 | Development of a high-throughput LC/APCI-MS method for the determination of thirteen phytoestrogens including gut microbial metabolites in human urine and serum. <b>2010</b> , 878, 949-56                 | 23  |
| 1052 | Breast cancer in Lebanon: incidence and comparison to regional and Western countries. <b>2010</b> , 34, 221-5   | 47  |
| 1051 | The impact of menopausal hormone therapy on the incidence of different breast cancer types--data from the Cancer Registry Hamburg 1991-2006. <b>2010</b> , 34, 639-43                                       | 7   |
| 1050 | The use of Complementary and Alternative Medicine by women experiencing menopausal symptoms in Bologna. <b>2010</b> , 10, 7   | 46  |
| 1049 | Treatment of menopausal symptoms by an extract from the roots of rhapontic rhubarb: the role of estrogen receptors. <b>2010</b> , 5, 7  | 8   |
| 1048 | Absence of positive effect of black cohosh ( <i>Cimicifuga racemosa</i> ) on fracture healing in osteopenic rodent model. <b>2010</b> , 24, 1796-806  | 3   |
| 1047 | Role of oestrogen replacement therapy in women with diabetes. <b>2010</b> , 27, 180-180   |     |
| 1046 | Hormone therapy and fatal breast cancer. <b>2010</b> , 19, 440-7  | 10  |
| 1045 | Influence of ferutinin on bone metabolism in ovariectomized rats. II: role in recovering osteoporosis. <b>2010</b> , 217, 48-56   | 48  |
| 1044 | Icariin protects against bone loss induced by oestrogen deficiency and activates oestrogen receptor-dependent osteoblastic functions in UMR 106 cells. <b>2010</b> , 159, 939-49                            | 113 |

|      |   |     |
|------|---|-----|
| 1043 | Osteoclast differentiation factor RANKL controls development of progesterin-driven mammary cancer. <b>2010</b> , 468, 98-102  | 434 |
| 1042 | Differences in breast cancer incidence in Australia and England by age, extent of disease and deprivation status: women diagnosed 1980-2002. <b>2010</b> , 34, 206-13                               | 4   |
| 1041 | Incidence trend for breast cancer among young women in Goiânia, Brazil. <b>2010</b> , 128, 81-4   | 15  |
| 1040 | Could recent decreases in breast cancer incidence really be due to lower HRT use? Trends in attributable risk for modifiable breast cancer risk factors in Canadian women. <b>2010</b> , 101, 405-9 | 19  |
| 1039 | Bibliography. <b>2010</b> , 321-339   |     |
| 1038 | 5. Medicalization and Risk Scores: The Case of Menopause and HRT. <b>2010</b> , 116-139   | 1   |
| 1037 | [Adjuvant chemotherapy of early stage breast cancer]. <b>2010</b> , 151, 344-53   | 2   |
| 1036 | Progesterone and bone: actions promoting bone health in women. <b>2010</b> , 2010, 845180   | 57  |
| 1035 | Data analysis of epidemiological studies: part 11 of a series on evaluation of scientific publications. <b>2010</b> , 107, 187-92   | 29  |
| 1034 | Management of menopause-associated vasomotor symptoms: Current treatment options, challenges and future directions. <b>2010</b> , 2, 123-35   | 48  |
| 1033 | Breast density in women with premature ovarian failure or postmenopausal women using hormone therapy: analytical cross-sectional study. <b>2010</b> , 128, 211-4                                    | 12  |
| 1032 | The first national public breast cancer screening program in Saudi Arabia. <b>2010</b> , 30, 350-7  | 42  |
| 1031 | Hormone Replacement Therapy and Breast Cancer: The Situation in Korea. <b>2010</b> , 13, 237  | 1   |
| 1030 | Quantitative detection of 4-hydroxyequilenin-DNA adducts in mammalian cells using an immunoassay with a novel monoclonal antibody. <b>2010</b> , 38, e133   | 12  |
| 1029 | Breast cancer incidence and hormone replacement therapy in Canada. <b>2010</b> , 102, 1489-95   | 56  |
| 1028 | Estrogen plus progesterin and breast cancer incidence and mortality in postmenopausal women. <b>2010</b> , 304, 1684-92   | 391 |
| 1027 | Mechanisms of Oncogenesis. <b>2010</b> ,  | 3   |
| 1026 | What was the immediate impact on population health of the recent fall in hormone replacement therapy prescribing in England? Ecological study. <b>2010</b> , 32, 555-64                             | 13  |



|      |   |     |
|------|---|-----|
| 1025 | Non-hormonal interventions for hot flushes in women with a history of breast cancer. <b>2010</b> , CD004923   | 60  |
| 1024 | Significant fall in hormone replacement therapy prescription in general practice. <b>2010</b> , 27, 424-9   | 15  |
| 1023 | Angiogenin regulation by estradiol in breast tissue: tamoxifen inhibits angiogenin nuclear translocation and antiangiogenin therapy reduces breast cancer growth in vivo. <b>2010</b> , 16, 3659-69 | 40  |
| 1022 | Assessing women at high risk of breast cancer: a review of risk assessment models. <b>2010</b> , 102, 680-91  | 334 |
| 1021 | Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investigation Into Cancer and Nutrition. <b>2010</b> , 172, 1394-403            | 99  |
| 1020 | Is the decrease in breast cancer incidence related to a decrease in postmenopausal hormone therapy?. <b>2010</b> , 1205, 268-76   | 32  |
| 1019 | Nomegestrol acetate is an anti-aromatase agent in human MCF-7aro breast cancer cells. <b>2010</b> , 3, 417-24   | 3   |
| 1018 | Non-conventional hormone therapy - Tissue-specific Tibolone-Caution. <b>2010</b> , 1, 59-62   |     |
| 1017 | Low-dose hormone therapy in postmenopausal women in China. <b>2010</b> , 13, 544-52   | 7   |
| 1016 | Intravaginal DHEA, by a strictly local action, exerts beneficial effects on both vaginal atrophy symptoms and sexual dysfunction. <b>2010</b> , 4, 499-507  | 1   |
| 1015 | Basic properties and molecular mechanisms of exogenous chemical carcinogens. <b>2010</b> , 31, 135-48   | 84  |
| 1014 | What can be done about hot flushes after treatment for breast cancer?. <b>2010</b> , 13, 4-21   | 17  |
| 1013 | Mechanisms for differential effects between natural progesterone and synthetic progestogens on normal breast tissue. <b>2010</b> , 3, 437-40  | 1   |
| 1012 | Decline in breast cancer incidence in the Flemish region of Belgium after a decline in hormonal replacement therapy. <b>2010</b> , 21, 2356-2360  | 10  |
| 1011 | Menopausal hormone therapy and subsequent risk of specific invasive breast cancer subtypes in the California Teachers Study. <b>2010</b> , 19, 2366-78  | 46  |
| 1010 | Estrogen and xenoestrogens in breast cancer. <b>2010</b> , 38, 110-22   | 138 |
| 1009 | Should transdermal rather than oral estrogens be used in menopausal hormone therapy? A review. <b>2010</b> , 16, 23-32  | 7   |
| 1008 | Postmenopausal hormone therapy: an Endocrine Society scientific statement. <b>2010</b> , 95, s1-s66   | 429 |

|      |  |     |
|------|--|-----|
| 1007 | Oestrogen receptor beta ligand: a novel treatment to enhance endogenous functional remyelination. <b>2010</b> , 133, 2999-3016   | 108 |
| 1006 | Tibolone reduces osteoporotic fracture risk and breast cancer risk, but increases the risk of stroke. <b>2010</b> , 26, 73-5   | 3   |
| 1005 | Uptake of breast cancer prevention and screening trials. <b>2010</b> , 47, 853-5   | 15  |
| 1004 | Use of dietary supplements and medication among postmenopausal women with vasomotor symptoms. <b>2010</b> , 13, 585-93   | 2   |
| 1003 | Current knowledge of the effect of tibolone on the breast and uterus: an extract from the guidelines for the use of tibolone in South Africa. <b>2010</b> , 2, 34-36                   |     |
| 1002 | Mortality in patients with pituitary disease. <b>2010</b> , 31, 301-42   | 264 |
| 1001 | Emerging facade of menopausal hormone therapy. <b>2010</b> , 28, 351-9   | 2   |
| 1000 | Effects of black cohosh ( <i>Cimicifuga racemosa</i> ) and estrogen on metaphyseal fracture healing in the early stage of osteoporosis in ovariectomized rats. <b>2010</b> , 76, 850-7 | 18  |
| 999  | The progesterone receptor hinge region regulates the kinetics of transcriptional responses through acetylation, phosphorylation, and nuclear retention. <b>2010</b> , 24, 2126-38      | 57  |
| 998  | Equine estrogen-induced mammary tumors in rats. <b>2010</b> , 193, 224-8   | 7   |
| 997  | Long-term dietary isoflavone exposure enhances estrogen sensitivity of rat uterine responsiveness mediated through estrogen receptor alpha. <b>2010</b> , 196, 142-53                  | 50  |
| 996  | Nomegestrol acetate: pharmacology, safety profile and therapeutic efficacy. <b>2010</b> , 70, 541-59   | 44  |
| 995  | A decade of safety-related regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from 1999 to 2009. <b>2010</b> , 33, 463-74 | 42  |
| 994  | Unexpected hormonal activity of a catechol equine estrogen metabolite reveals reversible glutathione conjugation. <b>2010</b> , 23, 1374-83  | 9   |
| 993  | Sex steroids as inflammatory regulators. <b>2010</b> , 120, 105-15   | 122 |
| 992  | Physical activity and estrogen treatment reduce visceral body fat and serum levels of leptin in an additive manner in a diet induced animal model of obesity. <b>2010</b> , 122, 100-5 | 50  |
| 991  | Estradiol and genistein antagonize the ovariectomy effects on skeletal muscle myosin heavy chain expression via ER-beta mediated pathways. <b>2010</b> , 120, 53-9                     | 26  |
| 990  | Estrogenic properties of naturally occurring prenylated isoflavones in U2OS human osteosarcoma cells: Structure-activity relationships. <b>2010</b> , 120, 184-91                      | 21  |

|     |   |       |
|-----|---|-------|
| 989 | Development of an image analysis screen for estrogen receptor alpha (ER) ligands through measurement of nuclear translocation dynamics. <b>2010</b> , 122, 341-51   | 10    |
| 988 | [Atypical epithelial hyperplasia of the breast: current state of knowledge and clinical practice]. <b>2010</b> , 39, 11-24  | 4     |
| 987 | [Individual factors and mortality associated with hormone replacement therapy in a French cohort of women from 60 to 69 years of age]. <b>2010</b> , 39, 453-65   | 1     |
| 986 | Hormone replacement therapy (HRT), breast cancer and tumor pathology. <b>2010</b> , 65, 183-9   | 18    |
| 985 | The Asian Menopause Survey: knowledge, perceptions, hormone treatment and sexual function. <b>2010</b> , 65, 276-83   | 76    |
| 984 | The breast cancer "plunge" after initial publication of the WHI results: an alternative explanation. <b>2010</b> , 66, 277-84   | 5     |
| 983 | EMAS position statement: Managing the menopause in women with a past history of endometriosis. <b>2010</b> , 67, 94-7   | 36    |
| 982 | Oral ultra-low dose continuous combined hormone replacement therapy with 0.5 mg 17βestradiol and 2.5 mg dydrogesterone for the treatment of vasomotor symptoms: results from a double-blind, controlled study. <b>2010</b> , 67, 227-32 | 33    |
| 981 | Managing menopausal symptoms and depression in tamoxifen users: implications of drug and medicinal interactions. <b>2010</b> , 67, 296-308  | 36    |
| 980 | [Prevalence of use of hormone replacement therapy in women participating in a breast cancer screening program]. <b>2010</b> , 134, 439-42   | 2     |
| 979 | [Which hormones promote breast cancer in postmenopause: estrogens, progestins, insulin and/or adipocytokines?]. <b>2010</b> , 38, 1-3   |       |
| 978 | Effects of soy isoflavone supplements on bone turnover markers in menopausal women: systematic review and meta-analysis of randomized controlled trials. <b>2010</b> , 47, 413-23   | 82    |
| 977 | Reduced risk of oestrogen receptor positive breast cancer among peri- and post-menopausal women in Scotland following a striking decrease in use of hormone replacement therapy. <b>2010</b> , 46, 937-43                               | 19    |
| 976 | Discontinuation of hormone therapy in the French GAZEL cohort 1990-2006. <b>2010</b> , 94, 1387-1391  | 7     |
| 975 | Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study. <b>2010</b> , 117, 68-74  | 78    |
| 974 | Breast cancer diagnosis following ovarian stimulation: are the tumours different?. <b>2010</b> , 21, 266-71   | 5     |
| 973 | Gene-environment interactions in 7610 women with breast cancer: prospective evidence from the Million Women Study. <i>Lancet, The</i> , <b>2010</b> , 375, 2143-51  | 40 97 |
| 972 | Genes, the environment, and breast cancer. <i>Lancet, The</i> , <b>2010</b> , 375, 2123-4   | 40 8  |

|     |  |    |      |
|-----|--|----|------|
| 971 | Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. <i>Lancet, The</i> , <b>2010</b> , 376, 235-44           | 40 | 1395 |
| 970 | DHEA, important source of sex steroids in men and even more in women. <b>2010</b> , 182, 97-148  |    | 116  |
| 969 | Prescriptions for selective cyclooxygenase-2 inhibitors, non-selective non-steroidal anti-inflammatory drugs, and risk of breast cancer in a population-based case-control study. <b>2010</b> , 12, R15      |    | 25   |
| 968 | Recent declines in breast cancer incidence: mounting evidence that reduced use of menopausal hormones is largely responsible. <b>2010</b> , 12, 103  |    | 9    |
| 967 | Recent breast cancer incidence trends according to hormone therapy use: the California Teachers Study cohort. <b>2010</b> , 12, R4   |    | 37   |
| 966 | Long-term endometrial and breast safety of a specific, standardized soy extract. <b>2010</b> , 13, 368-75  |    | 20   |
| 965 | Updated clinical recommendations for the use of tibolone in Asian women. <b>2010</b> , 13, 317-27  |    | 19   |
| 964 | Tibolone in postmenopausal women: a review based on recent randomised controlled clinical trials. <b>2010</b> , 26, 804-14   |    | 49   |
| 963 | Assessing fatal cardiovascular disease risk with the SCORE (Systematic Coronary Risk Evaluation) scale in post-menopausal women 10 years after different hormone treatment regimens. <b>2010</b> , 26, 533-8 |    | 4    |
| 962 | Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy. <b>2010</b> , 26, 568-77               |    | 24   |
| 961 | Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. <b>2011</b> , 14, 302-20   |    | 147  |
| 960 | Effects of drospirenone/estradiol on steroid receptors and Bcl-2 in the postmenopausal endometrium. <b>2011</b> , 14, 551-7  |    | 2    |
| 959 | The assessment of efficacy of <i>Dioscorea alata</i> for menopausal symptom treatment in Taiwanese women. <b>2011</b> , 14, 132-9  |    | 11   |
| 958 | Local thermal therapy effects on menopausal symptoms and bone mineral density. <b>2011</b> , 17, 1133-40   |    | 2    |
| 957 | Topical oxytocin reverses vaginal atrophy in postmenopausal women: a double-blind randomized pilot study. <b>2011</b> , 17, 120-5  |    | 25   |
| 956 | Introduction to the interaction between gonadal steroids and the central nervous system. <b>2011</b> , 8, 1-13   |    | 6    |
| 955 | Prevention of osteoporosis: one step forward, two steps back. <b>2011</b> , 17, 137-41   |    | 10   |
| 954 | Progesterone receptor action: defining a role in breast cancer. <b>2011</b> , 6, 359-369   |    | 66   |

|     |   |    |
|-----|---|----|
| 953 | Postmenopausal hormone therapy and breast cancer risk: current status and unanswered questions. <b>2011</b> , 40, 509-18, viii  | 8  |
| 952 | Hormone replacement therapy in the geriatric patient: current state of the evidence and questions for the future. Estrogen, progesterone, testosterone, and thyroid hormone augmentation in geriatric clinical practice: part 1. <b>2011</b> , 27, 541-59 | 8  |
| 951 | Influence of sex and hormone status on circulating natriuretic peptides. <b>2011</b> , 58, 618-26   | 98 |
| 950 | Exercise beyond menopause: Dos and Don'ts. <b>2011</b> , 2, 51-6  | 12 |
| 949 | Exercise for vasomotor menopausal symptoms. <b>2011</b> , CD006108  | 17 |
| 948 | Hormone replacement therapy dependent changes in breast cancer-related gene expression in breast tissue of healthy postmenopausal women. <b>2011</b> , 5, 504-16  | 4  |
| 947 | Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. <b>2011</b> , 14, 282-8  | 71 |
| 946 | Androgens and breast cancer in men and women. <b>2011</b> , 40, 533-47, viii  | 18 |
| 945 | Hodgkin Lymphoma. <b>2011</b> ,   | 3  |
| 944 | Hormone replacement therapy and the risk of breast cancer. <b>2011</b> , 8, 669-76  | 99 |
| 943 | Effects of different progestogens on human breast tumor cell growth. <b>2011</b> , 14, 345-51   | 6  |
| 942 | William Hunter Harridge Lecture: Contemporary management of pre-invasive and early breast cancer. <b>2011</b> , 201, 279-89   | 3  |
| 941 | Age at menopause: imputing age at menopause for women with a hysterectomy with application to risk of postmenopausal breast cancer. <b>2011</b> , 21, 450-60  | 22 |
| 940 | The anti-progestin RU-486 inhibits viability of MCF-7 breast cancer cells by suppressing WNT1. <b>2011</b> , 312, 101-8   | 13 |
| 939 | Effects of percutaneous estradiol-oral progesterone versus oral conjugated equine estrogens-medroxyprogesterone acetate on breast cell proliferation and bcl-2 protein in healthy women. <b>2011</b> , 95, 1188-91  | 34 |
| 938 | Hormone replacement therapy and women with premature menopause--a cancer survivorship issue. <b>2011</b> , 47, 1623-32  | 29 |
| 937 | Acute misoprostol toxicity during the first trimester of pregnancy. <b>2011</b> , 113, 157-8  | 7  |
| 936 | Hyaluronic acid in the treatment of postmenopausal women with atrophic vaginitis. <b>2011</b> , 113, 156-7  | 9  |

|     |  |     |
|-----|--|-----|
| 935 | Menopausal hormone therapy--benefits, adverse reactions, concerns and information sources in 2009. <b>2011</b> , 70, 69-73   | 9   |
| 934 | A critical view of the effects of phytoestrogens on hot flashes and breast cancer risk. <b>2011</b> , 70, 222-6  | 25  |
| 933 | Digitized assessment of mammographic breast density--effects of continuous combined hormone therapy, tibolone and black cohosh compared to placebo. <b>2011</b> , 70, 361-4      | 26  |
| 932 | Soy isoflavones for osteoporosis: an evidence-based approach. <b>2011</b> , 70, 333-8  | 92  |
| 931 | Hormone therapy and coronary heart disease risk by vasomotor menopausal symptoms. <b>2011</b> , 70, 373-8  | 4   |
| 930 | Symptom prevalence during menopause and factors associated with symptoms and menopausal age. Results from the Norwegian Hordaland Women's Cohort study. <b>2011</b> , 70, 383-90 | 40  |
| 929 | Estrogens in rheumatoid arthritis; the immune system and bone. <b>2011</b> , 335, 14-29  | 83  |
| 928 | The antiprogestin Lonaprisan inhibits breast cancer cell proliferation by inducing p21 expression. <b>2011</b> , 333, 37-46  | 13  |
| 927 | Anti-osteoporosis activity of Cibotium barometz extract on ovariectomy-induced bone loss in rats. <b>2011</b> , 137, 1083-8  | 63  |
| 926 | Identifying the educational needs of menopausal women: a feasibility study. <b>2011</b> , 21, 145-52   | 19  |
| 925 | Steroid hormone levels associated with passive and active smoking. <b>2011</b> , 76, 653-9   | 66  |
| 924 | Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception. <b>2011</b> , 76, 636-52  | 158 |
| 923 | RANKL and RANK in sex hormone-induced breast cancer and breast cancer metastasis. <b>2011</b> , 22, 188-94   | 43  |
| 922 | Preventive therapy for breast cancer: a consensus statement. <b>2011</b> , 12, 496-503   | 177 |
| 921 | AGO Recommendations for Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Update 2011. <b>2011</b> , 6, 299-313                                     | 6   |
| 920 | The Survey on Korean Menopausal Women's Behavior and Perception of Hormone Therapy. <b>2011</b> , 17, 142  | 1   |
| 919 | One more look at guidelines for primary and secondary prevention of cardiovascular disease in women. <b>2011</b> , 7, 747-55   | 5   |
| 918 | The proper approaches for breast disease. <b>2011</b> , 54, 67   |     |

|     |   |     |
|-----|---|-----|
| 917 | Ginger Supplementation Enhances Working Memory of the Post-Menopause Women. <b>2011</b> , 8, 1241-1248  | 1   |
| 916 | Urban-rural differences in a population-based breast cancer screening program in Croatia. <b>2011</b> , 52, 76-86   | 18  |
| 915 | The microenvironment in health and cancer of the mammary gland. 50-79   |     |
| 914 | Effects of the levonorgestrel-releasing intrauterine system plus estrogen therapy in perimenopausal and postmenopausal women: systematic review and meta-analysis. <b>2011</b> , 18, 1060-6 | 38  |
| 913 | Depression in postmenopause: a study on a subsample of the Acupuncture on Hot Flushes Among Menopausal Women (ACUFLASH) study. <b>2011</b> , 18, 525-30                                     | 11  |
| 912 | Hormonal Intervention for Religious Concerns: A Halakhic and Ethical Discussion. <b>2011</b> , 114  | 1   |
| 911 | The TU-025 keishibukuryogan clinical trial for hot flash management in postmenopausal women: results and lessons for future research. <b>2011</b> , 18, 886-92                              | 24  |
| 910 | Impact of hormones on female sexual function and dysfunction. <b>2011</b> , 17, 8-16  | 3   |
| 909 | Wide distribution of the serum dehydroepiandrosterone and sex steroid levels in postmenopausal women: role of the ovary?. <b>2011</b> , 18, 30-43   | 109 |
| 908 | Molecular targeting of breast cancer: imaging and therapy. <b>2011</b> , 12, 528-38   | 3   |
| 907 | GATA-binding protein 1 is a novel transcription regulator of peroxiredoxin 5 in human breast cancer cells. <b>2012</b> , 40, 655-64   | 13  |
| 906 | Estrogen inhibits the effects of obesity and alcohol on mammary tumors and fatty liver. <b>2011</b> , 39, 1443-53   | 9   |
| 905 | American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of menopause. <b>2011</b> , 17 Suppl 6, 1-25                     | 37  |
| 904 | Promoting the sexual health of the older couple. <b>2011</b> , 7, 681-693   |     |
| 903 | Update in women's health: evidence published in 2010. <b>2011</b> , 155, 52-7   | 1   |
| 902 | Current overview of the management of urogenital atrophy in women with breast cancer. <b>2011</b> , 17, 403-8   | 45  |
| 901 | Change in the frequency of HRT use from 2000 to 2005 and reasons to discontinue: follow-up of a normal cohort in Finland. <b>2011</b> , 90, 351-7   | 12  |
| 900 | Sex hormones in postmenopausal women receiving low-dose hormone therapy: the effect of BMI. <b>2011</b> , 19, 988-93  | 9   |

- 899 Rebas sanitarias racionales en tiempos de crisis econ3mica. **2011**, 18, 615-623
- 898 A postmenopause-like model of ovariectomized Wistar rats to identify active principles of Erythrina lysistemon (Fabaceae). **2011**, 82, 939-49 17
- 897 Breast cancer after hormone replacement therapy--does prognosis differ in perimenopausal and postmenopausal women?. **2011**, 20, 448-54 10
- 896 Hypermethylation of the progesterone receptor A in constitutive antiprogestin-resistant mouse mammary carcinomas. **2011**, 126, 319-32 23
- 895 The contribution of postmenopausal hormone use cessation to the declining incidence of breast cancer. **2011**, 22, 125-34 19
- 894 Simvastatin induces estrogen receptor-alpha expression in bone, restores bone loss, and decreases ER $\beta$  expression and uterine wet weight in ovariectomized rats. **2011**, 29, 396-403 33
- 893 Increased fracture risk in normocalcemic postmenopausal women with high parathyroid hormone levels: a 16-year follow-up study. **2011**, 88, 238-45 48
- 892 Use of bisphosphonates and risk of breast cancer. **2011**, 88, 255-62 34
- 891 Assessing critical illness trends: the facts behind the stats. **2011**, 1, 61-84
- 890 Verminderling in hormoonsubstitutie?. **2011**, 54, 484-487
- 889 Complementary and alternative medicine in the treatment of menopausal symptoms. **2011**, 17, 883-8 13
- 888 Sex hormones and gene expression signatures in peripheral blood from postmenopausal women - the NOWAC postgenome study. **2011**, 4, 29 7
- 887 High burden of breast cancer in Belgium: recent trends in incidence (1999-2006) and historical trends in mortality (1954-2006). **2011**, 69, 2 18
- 886 "Every obese male with type 2 diabetes should be screened for hypogonadism" **2011**, 28, 14-17b
- 885 Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition. **2011**, 128, 144-56 101
- 884 Vitamin D-effective solar UV radiation, dietary vitamin D and breast cancer risk. **2011**, 128, 1425-33 46
- 883 Breast Cancer Risk - Genes, Environment and Clinics. **2011**, 71, 1056-1066 45
- 882 Menopausal hot flushes and vascular health. **2011**, 43, 283-91 18



|     |  |     |
|-----|--|-----|
| 881 | ck2-dependent phosphorylation of progesterone receptors (PR) on Ser81 regulates PR-B isoform-specific target gene expression in breast cancer cells. <b>2011</b> , 31, 2439-52   | 51  |
| 880 | Total flavonoid fraction of the Herba epimedii extract suppresses urinary calcium excretion and improves bone properties in ovariectomised mice. <b>2011</b> , 105, 180-9  | 35  |
| 879 | The induction of KLF5 transcription factor by progesterone contributes to progesterone-induced breast cancer cell proliferation and dedifferentiation. <b>2011</b> , 25, 1137-44   | 42  |
| 878 | Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. <b>2011</b> , 305, 1305-14   | 381 |
| 877 | Identifying and treating sexual dysfunction in postmenopausal women: the role of estrogen. <b>2011</b> , 20, 1453-65   | 43  |
| 876 | Breast cancer risk in relation to the interval between menopause and starting hormone therapy. <b>2011</b> , 103, 296-305  | 209 |
| 875 | Why does oestrogen-only hormone therapy have such a small impact on breast cancer risk? A hypothesis. <b>2011</b> , 27, 170-5  | 4   |
| 874 | Breast cancer risk and the interval between menopause and starting HT. <b>2011</b> , 14, 598-9   |     |
| 873 | Stopping hormone replacement therapy: were women ill advised?. <b>2011</b> , 17, 82-7  | 7   |
| 872 | Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene. <b>2011</b> , 12, 657-74  | 20  |
| 871 | Herbal medicines for menopausal symptoms. <b>2009</b> , 47, 2-6  | 2   |
| 870 | Re: Breast cancer risk in relation to the interval between menopause and starting hormone therapy. <b>2011</b> , 103, 1069; reply 1069-70  |     |
| 869 | Perimenopausal risk factors and future health. <b>2011</b> , 17, 706-17  | 28  |
| 868 | Digoxin use and the risk of breast cancer in women. <b>2011</b> , 29, 2165-70  | 54  |
| 867 | Effect of drospirenone on proliferation of human benign and cancerous epithelial breast cells. <b>2011</b> , 6, 211-4  | 0   |
| 866 | Effect of tibolone and its principal metabolites (3 $\beta$ -and 3 $\beta$ -hydroxy, 3 $\beta$ -sulfate, and 4-ene derivatives) on estrone sulfatase activity in normal and cancerous human breast tissue. <b>2011</b> , 8, 491-8      | 1   |
| 865 | Evolution of breast cancer incidence in relation to hormone replacement therapy use in Belgium. <b>2011</b> , 14, 464-71   | 6   |
| 864 | The reality is that the number of women with menopausal symptoms wanting to consider alternative therapies rather than hormone replacement therapy (HRT) has increased over the last decade. Introduction. <b>2011</b> , 14 Suppl 2, 1 |     |

|     |   |    |
|-----|---|----|
| 863 | Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies: part 3. The Women's Health Initiative: unopposed estrogen. <b>2011</b> , 37, 225-30                               | 20 |
| 862 | Hormone replacement therapy: 1815.84 woman-years of follow-up main clinical events. <b>2011</b> , 8, 479-90   |    |
| 861 | Empirical evaluation of gene and environment interactions: methods and potential. <b>2011</b> , 103, 1209-10  | 9  |
| 860 | Breast Cancer in Postmenopausal Women After Hormone TherapyâReply. <b>2011</b> , 305, 466   |    |
| 859 | Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies: Part 1. The Collaborative Reanalysis. <b>2011</b> , 37, 103-9   | 22 |
| 858 | Bisphosphonates in the adjuvant treatment of breast cancer: rationale and clinical data. <b>2011</b> , 1, 97-107  | 1  |
| 857 | Vaginal pH-balanced gel for the control of atrophic vaginitis among breast cancer survivors: a randomized controlled trial. <b>2011</b> , 117, 922-927  | 74 |
| 856 | Breast cancer incidence and time trend in France from 1990 to 2007: a population-based study from two French cancer registries. <b>2011</b> , 22, 329-34  | 27 |
| 855 | Comparison of increased aromatase versus ER $\beta$ in the generation of mammary hyperplasia and cancer. <b>2011</b> , 71, 5477-87  | 23 |
| 854 | Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: significant bone health issues in those not taking HRT. <b>2011</b> , 105, 22-7                                       | 46 |
| 853 | 10. Cancers attributable to exposure to hormones in the UK in 2010. <b>2011</b> , 105 Suppl 2, S42-8  | 31 |
| 852 | Metabolic and hormonal parameters in post-menopausal women 10 years after transdermal oestradiol treatment, alone or combined to micronized oral progesterone. <b>2011</b> , 27, 156-62                                       | 9  |
| 851 | Role of bisphosphonates in the management of postmenopausal osteoporosis: an update on recent safety anxieties. <b>2011</b> , 17, 66-72   | 35 |
| 850 | The influence of time from menopause and mammography on hormone therapy-related breast cancer risk assessment. <b>2011</b> , 103, 284-5   | 14 |
| 849 | National Osteoporosis Society's Position statement on hormone replacement therapy in the prevention and treatment of osteoporosis. <b>2011</b> , 17, 63-5   | 41 |
| 848 | Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies: part 2. The Women's Health Initiative: estrogen plus progestogen. <b>2011</b> , 37, 165-72                        | 32 |
| 847 | "They're made in factories and not by witches on the allotment": a qualitative study of midlife women in the united kingdom, exploring their approaches to complementary and alternative medicines. <b>2011</b> , 32, 1046-67 | 5  |
| 846 | Acupuncture for hot flushes in perimenopausal and postmenopausal women: a randomised, sham-controlled trial. <b>2011</b> , 29, 249-56   | 42 |

|     |   |     |
|-----|---|-----|
| 845 | Risk of osteoporotic fractures after discontinuation of menopausal hormone therapy: results from the E3N cohort. <b>2011</b> , 174, 12-21   | 11  |
| 844 | The effect of acupuncture on postmenopausal symptoms and reproductive hormones: a sham controlled clinical trial. <b>2011</b> , 29, 27-31   | 39  |
| 843 | Injectable and oral contraceptive use and cancers of the breast, cervix, ovary, and endometrium in black South African women: case-control study. <b>2012</b> , 9, e1001182                     | 62  |
| 842 | Acupuncture as treatment of hot flashes and the possible role of calcitonin gene-related Peptide. <b>2012</b> , 2012, 579321  | 13  |
| 841 | NAFLD, Estrogens, and Physical Exercise: The Animal Model. <b>2012</b> , 2012, 914938   | 31  |
| 840 | Dose-Dependent Effects of the Cimicifuga racemosa Extract Ze 450 in the Treatment of Climacteric Complaints: A Randomized, Placebo-Controlled Study. <b>2012</b> , 2012, 260301                 | 18  |
| 839 | The bone-protective effect of genistein in the animal model of bilateral ovariectomy: roles of phytoestrogens and PTH/PTHr1 against post-menopausal osteoporosis. <b>2012</b> , 13, 56-70       | 41  |
| 838 | Attributable causes of cancer in Japan in 2005--systematic assessment to estimate current burden of cancer attributable to known preventable risk factors in Japan. <b>2012</b> , 23, 1362-1369 | 117 |
| 837 | Chemoprevention of Breast Cancer: The Paradox of Evidence versus Advocacy Inaction. <b>2012</b> , 4, 1146-60  | 7   |
| 836 | Hormone replacement therapy. <b>2012</b> , 344, e763  | 36  |
| 835 | Declining incidence of breast cancer after decreased use of hormone-replacement therapy: magnitude and time lags in different countries. <b>2012</b> , 66, 1-7                                  | 69  |
| 834 | Amenorrhoea. <b>2012</b> , 5, 528-540   |     |
| 833 | Dispersal evolution in neoplasms: the role of disregulated metabolism in the evolution of cell motility. <b>2012</b> , 5, 266-75  | 34  |
| 832 | Changing concepts: Menopausal hormone therapy and breast cancer. <b>2012</b> , 104, 517-27  | 105 |
| 831 | An ounce of breast cancer prevention--let's try for a pound. <b>2012</b> , 21, 705-6  |     |
| 830 | Mammographic screening and breast cancer mortality: a case-control study and meta-analysis. <b>2012</b> , 21, 1479-88   | 78  |
| 829 | Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies. Part 4: the Million Women Study. <b>2012</b> , 38, 102-9                            | 23  |
| 828 | Primärprävention des Mammakarzinoms - State of the Art. <b>2012</b> , 41, 119-126   |     |

|     |  |    |
|-----|--|----|
| 827 | AACR Cancer Progress Report 2012. <b>2012</b> , 18, S1-100   | 20 |
| 826 | Dose-dependent effects of genistein on bone homeostasis in rats' mandibular subchondral bone. <b>2012</b> , 33, 66-74  | 30 |
| 825 | Commentary regarding recent Million Women Study critique and subsequent publicity. <b>2012</b> , 18, 33-5  | 4  |
| 824 | Ductal carcinoma in situ of the breast. <b>2012</b> , 344, e797  | 22 |
| 823 | Daidzein-estrogen interaction in the rat uterus and its effect on human breast cancer cell growth. <b>2012</b> , 15, 1081-90   | 21 |
| 822 | Does HRT increase the risk of breast cancer? Don't forget the menopausal woman!. <b>2012</b> , 15, 103-4   |    |
| 821 | The hormonal profile of norethindrone acetate: rationale for add-back therapy with gonadotropin-releasing hormone agonists in women with endometriosis. <b>2012</b> , 19, 563-71 | 37 |
| 820 | A short-term increase in cancer risk associated with daytime napping is likely to reflect pre-clinical disease: prospective cohort study. <b>2012</b> , 107, 527-30              | 16 |
| 819 | Postmenopausal endometrial cancer risk and body size in early life and middle age: prospective cohort study. <b>2012</b> , 107, 169-75   | 30 |
| 818 | Small ubiquitin-like modifier (SUMO) modification of zinc finger protein 131 potentiates its negative effect on estrogen signaling. <b>2012</b> , 287, 17517-17529               | 17 |
| 817 | Special biological issues in the management of women with schizophrenia. <b>2012</b> , 12, 823-33  | 8  |
| 816 | Randomized placebo- and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms. <b>2012</b> , 15, 12-20   | 28 |
| 815 | Antiprogestins in breast cancer treatment: are we ready?. <b>2012</b> , 19, R35-50   | 55 |
| 814 | Assuring the safety and effectiveness of new drugs: rigorous phase IV trials randomizing general practices to delayed access to new drugs. <b>2012</b> , 17, 56-9                | 1  |
| 813 | A population-based cohort study of HRT use and breast cancer in Korea. <b>2012</b> , 24, 415-22  | 5  |
| 812 | What really matters is the menopausal woman!. <b>2012</b> , 38, 136-7  | 1  |
| 811 | Update: estrogen and estrogen plus progestin therapy in the care of women at and after the menopause. <b>2012</b> , 8, 169-89  | 15 |
| 810 | Is acupuncture effective in treatment of hot flashes?. <b>2012</b> , 4, 319-323  |    |

|     |  |     |
|-----|--|-----|
| 809 | An estrogen model: the relationship between body mass index, menopausal status, estrogen replacement therapy, and breast cancer risk. <b>2012</b> , 2012, 792375                               | 21  |
| 808 | Treating menopausal symptoms with a complex remedy or placebo: a randomized controlled trial. <b>2012</b> , 15, 358-67   | 4   |
| 807 | Determinants of breast appearance and aging in identical twins. <b>2012</b> , 32, 846-60   | 11  |
| 806 | [Analysis of prescriptions associated to hormone replacement therapy in Midi-Pyr nes region]. <b>2012</b> , 67, 121-8  |     |
| 805 | Estrogens plus raloxifene on endometrial safety and menopausal symptoms--semisystematic review. <b>2012</b> , 19, 830-4  | 7   |
| 804 | Bayesian Meta-Analysis. <b>2012</b> , 118-140  | 4   |
| 803 | Extracted or synthesized soybean isoflavones reduce menopausal hot flash frequency and severity: systematic review and meta-analysis of randomized controlled trials. <b>2012</b> , 19, 776-90 | 113 |
| 802 | Bias in Observational Studies of the Association between Menopausal Hormone Therapy and Breast Cancer. <b>2015</b> , 10, e0124076  | 5   |
| 801 | Invasive Breast Cancer Incidence in 2,305,427 Screened Asymptomatic Women: Estimated Long Term Outcomes during Menopause Using a Systematic Review. <b>2015</b> , 10, e0128895                 | 2   |
| 800 | Divide and Conquer May Not Be the Optimal Approach to Retain the Desirable Estrogenic Attributes of the Cyclopia Nutraceutical Extract, SM6Met. <b>2015</b> , 10, e0132950                     | 9   |
| 799 | Ulipristal Acetate Inhibits Progesterone Receptor Isoform A-Mediated Human Breast Cancer Proliferation and BCL2-L1 Expression. <b>2015</b> , 10, e0140795                                      | 16  |
| 798 | Endocrine Disruption and Female Reproductive Health. <b>2015</b> , 143-158   | 1   |
| 797 | Exercise training and calorie restriction influence the metabolic parameters in ovariectomized female rats. <b>2015</b> , 2015, 787063   | 23  |
| 796 | The history and politics of menopause. 20-28   |     |
| 795 | Endocrine Disruption and Cancer of Reproductive Tissues. <b>2015</b> , 177-200   | 1   |
| 794 | [Effects of tibolone on the breast parenchyma: experimental study]. <b>2015</b> , 37, 233-40   | 1   |
| 793 | Breast cancer in male-to-female (MtF) transgender patients: is hormone receptor negativity a feature?. <b>2015</b> , 2015,   | 9   |
| 792 | Effects of estradiol, progestogens, and of tibolone on breast proliferation and apoptosis. <b>2015</b> , 18, 518-22  | 4   |

|     |  |     |
|-----|--|-----|
| 791 | Lifestyle and reproductive risk factors associated with anal cancer in women aged over 50 years. <b>2015</b> , 112, 1568-74  | 21  |
| 790 | The Tumor Microenvironment: Cancer-Promoting Networks Beyond Tumor Beds. <b>2015</b> , 128, 235-62   | 38  |
| 789 | Alternativas al tratamiento hormonal sustitutivo de la menopausia. <b>2015</b> , 51, 1-12  |     |
| 788 | Development and validation of risk prediction algorithms to estimate future risk of common cancers in men and women: prospective cohort study. <b>2015</b> , 5, e007825        | 67  |
| 787 | Black cohosh ( <i>Cimicifuga racemosa</i> ) is a non-estrogenic alternative to hormone replacement therapy. <b>2015</b> , 1,   | 6   |
| 786 | Hormone therapy might be underutilized in women with early menopause. <b>2015</b> , 30, 848-52   | 10  |
| 785 | Tea and coffee and risk of endometrial cancer: cohort study and meta-analysis. <b>2015</b> , 101, 570-8  | 32  |
| 784 | Critical-size bone defect repair using amniotic fluid stem cell/collagen constructs: effect of oral ferutinin treatment in rats. <b>2015</b> , 121, 174-83                     | 21  |
| 783 | Evidence-based review of Colles's Fracture. <b>2015</b> , 17, 191-200  | 2   |
| 782 | Recommendations for hormone therapy in hysterectomized women: importance of new data in clinical management. <b>2015</b> , 10, 55-63   | 5   |
| 781 | Receptor activator for nuclear factor- $\kappa$ B ligand signaling promotes progesterone-mediated estrogen-induced mammary carcinogenesis. <b>2015</b> , 106, 25-33            | 12  |
| 780 | The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer. <b>2015</b> , 22, R1-31  | 93  |
| 779 | Hodgkin Lymphoma. <b>2015</b> ,  | 11  |
| 778 | Combination therapy of Chinese herbal medicine Fructus Ligustri Lucidi with high calcium diet on calcium imbalance induced by ovariectomy in mice. <b>2015</b> , 53, 1082-5    | 14  |
| 777 | Endogenous estrogens and the risk of breast, endometrial, and ovarian cancers. <b>2015</b> , 99, 8-10  | 119 |
| 776 | Frequent physical activity may not reduce vascular disease risk as much as moderate activity: large prospective study of women in the United Kingdom. <b>2015</b> , 131, 721-9 | 135 |
| 775 | The RANKL-RANK Story. <b>2015</b> , 61, 534-42   | 85  |
| 774 | Conflicts of interest in government-funded studies. <b>2015</b> , 18, 339-42   | 4   |

|     |   |     |
|-----|---|-----|
| 773 | A systematic review of non-hormonal treatments of vasomotor symptoms in climacteric and cancer patients. <b>2015</b> , 4, 65  | 43  |
| 772 | Invasive Ductal Carcinoma in a 46,XY Partial Androgen Insensitivity Syndrome Patient on Hormone Therapy. <b>2015</b> , 28, e95-7  | 5   |
| 771 | Author's reply: To PMID 24990143. <b>2015</b> , 18, 432-3   | 1   |
| 770 | The Effect of Menopausal Hormone Therapies on Breast Cancer: Avoiding the Risk. <b>2015</b> , 44, 587-602   | 4   |
| 769 | Hormone therapy and young-onset breast cancer. <b>2015</b> , 181, 799-807   | 19  |
| 768 | 17Estradiol-Loaded PEGlyated Upconversion Nanoparticles as a Bone-Targeted Drug Nanocarrier. <b>2015</b> , 7, 15803-11  | 20  |
| 767 | The need to do better - Are we still letting our patients down and at what cost?. <b>2015</b> , 21, 56-62   | 16  |
| 766 | The proportion of postmenopausal breast cancer cases in the Netherlands attributable to lifestyle-related risk factors. <b>2015</b> , 152, 155-162  | 24  |
| 765 | Management of endometrial modifications in perimenopausal women. <b>2015</b> , 88, 101-10   | 4   |
| 764 | Connecting prosocial behavior to improved physical health: Contributions from the neurobiology of parenting. <b>2015</b> , 55, 1-17   | 174 |
| 763 | Emerging hormonal treatments for menopausal symptoms. <b>2015</b> , 20, 31-46   | 12  |
| 762 | Nationwide bowel cancer screening programme in England: cohort study of lifestyle factors affecting participation and outcomes in women. <b>2015</b> , 112, 1562-7                        | 24  |
| 761 | Evaluaci3n de la calidad de vida en la mujer menop3sica mediante la escala Cervantes: impacto del tratamiento en la pr3ctica cl3nica. <b>2015</b> , 58, 177-182                           | 0   |
| 760 | In vivo estrogenic-like activities of <i>Gouania longipetala</i> Hemsl. (Rhamnaceae) bark extracts in a post-menopause-like model of ovariectomized Wistar rats. <b>2015</b> , 168, 122-8 | 10  |
| 759 | Hormone Use in Food Animal Production: Assessing Potential Dietary Exposures and Breast Cancer Risk. <b>2015</b> , 2, 1-14  | 22  |
| 758 | Progesterone action in breast, uterine, and ovarian cancers. <b>2015</b> , 54, R31-53   | 110 |
| 757 | Cimicifuga racemosa extract for relieving menopausal symptoms: a randomized controlled trial. <b>2015</b> , 18, 79-85   | 18  |
| 756 | Prediagnostic Sex Steroid Hormones in Relation to Male Breast Cancer Risk. <b>2015</b> , 33, 2041-50  | 44  |

|     |   |     |
|-----|---|-----|
| 755 | Progestogens in Obstetrics and Gynecology. <b>2015</b> ,  | 1   |
| 754 | MECHANISMS IN ENDOCRINOLOGY: Medical consequences of doping with anabolic androgenic steroids: effects on reproductive functions. <b>2015</b> , 173, R47-58                                 | 115 |
| 753 | Is expression of rat breast matrix components influenced by estrogen, progestins and tibolone?. <b>2015</b> , 18, 523-7   | 1   |
| 752 | Adult body size and physical activity in relation to risk of breast cancer according to tumor androgen receptor status. <b>2015</b> , 24, 962-8   | 14  |
| 751 | European Code against Cancer 4th Edition: Medical exposures, including hormone therapy, and cancer. <b>2015</b> , 39 Suppl 1, S107-19   | 31  |
| 750 | Hormone Therapy and its Effect on the Prognosis in Breast Cancer Patients. <b>2015</b> , 75, 588-596  | 6   |
| 749 | Reprint of "Use of medroxyprogesterone acetate for hormone therapy in postmenopausal women: Is it safe?". <b>2015</b> , 153, 151-9  | 7   |
| 748 | A Root-Based Combination Supplement Containing Pueraria lobata and Rehmannia glutinosa and Exercise Preserve Bone Mass in Ovariectomized Rats Fed a High-Fat Diet. <b>2015</b> , 97, 624-33 | 13  |
| 747 | Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women's Health Initiative Randomized Clinical Trials. <b>2015</b> , 1, 296-305               | 141 |
| 746 | Luteolin inhibits progestin-dependent angiogenesis, stem cell-like characteristics, and growth of human breast cancer xenografts. <b>2015</b> , 4, 444                                      | 40  |
| 745 | The safety and tolerability profile of therapies for the prevention and treatment of osteoporosis in postmenopausal women. <b>2015</b> , 8, 769-84  | 37  |
| 744 | Hormone Therapy in Normal Postmenopausal Women and After Treatment for Endometrial Cancer. <b>2015</b> , 425-435  |     |
| 743 | Menopausia. <b>2015</b> , 51, 1-18  |     |
| 742 | Progesterone and Overlooked Endocrine Pathways in Breast Cancer Pathogenesis. <b>2015</b> , 156, 3442-50  | 48  |
| 741 | Geographic variation in volumetric breast density between screening regions in the Netherlands. <b>2015</b> , 25, 3328-37   | 14  |
| 740 | Evidenzbasierung in der Suchtprävention. <b>2015</b> ,  | 2   |
| 739 | regeneration of shoots and rooting of an important medicinal plant L. through nodal segment cultures. <b>2015</b> , 13, 209-214   | 28  |
| 738 | Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. <b>2015</b> , 100, 3975-4011  | 434 |



|     |  |     |
|-----|--|-----|
| 737 | Menopausal hormone therapy and breast cancer mortality: clinical implications. <b>2015</b> , 6, 45-56  | 24  |
| 736 | Estrogen as a new option for prevention and treatment of breast cancer âDoes this need a 'time gap'?. <b>2015</b> , 18, 444-7  | 4   |
| 735 | Uterine Cancer. <b>2015</b> ,  | 2   |
| 734 | Minireview: Progesterone Regulation of Proliferation in the Normal Human Breast and in Breast Cancer: A Tale of Two Scenarios?. <b>2015</b> , 29, 1230-42  | 24  |
| 733 | The metabolic syndrome and mammographic breast density in a racially diverse and predominantly immigrant sample of women. <b>2015</b> , 26, 1393-403   | 10  |
| 732 | Interaction between common breast cancer susceptibility variants, genetic ancestry, and nongenetic risk factors in Hispanic women. <b>2015</b> , 24, 1731-8  | 12  |
| 731 | An evidence-based future for menopausal hormone therapy. <b>2015</b> , 11, 785-8   | 4   |
| 730 | Commissioning for menopause specialist services: A local perspective: An internet-based survey to assess the potential demand for menopause care in West Cheshire and the skills of local primary care clinicians in this field, with a view to informing future commissioning locally. <b>2015</b> , 21, 98-104 | 1   |
| 729 | RANK Signaling Amplifies WNT-Responsive Mammary Progenitors through R-SPONDIN1. <b>2015</b> , 5, 31-44   | 50  |
| 728 | Estrogen withdrawal, increased breast cancer risk and the KRAS-variant. <b>2015</b> , 14, 2091-9   | 9   |
| 727 | Latest evidence on using hormone replacement therapy in the menopause. <b>2015</b> , 17, 20-28   | 12  |
| 726 | Global burden of cancer attributable to high body-mass index in 2012: a population-based study. <b>2015</b> , 16, 36-46  | 529 |
| 725 | Progesterone regulation of tissue factor depends on MEK1/2 activation and requires the proline-rich site on progesterone receptor. <b>2015</b> , 48, 309-20  | 6   |
| 724 | Progestin and antiprogestin responsiveness in breast cancer is driven by the PRA/PRB ratio via AIB1 or SMRT recruitment to the CCND1 and MYC promoters. <b>2015</b> , 136, 2680-92   | 28  |
| 723 | Selective estrogen-receptor modulators suppress microglial activation and neuronal cell death via an estrogen receptor-dependent pathway. <b>2015</b> , 145, 85-93   | 58  |
| 722 | Hot flushes, hormone therapy and alternative treatments: 30 years of experience from Sweden. <b>2015</b> , 18, 53-62   | 10  |
| 721 | Endocrinology and Aging. <b>2016</b> , 1234-1251   | 1   |
| 720 | RANK and RANKL of Bones, T Cells, and the Mammary Glands. <b>2016</b> , 121-142  | 1   |

|     |   |    |
|-----|---|----|
| 719 | Clinical prognostic significance and pro-metastatic activity of RANK/RANKL via the AKT pathway in endometrial cancer. <b>2016</b> , 7, 5564-75                        | 15 |
| 718 | The Effects of Nutritional Juice Supplementation on the Extent of Climacteric Symptoms: An Observational Study. <b>2016</b> , 2016, 2636542                           |    |
| 717 | Hormone replacement therapy—estrogens. <b>2016</b> , 840-852  |    |
| 716 | Prevention of breast cancer. <b>2016</b> , 205, 475-479   | 12 |
| 715 | High DRC Levels Are Associated with Let-7b Overexpression in Women with Breast Cancer. <b>2016</b> , 17,  | 7  |
| 714 | Progesterone receptor blockade in human breast cancer cells decreases cell cycle progression through G2/M by repressing G2/M genes. <b>2016</b> , 16, 326             | 9  |
| 713 | Peroral Estradiol Is Sufficient to Induce Carcinogen-Induced Mammary Tumorigenesis in Ovariectomized Rats without Progesterone. <b>2016</b> , 11, e0162662            | 2  |
| 712 | The Risk of Breast Cancer in Women Using Menopausal Hormone Replacement Therapy in Taiwan. <b>2016</b> , 13,  | 4  |
| 711 | Postmenopausal Osteoporosis and Its Therapies?. <b>2016</b> ,   |    |
| 710 | Comparative Assessment of the Effects of Hatha Yoga and Physical Exercise on Biochemical Functions in Perimenopausal Women. <b>2016</b> , 10, KC01-4                  | 2  |
| 709 | Mammographic Breast Density and Breast Cancer Risk: Implications of the Breast Density Legislation for Health Care Practitioners. <b>2016</b> , 59, 419-38            | 9  |
| 708 | Use of vaginal estrogen in Danish women: a nationwide cross-sectional study. <b>2016</b> , 95, 280-4  | 4  |
| 707 | A randomized, double-blind, placebo-controlled trial of Chinese herbal medicine granules for the treatment of menopausal symptoms by stages. <b>2016</b> , 23, 311-23 | 17 |
| 706 | Postmenopausal hormone therapy in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil): who still uses it?. <b>2016</b> , 25, 609-17                        | 3  |
| 705 | Postmenopausal hormone therapy and the risk of breast cancer in Norway. <b>2016</b> , 138, 584-93   | 15 |
| 704 | Progesterone Receptor Signaling Mechanisms. <b>2016</b> , 428, 3831-49  | 95 |
| 703 | Atypical epithelial hyperplasia of the breast: state of the art. <b>2016</b> , 16, 943-53   | 7  |
| 702 | Breast Cancer Survivorship. <b>2016</b> ,   | 3  |

|     |   |    |
|-----|---|----|
| 701 | Body size from birth to middle age and the risk of hip and knee replacement. <b>2016</b> , 17, 260  | 5  |
| 700 | Molecular mechanisms underlying progesterone-enhanced breast cancer cell migration. <b>2016</b> , 6, 31509  | 8  |
| 699 | Polyphenols for Brain and Cognitive Health. <b>2016</b> , 259-288   | 4  |
| 698 | Cancer incidence attributable to the use of oral contraceptives and hormone therapy in Alberta in 2012. <b>2016</b> , 4, E754-E759  | 8  |
| 697 | Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer. <b>2016</b> , 2, e1501924   | 69 |
| 696 | RANKL/RANK: from bone loss to the prevention of breast cancer. <b>2016</b> , 6,   | 37 |
| 695 | Modulating Skeletal Responses to Mechanical Loading by Targeting Estrogen Receptor Signaling. <b>2016</b> , 115-129   |    |
| 694 | The Complete Guide to Fertility Awareness. <b>2016</b> ,  | 2  |
| 693 | Safety and comfort of long-term continuous combined transdermal estrogen and intrauterine levonorgestrel administration for postmenopausal hormone substitution - a review. <b>2016</b> , 32, 598-601 | 8  |
| 692 | Luteolin suppresses development of medroxyprogesterone acetate-accelerated 7,12-dimethylbenz(a)anthracene-induced mammary tumors in Sprague-Dawley rats. <b>2016</b> , 35, 825-32                     | 14 |
| 691 | Differential Regulation of Progesterone Receptor-Mediated Transcription by CDK2 and DNA-PK. <b>2016</b> , 30, 158-72  | 9  |
| 690 | Tubal ligation and incidence of 26 site-specific cancers in the Million Women Study. <b>2016</b> , 114, 1033-7  | 19 |
| 689 | Aktuelle Entwicklungen der Krebsinzidenz und Mortalität in Deutschland. <b>2016</b> , 11, 38-45   | 1  |
| 688 | Short-term and long-term effects of tibolone in postmenopausal women. <b>2016</b> , 10, CD008536  | 22 |
| 687 | [Utilization of hormone replacement therapy in Spain: Trends in the period 2000-2014]. <b>2016</b> , 147, 287-92  | 8  |
| 686 | Hormone replacement therapy for women previously treated for endometrial cancer. <b>2016</b> ,  |    |
| 685 | Botanicals and Their Bioactive Phytochemicals for Women's Health. <b>2016</b> , 68, 1026-1073   | 85 |
| 684 | Efficacy of Femarelle for the treatment of climacteric syndrome in postmenopausal women: An open label trial. <b>2016</b> , 55, 336-40  | 6  |

|     |  |     |
|-----|--|-----|
| 683 | Long-term benefits and risks of HRT (Section 11): Breast cancer. <b>2016</b> , 22, 85-91   | 5   |
| 682 | Past cervical intraepithelial neoplasia grade 3, obesity, and earlier menopause are associated with an increased risk of vulval cancer in postmenopausal women. <b>2016</b> , 115, 599-606                       | 13  |
| 681 | Clinical effects of the fetal estrogen estetrol in a multiple-rising-dose study in postmenopausal women. <b>2016</b> , 91, 93-100  | 32  |
| 680 | The Effects of Age, Adiposity, and Physical Activity on the Risk of Seven Site-Specific Fractures in Postmenopausal Women. <b>2016</b> , 31, 1559-68   | 30  |
| 679 | Menopausal hormone therapy and breast cancer: what is the true size of the increased risk?. <b>2016</b> , 115, 607-15  | 47  |
| 678 | Biomarker assessment and molecular testing for prognostication in breast cancer. <b>2016</b> , 68, 70-85   | 44  |
| 677 | Relationship of Height to Site-Specific Fracture Risk in Postmenopausal Women. <b>2016</b> , 31, 725-31  | 12  |
| 676 | Postmenopausal Hormone Therapy and Breast Cancer Prognostic Characteristics: A Linkage between Nationwide Registries. <b>2016</b> , 25, 1464-1473  | 7   |
| 675 | Utilization of hormone replacement therapy in Spain: Trends in the period 2000â2014. <b>2016</b> , 147, 287-292  | 1   |
| 674 | Menopausal Hormone Therapy, Age, and Chronic Diseases: Perspectives on Statistical Trends. <b>2016</b> , 29, 1583-1590   | 14  |
| 673 | Interpretation of the evidence for the efficacy and safety of statin therapy. <i>Lancet, The</i> , <b>2016</b> , 388, 2532-2561  | 961 |
| 672 | [Menopausal hormonal therapy and cancer risks]. <b>2016</b> , 44, 424-7  | 1   |
| 671 | Retrospective analysis of molecular scores for the prediction of distant recurrence according to baseline risk factors. <b>2016</b> , 159, 71-8  | 7   |
| 670 | Risk Factors for Cataracts Treated Surgically in Postmenopausal Women. <b>2016</b> , 123, 1704-1710  | 13  |
| 669 | The role of health-related behavioural factors in accounting for inequalities in coronary heart disease risk by education and area deprivation: prospective study of 1.2 million UK women. <b>2016</b> , 14, 145 | 20  |
| 668 | Dense breast tissue in postmenopausal women is associated with a pro-inflammatory microenvironment. <b>2016</b> , 5, e1229723  | 11  |
| 667 | Estrogens. <b>2016</b> , 122-151   |     |
| 666 | Physical Assessment. <b>2016</b> , 148-233   |     |

|     |   |     |
|-----|---|-----|
| 665 | Breast Cancer Epidemiology and Risk Factors. <b>2016</b> , 59, 651-672  | 182 |
| 664 | Influence of health warnings on the use of rosiglitazone and pioglitazone in an area of Spain: A time-series study. <b>2016</b> , 4, 2050312116653054   | 3   |
| 663 | Comparison of dementia recorded in routinely collected hospital admission data in England with dementia recorded in primary care. <b>2016</b> , 13, 11  | 36  |
| 662 | Reduced risk of breast cancer mortality in women using postmenopausal hormone therapy: a Finnish nationwide comparative study. <b>2016</b> , 23, 1199-1203  | 25  |
| 661 | Extended-release oxybutynin therapy for vasomotor symptoms in women: a randomized clinical trial. <b>2016</b> , 23, 1214-1221   | 25  |
| 660 | Evaluation of the Biological Activity of <i>Opuntia ficus indica</i> as a Tissue- and Estrogen Receptor Subtype-Selective Modulator. <b>2016</b> , 30, 971-80   | 8   |
| 659 | Relationship between menopausal hormone therapy and mortality after breast cancer The MARIEplus study, a prospective case cohort. <b>2016</b> , 138, 2098-108   | 9   |
| 658 | Modifications to glucocorticoid and progesterone receptors alter cell fate in breast cancer. <b>2016</b> , 56, R99-R114   | 17  |
| 657 | Breast Cancer Prevention and Treatment. <b>2016</b> ,   | 4   |
| 656 | Weight loss reduces basal-like breast cancer through kinome reprogramming. <b>2016</b> , 16, 26   | 9   |
| 655 | Interactions between breast cancer susceptibility loci and menopausal hormone therapy in relationship to breast cancer in the Breast and Prostate Cancer Cohort Consortium. <b>2016</b> , 155, 531-40 | 2   |
| 654 | Hop ( <i>Humulus lupulus</i> L.) Extract and 6-Prenylnaringenin Induce P450 1A1 Catalyzed Estrogen 2-Hydroxylation. <b>2016</b> , 29, 1142-50   | 34  |
| 653 | Effects of genistein on cognitive dysfunction and hippocampal synaptic plasticity impairment in an ovariectomized rat kainic acid model of seizure. <b>2016</b> , 786, 1-9                            | 11  |
| 652 | Hypothalamic orexin's role in exacerbated cutaneous vasodilation responses to an anxiogenic stimulus in a surgical menopause model. <b>2016</b> , 65, 127-37  | 7   |
| 651 | Social participation and coronary heart disease risk in a large prospective study of UK women. <b>2016</b> , 23, 995-1002   | 7   |
| 650 | Risks of developing breast and colorectal cancer in association with incomes and geographic locations in Texas: a retrospective cohort study. <b>2016</b> , 16, 294                                   | 15  |
| 649 | Menopausal hormone therapy use and breast cancer risk in Australia: Findings from the New South Wales Cancer, Lifestyle and Evaluation of Risk study. <b>2016</b> , 138, 1905-14                      | 8   |
| 648 | Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study. <b>2016</b> , 155, 365-73   | 43  |

|     |  |        |
|-----|--|--------|
| 647 | Natural products for treatment of osteoporosis: The effects and mechanisms on promoting osteoblast-mediated bone formation. <b>2016</b> , 147, 46-58                               | 228    |
| 646 | The influence of hormone therapies on colon and rectal cancer. <b>2016</b> , 31, 481-9   | 39     |
| 645 | Postmenopausal Female Hormone Use and Estrogen Receptor-Positive and -Negative Breast Cancer in African American Women. <b>2016</b> , 108,   | 15     |
| 644 | Menopausal hormone therapy use in relation to breast cancer incidence in 11 European countries. <b>2016</b> , 84, 81-8   | 10     |
| 643 | Erythrina excelsa exhibits estrogenic effects in vivo and in vitro and is cytotoxic on breast and colon cancer cell lines. <b>2016</b> , 54, 835-44                                | 1      |
| 642 | Treatment with kaempferol suppresses breast cancer cell growth caused by estrogen and triclosan in cellular and xenograft breast cancer models. <b>2016</b> , 28, 70-82            | 83     |
| 641 | Tubal ligation and ovarian cancer risk in a large cohort: Substantial variation by histological type. <b>2016</b> , 138, 1076-84   | 35     |
| 640 | Coffee consumption and the risk of cancer in the Norwegian Women and Cancer (NOWAC) Study. <b>2016</b> , 31, 905-16  | 22     |
| 639 | NICE guideline: diagnosis and management of the menopause. <b>2016</b> , 27, 27-32   | 5      |
| 638 | Bioanalytical LC-MS Method for the Quantification of Plasma Androgens and Androgen Glucuronides in Breast Cancer. <b>2016</b> , 54, 583-92   | 3      |
| 637 | Phytoestrogen Suppresses Efflux of the Diagnostic Marker Protoporphyrin IX in Lung Carcinoma. <b>2016</b> , 76, 1837-46  | 10     |
| 636 | 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. <b>2016</b> , 19, 109-50   | 470    |
| 635 | Behaviours and attitudes influencing treatment decisions for menopausal symptoms in five European countries. <b>2016</b> , 22, 112-22  | 19     |
| 634 | Case 227: Endobronchial Carcinoid Tumor with Incidental Metastatic Breast Cancer Detected with Somatostatin Receptor Scintigraphy ((111)In Pentreotide). <b>2016</b> , 278, 949-55 | 1      |
| 633 | Beneficial Effects of a Flavonoid Fraction of Herba Epimedii on Bone Metabolism in Ovariectomized Rats. <b>2016</b> , 82, 322-9  | 27     |
| 632 | Current Findings on Soya and Isoflavones. <b>2016</b> , 177-184  |        |
| 631 | Does happiness itself directly affect mortality? The prospective UK Million Women Study. <i>Lancet, The</i> , <b>2016</b> , 387, 874-81  | 40 151 |
| 630 | Physical activity, hormone replacement therapy and breast cancer risk: A meta-analysis of prospective studies. <b>2016</b> , 52, 138-54  | 84     |

|     |   |     |
|-----|---|-----|
| 629 | Use of exogenous hormones and the risk of breast cancer: results from self-reported survey data with validity assessment. <b>2016</b> , 27, 249-58  | 15  |
| 628 | Estrogenic effects of <i>Ficus umbellata</i> Vahl. (Moraceae) extracts and their ability to alleviate some menopausal symptoms induced by ovariectomy in Wistar rats. <b>2016</b> , 179, 332-44                       | 12  |
| 627 | Frontiers in Gynecological Endocrinology. <b>2016</b> ,   | 1   |
| 626 | Narrowing of racial disparities in breast cancer incidence: insights from menopausal hormone therapy study findings. <b>2016</b> , 108,   | 1   |
| 625 | Time trends in breast cancer and menopause hormone therapy use in New Zealand. <b>2016</b> , 19, 42-8   | 2   |
| 624 | The pharmacological and hormonal therapy of hot flushes in breast cancer survivors. <b>2016</b> , 23, 178-82  | 19  |
| 623 | <i>Asparagus racemosus</i> : a review on its phytochemical and therapeutic potential. <b>2016</b> , 30, 1896-908  | 29  |
| 622 | Chronic black tea extract consumption improves endothelial function in ovariectomized rats. <b>2016</b> , 55, 1963-72   | 12  |
| 621 | The Current Understanding of Sarcopenia: Emerging Tools and Interventional Possibilities. <b>2017</b> , 11, 167-181   | 10  |
| 620 | Long-term hormone therapy for perimenopausal and postmenopausal women. <b>2017</b> , 1, CD004143  | 110 |
| 619 | Males develop faster and more severe hepatocellular carcinoma than females in <i>kras</i> transgenic zebrafish. <b>2017</b> , 7, 41280  | 37  |
| 618 | Nociones de epidemiología en dermatología. <b>2017</b> , 51, 1-10   |     |
| 617 | MECHANISMS IN ENDOCRINOLOGY: Aging and anti-aging: a Combo-Endocrinology overview. <b>2017</b> , 176, R283-R308   | 55  |
| 616 | Estrogen-progestin use and breast cancer characteristics in lean and overweight postmenopausal women. <b>2017</b> , 163, 363-373  |     |
| 615 | Feruloyl dopamine-O-hexosides are efficient marker compounds as orthogonal validation for authentication of black cohosh ( <i>Actaea racemosa</i> )-an UHPLC-HRAM-MS chemometrics study. <b>2017</b> , 409, 2591-2600 | 11  |
| 614 | Physical activity and risk of endometrial cancer in the Norwegian Women and Cancer (NOWAC) study. <b>2017</b> , 140, 1809-1818  | 18  |
| 613 | Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort. <b>2017</b> , 15, 26  | 18  |
| 612 | Butyl paraben and propyl paraben modulate bisphenol A and estradiol concentrations in female and male mice. <b>2017</b> , 325, 18-24  | 33  |

|     |   |     |
|-----|---|-----|
| 611 | Committee Opinion No. 698: Hormone Therapy in Primary Ovarian Insufficiency. <b>2017</b> , 129, e134-e141   | 46  |
| 610 | The management of menopause in women with a history of endometriosis: a systematic review. <b>2017</b> , 23, 481-500  | 60  |
| 609 | Long-term breast cancer risk following ovarian stimulation in young egg donors: a call for follow-up, research and informed consent. <b>2017</b> , 34, 480-485  | 15  |
| 608 | Combined Docking and Quantum Chemical Study on CYP-Mediated Metabolism of Estrogens in Man. <b>2017</b> , 30, 583-594   | 3   |
| 607 | Impact of risk-reducing salpingo-oophorectomy in premenopausal women. <b>2017</b> , 20, 212-221   | 27  |
| 606 | NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk. <b>2017</b> , 34, 1291-1326  | 232 |
| 605 | Celecoxib affects estrogen sulfonation catalyzed by several human hepatic sulfotransferases, but does not stimulate 17-sulfonation in rat liver. <b>2017</b> , 172, 46-54   | 5   |
| 604 | The presence of a membrane-bound progesterone receptor induces growth of breast cancer with norethisterone but not with progesterone: A xenograft model. <b>2017</b> , 102, 26-33   | 16  |
| 603 | Treatment with Standard and Low Dose of Conjugated Equine Estrogen Differentially Modulates Estrogen Receptor Expression and Response to Angiotensin II in Mesenteric Venular Bed of Surgically Postmenopausal Hypertensive Rats. <b>2017</b> , 362, 98-107 | 3   |
| 602 | Emmenagogue properties of <i>Milicia excelsa</i> (Welw.) C.C. Berg (Moraceae) based, at least in part, on its ability to correlate the activity of the hypothalamic-pituitary axis to that of the ovaries. <b>2017</b> , 206, 283-289                       | 4   |
| 601 | Hormone replacement therapy and breast cancer survival: a systematic review and meta-analysis of observational studies. <b>2017</b> , 24, 643-657   | 18  |
| 600 | Foliar Micromorphology of In Vitro-cultured Shoots and Field-grown Plants of <i>Passiflora foetida</i> . <b>2017</b> , 3, 34-40   | 13  |
| 599 | Progesterone Receptor Isoform Ratio: A Breast Cancer Prognostic and Predictive Factor for Antiprogestin Responsiveness. <b>2017</b> , 109,  | 35  |
| 598 | Lifelong vegetarianism and breast cancer risk: a large multicentre case control study in India. <b>2017</b> , 17, 6   | 9   |
| 597 | The role of progesterone and the progesterone receptor in cancer. <b>2017</b> , 12, 187-197   | 10  |
| 596 | Clinical implications of estrone sulfate measurement in laboratory medicine. <b>2017</b> , 54, 73-86  | 5   |
| 595 | A low dose (6.5 mg) of intravaginal DHEA permits a strictly local action while maintaining all serum estrogens or androgens as well as their metabolites within normal values. <b>2017</b> , 29, 39-60  | 6   |
| 594 | Influence of equol and resveratrol supplementation on health-related quality of life in menopausal women: A randomized, placebo-controlled study. <b>2017</b> , 96, 77-83   | 74  |



|     |  |    |
|-----|--|----|
| 593 | Divergent oestrogen receptor-specific breast cancer trends in Ireland (2004-2013): Amassing data from independent Western populations provide etiologic clues. <b>2017</b> , 86, 326-333 | 15 |
| 592 | Breast cancer in the 21st century: From early detection to new therapies. <b>2017</b> , 59, 368-379  | 32 |
| 591 | Age at menopause and hormone replacement therapy as risk factors for head and neck and oesophageal cancer (Review). <b>2017</b> , 38, 1915-1922  | 6  |
| 590 | Menopause. <b>2017</b> ,   | 2  |
| 589 | Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutated patients: An evidence-based approach on what women should know. <b>2017</b> , 61, 1-5                                     | 13 |
| 588 | [Notice of expert for modality and prescriptions limits of local estrogenotherapy for urinary incontinence in women]. <b>2017</b> , 27, 585-593  | 1  |
| 587 | Osteopenia and Osteoporosis in Female Athletes. <b>2017</b> , 36, 687-702  | 10 |
| 586 | State of the evidence 2017: an update on the connection between breast cancer and the environment. <b>2017</b> , 16, 94  | 93 |
| 585 | Gene-environment interactions involving functional variants: Results from the Breast Cancer Association Consortium. <b>2017</b> , 141, 1830-1840   | 13 |
| 584 | Comparing the androgenic and estrogenic properties of progestins used in contraception and hormone therapy. <b>2017</b> , 491, 140-146   | 32 |
| 583 | The menopause: benefits and risks of available treatments. <b>2017</b> , 28, 19-28   | 2  |
| 582 | A comparative characterization of estrogens used in hormone therapy via estrogen receptor (ER)- $\alpha$ and - $\beta$ . <b>2017</b> , 174, 27-39  | 16 |
| 581 | RE: Night Shift Work and Breast Cancer Incidence: Three Prospective Studies and Meta-analysis of Published Studies. <b>2017</b> , 109,   | 9  |
| 580 | Knowledge of clinical trials regarding hormone therapy and likelihood of prescribing hormone therapy. <b>2017</b> , 24, 27-34  | 6  |
| 579 | Estrogen alone and health outcomes in black women by African ancestry: a secondary analyses of a randomized controlled trial. <b>2017</b> , 24, 133-141                                  | 9  |
| 578 | We still have a long way to go. <b>2017</b> , 24, 3-4  |    |
| 577 | The impact of estrogen alone hormone therapy on breast cancer risk and health outcomes: reassurance for the treatment of climacteric symptoms in black women?. <b>2017</b> , 24, 124-125 | 2  |
| 576 | The Management of Osteoporosis After Fragility Fracture: The Orthopaedic Perspective. <b>2017</b> , 5, e4  | 4  |

|     |  |    |
|-----|--|----|
| 575 | A Review on Bone Mineral Density Loss in Total Knee Replacements Leading to Increased Fracture Risk. <b>2017</b> , 15, 162-174   | 17 |
| 574 | Epidemiology, Lifestyle, and Environmental Factors. <b>2017</b> , 63-72  |    |
| 573 | Comparison of clinical outcomes among users of oral and transdermal estrogen therapy in the Women's Health Initiative Observational Study. <b>2017</b> , 24, 1145-1153 | 17 |
| 572 | RE: Night Shift Work and Breast Cancer Incidence: Three Prospective Studies and Meta-analysis of Published Studies. <b>2017</b> , 109,                                 | 11 |
| 571 | Effect of Gua sha therapy on perimenopausal syndrome: a randomized controlled trial. <b>2017</b> , 24, 299-307   | 10 |
| 570 | The effect of hormone therapy on quality of life and breast cancer risk after risk-reducing salpingo-oophorectomy: a systematic review. <b>2017</b> , 17, 22           | 14 |
| 569 | Menopausal hormone therapy: a systematic review of cost-effectiveness evaluations. <b>2017</b> , 17, 326   | 4  |
| 568 | Prevalence of Anal Dysplasia in Human Immunodeficiency Virus-Infected Transgender Women. <b>2017</b> , 44, 714-716   | 13 |
| 567 | Comparison of Pueraria mirifica gel and conjugated equine estrogen cream effects on vaginal health in postmenopausal women. <b>2017</b> , 24, 210-215                  | 20 |
| 566 | Bone Health in Athletes. <b>2017</b> , 9, 108-117  | 50 |
| 565 | Cardiac glycosides and breast cancer risk: A systematic review and meta-analysis of observational studies. <b>2017</b> , 140, 1035-1041                                | 12 |
| 564 | Heterogeneity of colorectal cancer risk by tumour characteristics: Large prospective study of UK women. <b>2017</b> , 140, 1082-1090                                   | 24 |
| 563 | Breast cancer incidence trends in Norway and estimates of overdiagnosis. <b>2017</b> , 24, 83-91   | 5  |
| 562 | Progestins used in endocrine therapy and the implications for the biosynthesis and metabolism of endogenous steroid hormones. <b>2017</b> , 441, 31-45                 | 9  |
| 561 | Epidemiology of Breast Cancer. <b>2017</b> , 151-172   |    |
| 560 | Fundamentals of Molecular Information and Communication Science. <b>2017</b> , 105, 306-318  | 71 |
| 559 | Deciphering the divergent roles of progestogens in breast cancer. <b>2017</b> , 17, 54-64  | 73 |
| 558 | Disability and participation in breast and bowel cancer screening in England: a large prospective study. <b>2017</b> , 117, 1711-1714                                  | 21 |

|     |   |     |
|-----|---|-----|
| 557 | HRT for women with premature ovarian insufficiency: a comprehensive review. <b>2017</b> , 2017, hox007  | 39  |
| 556 | Breast Cancer After Childhood, Adolescent, and Young Adult Cancer: It's Not Just About Chest Radiation. <b>2017</b> , 37, 736-745   | 2   |
| 555 | Symposium âBrustkrebs-Screening 2.0: Personalisiert âPrädiktiv âPräventiv-Partizipatorisch?â  | 1   |
| 554 | EFFECTS OF SOYA MILK ON MENOPAUSAL SYMPTOMS AMONG WOMEN RESIDING IN SELECTED RURAL COMMUNITY, BENGALURU, INDIA. <b>2017</b> , 7, 115-118  |     |
| 553 | Effect of , ginger, saffron, and Cinnamomum on menopausal symptoms: a randomised, placebo-controlled clinical trial. <b>2017</b> , 16, 19-22  | 7   |
| 552 | Antiosteoporotic Activity of Genistein Aglycone in Postmenopausal Women: Evidence from a Post-Hoc Analysis of a Multicenter Randomized Controlled Trial. <b>2017</b> , 9,   | 26  |
| 551 | Estrogen Effects on the Mammary Gland in Early and Late Life and Breast Cancer Risk. <b>2017</b> , 7, 110   | 59  |
| 550 | Editorial: How Reproductive History Influences Our Breast Cancer Risk. <b>2017</b> , 7, 289   | 2   |
| 549 | Schisandrae Fructus Reduces Symptoms of 4-Vinylcyclohexene Diepoxide-Induced Ovarian Failure in Mice. <b>2017</b> , 2017, 2564787   | 0   |
| 548 | A. Rich. (Anacardiaceae) Ethanol Extract Exhibits Estrogenic Effects and Prevents Bone Loss in an Ovariectomized Rat Model of Osteoporosis. <b>2017</b> , 2017, 7829059   | 5   |
| 547 | Neuroprotective and Memory-Enhancing Effect of the Combined Extract of Purple Waxy Corn Cob and Pandan in Ovariectomized Rats. <b>2017</b> , 2017, 5187102  | 16  |
| 546 | Functional training reduces body fat and improves functional fitness and cholesterol levels in postmenopausal women: a randomized clinical trial. <b>2017</b> , 57, 448-456   | 16  |
| 545 | Risk Factors and Preventions of Breast Cancer. <b>2017</b> , 13, 1387-1397  | 389 |
| 544 | The Importance of Microbial and Enzymatic Bioconversions of Isoflavones in Bioactive Compounds. <b>2017</b> , 55-93   | 3   |
| 543 | Cholesterol biosynthesis inhibitor RO 48-8071 reduces progesterone receptor expression and inhibits progestin-dependent stem cell-like cell growth in hormone-dependent human breast cancer cells. <b>2017</b> , 9, 487-494 | 2   |
| 542 | Pregnancy and Breast Cancer. <b>2017</b> , 151, 81-111  | 15  |
| 541 | Estrogen-like and tissue-selective effects of 7-methoxycoumarin from Ficus umbellata (Moraceae): an in vitro and in vivo study. <b>2017</b> , 17, 383   | 7   |
| 540 | Sexual health and wellbeing. <b>2017</b> , 148-166  |     |

|     |   |    |
|-----|---|----|
| 539 | Influence of Tetrabromobisphenol A, with or without Concurrent Triclosan, upon Bisphenol A and Estradiol Concentrations in Mice. <b>2017</b> , 125, 087014  | 13 |
| 538 | Change in risk of breast cancer after receiving hormone replacement therapy by considering effect-modifiers: a systematic review and dose-response meta-analysis of prospective studies. <b>2017</b> , 8, 81109-81124 | 25 |
| 537 | The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation. <b>2017</b> , 8, 9144-9154   | 17 |
| 536 | Natural and synthetic progestins enrich cancer stem cell-like cells in hormone-responsive human breast cancer cell populations in vitro. <b>2017</b> , 9, 347-357   | 6  |
| 535 | Gonadotropins and their receptors: coevolution, genetic variants, receptor imaging, and functional antagonists. <b>2018</b> , 99, 3-12  | 4  |
| 534 | Prevalence of hormone therapy, factors associated with its use, and knowledge about menopause: a population-based household survey. <b>2018</b> , 25, 683-690   | 8  |
| 533 | Barriers to care for women with breast cancer symptoms in rural Bangladesh. <b>2018</b> , 39, 536-554   | 7  |
| 532 | Genetic variation in sensitivity to estrogens and breast cancer risk. <b>2018</b> , 29, 24-37   | 13 |
| 531 | Efficacy and safety of Pueraria candollei var. mirifica (Airy Shaw & Suvat.) Niyomdham for menopausal women: A systematic review of clinical trials and the way forward. <b>2018</b> , 216, 162-174                   | 8  |
| 530 | Serum osteoprotegerin levels and mammographic density among high-risk women. <b>2018</b> , 29, 507-517  | 5  |
| 529 | Progress in preventive therapy for cancer: a reminiscence and personal viewpoint. <b>2018</b> , 118, 1155-1161  | 10 |
| 528 | Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers. <b>2018</b> , 4, 1059-1065   | 84 |
| 527 | Adiposity and breast cancer risk in postmenopausal women: Results from the UK Biobank prospective cohort. <b>2018</b> , 143, 1037-1046  | 27 |
| 526 | Effect of a tissue selective estrogen complex on breast cancer: Role of unique properties of conjugated equine estrogen. <b>2018</b> , 143, 1259-1268   | 8  |
| 525 | Bowel cancer screening for women at midlife. <b>2018</b> , 21, 243-248  |    |
| 524 | Anabolic Activity of a Soy Extract and Three Major Isoflavones in C2C12 Myotubes. <b>2018</b> , 84, 1022-1029   | 8  |
| 523 | Menopause Hormone Therapy Customization. <b>2018</b> , 253-259  |    |
| 522 | [Notions of epidemiology of value in dermatology]. <b>2018</b> , 145, 129-140   | 0  |

|     |   |    |
|-----|---|----|
| 521 | The stem cell division theory of cancer. <b>2018</b> , 123, 95-113  | 37 |
| 520 | A roadmap towards personalized immunology. <b>2018</b> , 4, 9   | 27 |
| 519 | The True Risks of HRT. <b>2018</b> , 245-252  |    |
| 518 | Hormone replacement therapy in cancer survivors: Utopia?. <b>2018</b> , 124, 51-60  | 14 |
| 517 | Pre-Menopause, Menopause and Beyond. <b>2018</b> ,  | 6  |
| 516 | Concentration range of serum sex steroids in normal postmenopausal women and those with diagnosis of vulvovaginal atrophy. <b>2018</b> , 25, 293-300                      | 6  |
| 515 | Mammary Myofibroblastoma in a Transgender Patient on Feminizing Hormones: Literature Review and Case Report. <b>2018</b> , 3, 1-9   | 6  |
| 514 | Corni fructus ameliorates menopause symptom in 4-vinylcyclohexene diepoxide. <b>2018</b> , 14, 35-42  | 1  |
| 513 | Progestin-only and combined oral contraceptives and receptor-defined premenopausal breast cancer risk: The Norwegian Women and Cancer Study. <b>2018</b> , 142, 2293-2302 | 18 |
| 512 | Exogenous reproductive hormone use in breast cancer survivors and previvors. <b>2018</b> , 15, 249-261  | 15 |
| 511 | Impact of microbiota on the use and effects of isoflavones in the relief of climacteric symptoms in menopausal women – A review. <b>2018</b> , 41, 100-111                | 12 |
| 510 | Management of Menopause in the Breast Cancer Patient. <b>2018</b> , 1024-1030.e4  |    |
| 509 | Breast Cancer Epidemiology. <b>2018</b> , 19-29   | 8  |
| 508 | Effect of Oestrogen Exposure, Obesity, Exercise and Diet on Breast Cancer Risk. <b>2018</b> , 31-42   |    |
| 507 | Revisiting progesterone receptor (PR) actions in breast cancer: Insights into PR repressive functions. <b>2018</b> , 133, 75-81   | 7  |
| 506 | Evaluating different breast tumor progression models using screening data. <b>2018</b> , 18, 209  |    |
| 505 | Stellate cells and mesenchymal stem cells in benign mammary stroma are associated with risk factors for breast cancer - an observational study. <b>2018</b> , 18, 230     | 4  |
| 504 | Breast and reproductive cancers in the transgender population: a systematic review. <b>2018</b> , 125, 1505-1512  | 47 |

|     |  |     |
|-----|--|-----|
| 503 | Cardiac autonomic modulation impairments in advanced breast cancer patients. <b>2018</b> , 107, 924-936  | 17  |
| 502 | Chromatin reprogramming in breast cancer. <b>2018</b> , 25, R385-R404  | 9   |
| 501 | A double-blinded, randomized, placebo controlled, parallel study of pollen pistil extract (SP115) on women reporting irritability as predominant PMS symptom. <b>2018</b> , 12, 23-32  | 1   |
| 500 | Menopausal hormone therapy: a better and safer future. <b>2018</b> , 21, 454-461   | 17  |
| 499 | Breast Cancer Knowledge and Screening Practice and Barriers Among Women in Madinah, Saudi Arabia. <b>2018</b> , 33, 201-207  | 36  |
| 498 | Progesterone receptors (PR) mediate STAT actions: PR and prolactin receptor signaling crosstalk in breast cancer models. <b>2018</b> , 176, 88-93  | 26  |
| 497 | Race, Menopausal Hormone Therapy, and Invasive Breast Cancer in the Carolina Breast Cancer Study. <b>2018</b> , 27, 377-386  | 4   |
| 496 | Genetic variation in the DNA repair pathway as a potential determinant of response to platinum-based chemotherapy in breast cancer. <b>2018</b> , 233, 2752-2758   | 9   |
| 495 | O-GlcNAc-Dependent Regulation of Progesterone Receptor Function in Breast Cancer. <b>2018</b> , 9, 12-21   | 15  |
| 494 | A mixture of five endocrine-disrupting chemicals modulates concentrations of bisphenol A and estradiol in mice. <b>2018</b> , 193, 321-328   | 20  |
| 493 | RANKL and RANK: From Mammalian Physiology to Cancer Treatment. <b>2018</b> , 28, 213-223   | 46  |
| 492 | A combined connectivity mapping and pharmacoepidemiology approach to identify existing medications with breast cancer causing or preventing properties. <b>2018</b> , 27, 78-86  | 10  |
| 491 | Cancer Risk-Reducing Opportunities in Gynecologic Surgery. <b>2018</b> , 25, 1179-1193   | 5   |
| 490 | Combinatory effects of phytoestrogens and exercise on body fat mass and lipid metabolism in ovariectomized female rats. <b>2018</b> , 178, 73-81   | 14  |
| 489 | Extranuclear signaling by sex steroid receptors and clinical implications in breast cancer. <b>2018</b> , 466, 51-72   | 23  |
| 488 | Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study. <b>2018</b> , 25, 11-20   | 103 |
| 487 | Menopausia y Terapia Hormonal de la Menopausia Las recomendaciones 2018 de la Unidad de Endocrinología Ginecológica de Clínica Alemana de Santiago -Sociedad Italiana de la Menopausia y la Sociedad Chilena de Endocrinología Ginecológica. <b>2018</b> , 83, 527-550 | 1   |
| 486 | Mortality and Risk of Cancer After Prophylactic Bilateral Oophorectomy in Women With a Family History of Cancer. <b>2018</b> , 2, pky034   | 4   |

|     |  |    |
|-----|--|----|
| 485 | INFLUENCE OF PROBIOTIC SUPPLEMENTATION ON CLIMACTERIC SYMPTOMS IN MENOPAUSAL WOMEN-A MINI REVIEW. <b>2018</b> , 10, 43   | 9  |
| 484 | Much room for optimism on measuring diet, preventing cancer and cardiovascular disease, and correcting for measurement error –discussion of the paper by R. L. Prentice and Y. Huang. <b>2018</b> , 2, 14-20           |    |
| 483 | Number of Risky Lifestyle Behaviors and Breast Cancer Risk. <b>2018</b> , 2, pky030  | 7  |
| 482 | Towards Digital Cancer Genetic Counseling. <b>2018</b> ,   | 1  |
| 481 | Menopausal Hormone Therapy use and breast cancer risk by receptor subtypes: Results from the New South Wales Cancer Lifestyle and EvaluAtion of Risk (CLEAR) study. <b>2018</b> , 13, e0205034                         | 5  |
| 480 | Cancers related to lifestyle and environmental factors in France in 2015. <b>2018</b> , 105, 103-113   | 30 |
| 479 | Associations between Phytoestrogens, Glucose Homeostasis, and Risk of Diabetes in Women: A Systematic Review and Meta-Analysis. <b>2018</b> , 9, 726-740   | 19 |
| 478 | Mutations and Breast Cancer Prevention. <b>2018</b> , 10,  | 43 |
| 477 | Overdiagnosis in the population-based organized breast cancer screening program estimated by a non-homogeneous multi-state model: a cohort study using individual data with long-term follow-up. <b>2018</b> , 20, 153 | 11 |
| 476 | Risk prediction for estrogen receptor-specific breast cancers in two large prospective cohorts. <b>2018</b> , 20, 147  | 13 |
| 475 | Deciphering Steroid Receptor Crosstalk in Hormone-Driven Cancers. <b>2018</b> , 159, 3897-3907   | 34 |
| 474 | Nipple-sparing mastectomy in women at high risk of developing breast cancer. <b>2018</b> , 7, 325-336  | 4  |
| 473 | Mechanism of Telapristone Acetate (CDB4124) on Progesterone Receptor Action in Breast Cancer Cells. <b>2018</b> , 159, 3581-3595   | 8  |
| 472 | Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis. <b>2018</b> , 132, 111-115                            | 44 |
| 471 | Circulating Receptor Activator of Nuclear Factor- <b>B</b> (RANK), RANK ligand (RANKL), and Mammographic Density in Premenopausal Women. <b>2018</b> , 11, 789-796   | 4  |
| 470 | Effects of (Moraceae) Aqueous Extract and 7-Methoxycoumarin on Scopolamine-Induced Spatial Memory Impairment in Ovariectomized Wistar Rats. <b>2018</b> , 2018, 5751864  | 3  |
| 469 | Factors Associated with High Weight Gain and Obesity Duration: The Norwegian Women and Cancer (NOWAC) Study. <b>2018</b> , 11, 381-392   | 5  |
| 468 | Screening breast magnetic resonance imaging in women with hormone replacement therapy. <b>2018</b> , 23, 48  | 2  |

|     |   |    |
|-----|---|----|
| 467 | Protective Effects of Female Reproductive Factors on Lauren Intestinal-Type Gastric Adenocarcinoma. <b>2018</b> , 59, 28-34   | 12 |
| 466 | Menopause and Postmenopausal Health. <b>2018</b> , 672-688  |    |
| 465 | Estrogen-alone therapy and invasive breast cancer incidence by dose, formulation, and route of delivery: findings from the WHI observational study. <b>2018</b> , 25, 985-991   | 12 |
| 464 | Conjugated equine estrogen and medroxyprogesterone acetate are associated with decreased risk of breast cancer relative to bioidentical hormone therapy and controls. <b>2018</b> , 13, e0197064  | 4  |
| 463 | Natural hormone replacement therapy with a functioning ovary after the menopause: dream or reality?. <b>2018</b> , 37, 359-366  | 12 |
| 462 | Medicolegal Issues in Obstetrics and Gynaecology. <b>2018</b> ,   | 0  |
| 461 | Hormone Replacement Therapy (HRT). <b>2018</b> , 317-323  |    |
| 460 | The actin cytoskeletal architecture of estrogen receptor positive breast cancer cells suppresses invasion. <b>2018</b> , 9, 2980  | 29 |
| 459 | Icariin, but Not Genistein, Exerts Osteogenic and Anti-apoptotic Effects in Osteoblastic Cells by Selective Activation of Non-genomic ER $\beta$ Signaling. <b>2018</b> , 9, 474  | 17 |
| 458 | Risk of breast cancer in the UK biobank female cohort and its relationship to anthropometric and reproductive factors. <b>2018</b> , 13, e0201097   | 17 |
| 457 | Integration of in vitro and in silico perspectives to explain chemical characterization, biological potential and anticancer effects of Hypericum salsugineum: A pharmacologically active source for functional drug formulations. <b>2018</b> , 13, e0197815 | 22 |
| 456 | Good Guy or Bad Guy? The Duality of Wild-Type p53 in Hormone-Dependent Breast Cancer Origin, Treatment, and Recurrence. <b>2018</b> , 10,   | 7  |
| 455 | Soybean-Hop Alleviates Estrogen Deficiency-Related Bone Loss and Metabolic Dysfunction in Ovariectomized Rats Fed a High-Fat Diet. <b>2018</b> , 23,  | 7  |
| 454 | Modulation of the endocannabinoid system by sex hormones: Implications for posttraumatic stress disorder. <b>2018</b> , 94, 302-320   | 27 |
| 453 | Millettia macrophylla (Fabaceae) phenolic fraction prevents differentiation of 3T3-L1 adipocytes and the increased risks of cardiovascular diseases in ovariectomized rats. <b>2018</b> , 222, 87-98  | 2  |
| 452 | A-C Estrogens as Potent and Selective Estrogen Receptor-Beta Agonists (SERBAs) to Enhance Memory Consolidation under Low-Estrogen Conditions. <b>2018</b> , 61, 4720-4738   | 10 |
| 451 | Fertility Drugs and Ovarian Cancer. <b>2018</b> , 18, 567-576   | 3  |
| 450 | Effects of isoflavones on breast tissue and the thyroid hormone system in humans: a comprehensive safety evaluation. <b>2018</b> , 92, 2703-2748  | 37 |



|     |  |    |
|-----|--|----|
| 449 | Hormone Therapy and Breast Cancer: Emerging Steroid Receptor Mechanisms. <b>2018</b> , 61, R133-R160   | 10 |
| 448 | Improved diagnostics and change of tumour characteristics in breast cancer: a retrospective study over two decades. <b>2018</b> , 57, 1331-1338                                | 0  |
| 447 | Discovery of a tetrazolyl $\beta$ -carboline with and osteoprotective activity under estrogen-deficient conditions. <b>2018</b> , 9, 1213-1225                                 | 3  |
| 446 | Different menopausal hormone regimens and risk of breast cancer. <b>2018</b> , 29, 1771-1776   | 21 |
| 445 | Bisphenol S modulates concentrations of bisphenol A and oestradiol in female and male mice. <b>2019</b> , 49, 540-548  | 8  |
| 444 | Menopause and Aging. <b>2019</b> , 322-356.e9  | 6  |
| 443 | Hormone-Responsive Cancers. <b>2019</b> , 717-741.e8   | 1  |
| 442 | Menopausal hormone therapy and breast cancer risk: effect modification by body mass through life. <b>2019</b> , 34, 267-278  | 3  |
| 441 | Cohort Profile: the Million Women Study. <b>2019</b> , 48, 28-29e  | 31 |
| 440 | Mammary stem cells and progenitors: targeting the roots of breast cancer for prevention. <b>2019</b> , 38, e100852   | 32 |
| 439 | Managing Menopause and Post-reproductive Health: Beyond Hormones and Medicines. <b>2019</b> , 439-465  |    |
| 438 | Hereditary breast cancer: screening and risk reducing surgery. <b>2019</b> , 8, S142-S149  | 4  |
| 437 | Risk-Reducing Bilateral Salpingo-Oophorectomy for BRCA Mutation Carriers and Hormonal Replacement Therapy: If It Should Rain, Better a Drizzle than a Storm. <b>2019</b> , 55, | 7  |
| 436 | Fatty Acid Profile of Postmenopausal Women Receiving, and Not Receiving, Hormone Replacement Therapy. <b>2019</b> , 16,  | 3  |
| 435 | Menopausal hormone therapy: is there cause for concern?. <b>2019</b> , 7, 825-827  | 2  |
| 434 | Molecular mechanisms underlying progesterone receptor action in breast cancer: Insights into cell proliferation and stem cell regulation. <b>2019</b> , 152, 108503            | 19 |
| 433 | [Hormone and breast cancer]. <b>2019</b> , 48, 1085-1091   | 7  |
| 432 | Effect of royal jelly on menopausal symptoms: A randomized placebo-controlled clinical trial. <b>2019</b> , 37, 47-50  | 10 |

|     |  |    |
|-----|--|----|
| 431 | Increased Extracellular Osteopontin Levels in Normal Human Breast Tissue at High Risk of Developing Cancer and Its Association With Inflammatory Biomarkers. <b>2019</b> , 9, 746  | 7  |
| 430 | Current Evidence of the Oncological Benefit-Risk Profile of Hormone Replacement Therapy. <b>2019</b> , 55,   | 16 |
| 429 | Daidzein and genistein have differential effects in decreasing whole body bone mineral density but had no effect on hip and spine density in premenopausal women: A 2-year randomized, double-blind, placebo-controlled study. <b>2019</b> , 68, 70-81 | 7  |
| 428 | Chapitre 3 : Hormonothérapie ménopausique et cancer du sein. <b>2019</b> , 41 Suppl 1, S58-S67   |    |
| 427 | A Modified Formulation of Sutaehwan Ameliorates Menopausal Anxiety, Depression and Heart Hypertrophy in the VCD-Induced Menopausal Mouse Model. <b>2019</b> , 42, 1471-1481  | 3  |
| 426 | Menopausal hormone therapy and biliary tract cancer: a population-based matched cohort study in Sweden. <b>2019</b> , 58, 290-295  | 4  |
| 425 | Supplementation with extract of pumpkin seeds exerts estrogenic effects upon the uterine, serum lipids, mammary glands, and bone density in ovariectomized rats. <b>2019</b> , 33, 891-900   | 1  |
| 424 | Neuroprotective Effects of the Anthocleista Schweinfurthii Gilg. (Loganiaceae) Stem Bark Extract in Postmenopause-Like Model of Ovariectomized Wistar Rats. <b>2019</b> , 16,  | 3  |
| 423 | [Menopausal hormone therapy: I am back!]. <b>2019</b> , 47, 91-92  |    |
| 422 | Association of ten gastrointestinal and other medical conditions with positivity to faecal occult blood testing in routine screening: a large prospective study of women in England. <b>2019</b> , 48, 549-558   | 2  |
| 421 | CGRP Is Critical for Hot Flushes in Ovariectomized Mice. <b>2018</b> , 9, 1452   | 4  |
| 420 | Delineation of critical amino acids in activation function 1 of progesterone receptor for recruitment of transcription coregulators. <b>2019</b> , 1862, 522-533   | 3  |
| 419 | Changes in breast density during hormone treatment with transdermal estrogens alone or in combination with progesterone. <b>2019</b> , 35, 991-994   |    |
| 418 | Hormonal control of seasonal color change in female spiny-footed lizards: an observational and experimental approach. <b>2019</b> , 65, 633-642  | 1  |
| 417 | Effects of 17βHSD2 inhibition in bones on osteoporosis based on an animal rat model. <b>2019</b> , 192, 105405   | 3  |
| 416 | Acupuncture or phytoestrogens (E)strogen plus progestin on menopausal symptoms. A randomized study. <b>2019</b> , 35, 995-998  | 9  |
| 415 | Osteoprotective effect of genistein 7-O-phosphate, a derivative of genistein with high bioavailability, in ovariectomized rats. <b>2019</b> , 58, 171-179  | 3  |
| 414 | Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands. <b>2019</b> , 365, 11652   | 98 |

|     |  |     |
|-----|--|-----|
| 413 | Phthalate Exposure and Breast Cancer Incidence: A Danish Nationwide Cohort Study. <b>2019</b> , 37, 1800-1809  | 39  |
| 412 | Use of hormone therapy (HT) among Swedish women with contraindications - A pharmacoepidemiological cohort study. <b>2019</b> , 123, 55-60  | 2   |
| 411 | Epigenome-wide association study for lifetime estrogen exposure identifies an epigenetic signature associated with breast cancer risk. <b>2019</b> , 11, 66  | 12  |
| 410 | Biochemical and biophysical study of chemopreventive and chemotherapeutic anti-tumor potential of some Egyptian plant extracts. <b>2019</b> , 18, 100637   | 3   |
| 409 | Epidemiological characteristics of and risk factors for breast cancer in the world. <b>2019</b> , 11, 151-164  | 185 |
| 408 | Safety of hormone replacement therapy following risk-reducing salpingo-oophorectomy: systematic review of literature and guidelines. <b>2019</b> , 22, 352-360   | 21  |
| 407 | Sex Hormones and Anticancer Immunity. <b>2019</b> , 25, 4603-4610  | 44  |
| 406 | Use of dietary supplements containing soy isoflavones and breast cancer risk among women aged >50 y: a prospective study. <b>2019</b> , 109, 597-605   | 11  |
| 405 | Ich lerne wie ein Zombie. <b>2019</b> ,  |     |
| 404 | PGRMC1 can trigger estrogen-dependent proliferation of breast cancer cells: estradiol vs. equilin vs. ethinylestradiol. <b>2019</b> , 22, 483-488  | 8   |
| 403 | The preventable burden of breast cancers for premenopausal and postmenopausal women in Australia: A pooled cohort study. <b>2019</b> , 145, 2383-2394  | 8   |
| 402 | A Randomized, Controlled Clinical Trial of Combining Therapy with Traditional Chinese Medicine-Based Psychotherapy and Chinese Herbal Medicine for Menopausal Women with Moderate to Serious Mood Disorder. <b>2019</b> , 2019, 9581087                | 1   |
| 401 | Change in mammographic density across birth cohorts of Dutch breast cancer screening participants. <b>2019</b> , 145, 2954-2962  | 3   |
| 400 | British Menopause Society consensus statement: The risks and benefits of HRT before and after a breast cancer diagnosis. <b>2019</b> , 25, 33-37   | 11  |
| 399 | Reproductive factors and risk of melanoma: a population-based cohort study. <b>2019</b> , 181, 282-289   | 4   |
| 398 | Update on Menopausal Hormone Therapy for Fracture Prevention. <b>2019</b> , 17, 465-473  | 18  |
| 397 | Assessing the Effectiveness of , a Classical Ayurvedic Formulation as Add-on Therapy to Vitamin D and Calcium Supplements in Patients with Osteopenia: A Randomized, Open-Labeled, Comparative, Controlled Clinical Study. <b>2019</b> , 25, 1044-1053 | 1   |
| 396 | Sexual functioning in 4,418 postmenopausal women participating in UKCTOCS: a qualitative free-text analysis. <b>2019</b> , 26, 1100-1009   | 13  |

|     |  |    |
|-----|--|----|
| 395 | Utilization pattern of hormone therapy in UK general practice between 1996 and 2015: a descriptive study. <b>2019</b> , 26, 741-749  | 4  |
| 394 | Endocrine Therapy for Hormone Receptor-Positive Breast Cancer. <b>2019</b> , 1-26  |    |
| 393 | Use of skincare products and risk of cancer of the breast and endometrium: a prospective cohort study. <b>2019</b> , 18, 105   | 0  |
| 392 | Hormone therapy in postmenopausal women associated with risk of stroke and venous thromboembolism: a population-based cohort study in Taiwan. <b>2019</b> , 26, 197-202                              | 6  |
| 391 | Genetics of breast cancer: management strategies and risk-reducing surgery. <b>2019</b> , 80, 720-725  | 9  |
| 390 | Metabolic switch induced by Cimicifuga racemosa extract prevents mitochondrial damage and oxidative cell death. <b>2019</b> , 52, 107-116  | 10 |
| 389 | Estrogen metabolism in menopausal hormone users in the women's health initiative observational study: Does it differ between estrogen plus progestin and estrogen alone?. <b>2019</b> , 144, 730-740 | 3  |
| 388 | Computerized hybrid decision-making system for hormone replacement therapy in menopausal women. <b>2019</b> , 27, 49-59  | 1  |
| 387 | Exogenous female sex steroids may reduce lung ageing after menopause: A 20-year follow-up study of a general population sample (ECRHS). <b>2019</b> , 120, 29-34                                     | 7  |
| 386 | The role of menopausal hormone therapy in women with or at risk of ovarian and breast cancers: Misconceptions and current directions. <b>2019</b> , 125, 499-514                                     | 9  |
| 385 | Effects of serum estradiol and progesterone on estrogen-regulated gene expression in breast cancers of premenopausal patients. <b>2019</b> , 49, 12-21   | 3  |
| 384 | Consensus statement on the use of HRT in postmenopausal women in the management of osteoporosis by SIE, SIOMMMS and SIGO. <b>2019</b> , 42, 609-618  | 7  |
| 383 | Efficacy of an orally active small-molecule inhibitor of RANKL in bone metastasis. <b>2019</b> , 7, 1  | 44 |
| 382 | Erxian decoction, a Chinese herbal formula, for menopausal syndrome: An updated systematic review. <b>2019</b> , 234, 8-20   | 12 |
| 381 | RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives. <b>2019</b> , 38, 12   | 66 |
| 380 | Diet and risk of breast, endometrial and ovarian cancer: UK Women's Cohort Study. <b>2019</b> , 122, 564-574   | 14 |
| 379 | Interdisciplinary Management of Transgender Individuals at Risk for Breast Cancer: Case Reports and Review of the Literature. <b>2019</b> , 19, e12-e19  | 22 |
| 378 | Progesterone and Breast Cancer. <b>2020</b> , 41,  | 33 |

|     |  |    |
|-----|--|----|
| 377 | Menopausal hormone therapy and breast cancer: Need to put risks in perspective. <b>2020</b> , 131, 89-90   | 1  |
| 376 | Lifestyle and occupational factors associated with participation in breast mammography screening among Western Australian women. <b>2020</b> , 27, 77-84   | 4  |
| 375 | Serial endometrial thickness and risk of non-endometrial hormone-dependent cancers in postmenopausal women in UK Collaborative Trial of Ovarian Cancer Screening. <b>2020</b> , 56, 267-275                    | 1  |
| 374 | Mammographic Density Change and Risk of Breast Cancer. <b>2020</b> , 112, 391-399  | 14 |
| 373 | Folic acid prevents the progesterone-promoted proliferation and migration in breast cancer cell lines. <b>2020</b> , 59, 2333-2344   | 3  |
| 372 | Carcinogenic potential of fluorinated estrogens in mammary tumorigenesis. <b>2020</b> , 318, 99-103  | 1  |
| 371 | Ethnic and age differences in right-left breast asymmetry in a large population-based screening population. <b>2020</b> , 93, 20190328   | 1  |
| 370 | S3-Leitlinie: Hormonersatztherapie und Krebsrisiko. <b>2020</b> , 53, 29-34  | 1  |
| 369 | Anti-proliferative transcriptional effects of medroxyprogesterone acetate in estrogen receptor positive breast cancer cells are predominantly mediated by the progesterone receptor. <b>2020</b> , 199, 105548 | 5  |
| 368 | Two novel polysaccharides from rhizomes of <i>Cibotium barometz</i> promote bone formation via activating the BMP2/SMAD1 signaling pathway in MC3T3-E1 cells. <b>2020</b> , 231, 115732                        | 11 |
| 367 | Menopausal hormone therapy for BRCA-mutation carriers: attitudes of Israeli healthcare providers before and after a brief educational intervention. <b>2020</b> , 27, 82-87                                    | 0  |
| 366 | Progestogens are the problem in hormone replacement therapy: Time to reappraise their use. <b>2020</b> , 26, 26-31   | 7  |
| 365 | Milk Consumption Decreases Risk for Breast Cancer in Korean Women under 50 Years of Age: Results from the Health Examinees Study. <b>2019</b> , 12,  | 5  |
| 364 | Trends in Prescribing Menopausal Hormone Therapy and Bisphosphonates in Australia and Manitoba, Canada and Adherence to Recommendations. <b>2020</b> , 29, 177-186   | 2  |
| 363 | News and views. <b>2020</b> , 26, 121-125  |    |
| 362 | The risks and benefits of hormone replacement therapy before and after a breast cancer diagnosis. <b>2020</b> , 26, 126-135  | 3  |
| 361 | The British Menopause Society & Women's Health Concern 2020 recommendations on hormone replacement therapy in menopausal women. <b>2020</b> , 26, 181-209  | 24 |
| 360 | Menopausal Hormone Therapy and breast cancer risk: Individualization is the key to safety. <b>2020</b> , 141, 85-86  | 1  |

|     |  |     |
|-----|--|-----|
| 359 | Actaea racemosa L. extract inhibits steroid sulfation in human breast cancer cells: Effects on androgen formation. <b>2020</b> , 79, 153357  | 1   |
| 358 | Postmenopausal hormone therapy in BRCA gene mutation carriers: to whom and which?. <b>2020</b> , 19, 1025-1030   | 4   |
| 357 | Breast Cancer and Microcalcifications: An Osteoimmunological Disorder?. <b>2020</b> , 21,  | 7   |
| 356 | Progestins in menopausal hormone therapy and breast cancer risk: The debate continues. <b>2020</b> , 15, 24-30   | 2   |
| 355 | Use of postmenopausal hormone therapies and risk of histology- and hormone receptor-defined breast cancer: results from a 15-year prospective analysis of NIH-AARP cohort. <b>2020</b> , 22, 129 | 4   |
| 354 | Targeting the RANKL/RANK/OPG Axis for Cancer Therapy. <b>2020</b> , 10, 1283   | 15  |
| 353 | Australian women's understanding of menopause and its consequences: a qualitative study. <b>2020</b> , 23, 622-628   | 5   |
| 352 | Medical Transition for Gender Diverse Patients. <b>2020</b> , 9, 166-177   |     |
| 351 | Population Trends in Lobular Carcinoma of the Breast: The Ontario Experience. <b>2020</b> , 27, 4711-4719  | 7   |
| 350 | Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases. <b>2020</b> , 371, m3873                                       | 33  |
| 349 | Long term absence of invasive breast cancer diagnosis in 2,402,672 pre and postmenopausal women: A systematic review and meta-analysis. <b>2020</b> , 15, e0237925                               | 1   |
| 348 | Breast effects of oral, combined 17 $\beta$ -estradiol, and progesterone capsules in menopausal women: a randomized controlled trial. <b>2020</b> , 27, 1388-1395                                | 5   |
| 347 | It is all in the name: The importance of correct terminology in hormone replacement therapy. <b>2020</b> , 26, 142-146   | 3   |
| 346 | Key steps for effective breast cancer prevention. <b>2020</b> , 20, 417-436  | 120 |
| 345 | The Effect of Aromatherapy on Sleep and Quality of Life in Menopausal Women with Sleeping Problems: A Non-Randomized, Placebo-Controlled Trial. <b>2020</b> , 27, 421-430                        | 0   |
| 344 | Hormone replacement therapy and mammographic density: a systematic literature review. <b>2020</b> , 182, 555-579   | 7   |
| 343 | Attitude and knowledge for menopause management among health professionals in mainland China. <b>2020</b> , 23, 614-621  | 4   |
| 342 | L. Is More Effective in Combination with L. for Relief of Menopausal Symptoms: A Randomized, Double-Blind, Placebo-Controlled Study. <b>2020</b> , 13,   | 4   |

|     |  |     |
|-----|--|-----|
| 341 | Hormone Replacement Therapy Prescription after Premature Surgical Menopause. <b>2020</b> , 27, 1618-1623   | 2   |
| 340 | HRT and breast cancer: a million women ride again. <b>2020</b> , 23, 226-228   | 8   |
| 339 | Comparison of exercise training and estrogen supplementation on mast cell-mediated doxorubicin-induced cardiotoxicity. <b>2020</b> , 318, R829-R842                        | 6   |
| 338 | Nanosensor networks for smart health care. <b>2020</b> , 387-403   | 4   |
| 337 | Systematic review of acceptability, cardiovascular, neurological, bone health and HRT outcomes following risk reducing surgery in BRCA carriers. <b>2020</b> , 65, 46-65   | 15  |
| 336 | S3-Leitlinie: Hormonersatztherapie und Krebsrisiko. <b>2020</b> , 18, 20-25  |     |
| 335 | Prognostic Impact of Menopausal Hormone Therapy in Breast Cancer Differs According to Tumor Characteristics and Treatment. <b>2020</b> , 10, 80                            | 5   |
| 334 | Healthcare Utilization and Prevalence of Symptoms in Women with Menopause: A Real-World Analysis. <b>2020</b> , 12, 445-454  | 7   |
| 333 | Menopausal hormone therapy use and long-term all-cause and cause-specific mortality in the Long Island Breast Cancer Study Project. <b>2020</b> , 147, 3404-3415           | 3   |
| 332 | Distal forearm fractures in immigrant groups: A national Swedish study. <b>2020</b> , 138, 115508  | 2   |
| 331 | Hormone Therapy and Cancer. <b>2020</b> , 208-222  | 1   |
| 330 | The Menstrual Cycle and Risk of Breast Cancer: A Review. <b>2020</b> , 10, 21  | 14  |
| 329 | 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. <b>2020</b> , 72, 529-556             | 135 |
| 328 | Dairy, soy, and risk of breast cancer: those confounded milks. <b>2020</b> , 49, 1526-1537   | 29  |
| 327 | Antineuroinflammation activity of n-butanol fraction of <i>Marsilea crenata</i> Presl. in microglia HMC3 cell line. <b>2020</b> , 30,                                      | 1   |
| 326 | A polysaccharide from the dried rhizome of <i>Drynaria fortunei</i> (Kunze) J. Sm. prevents ovariectomized (OVX)-induced osteoporosis in rats. <b>2020</b> , 24, 3692-3700 | 6   |
| 325 | 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. <b>2020</b> , 72, 461-488             | 54  |
| 324 | Underlying Breast Cancer Risk and Menopausal Hormone Therapy. <b>2020</b> , 105,   | 10  |

|     |  |    |
|-----|--|----|
| 323 | Progesterone and Breast Cancer: an NCI Workshop Report. <b>2020</b> , 11, 1-12   | 8  |
| 322 | APOBEC3B expression in breast cancer cell lines and tumors depends on the estrogen receptor status. <b>2020</b> , 41, 1030-1037  | 3  |
| 321 | Physical activity and breast cancer risk: results from the UK Biobank prospective cohort. <b>2020</b> , 122, 726-732   | 14 |
| 320 | Association of Circulating Progesterone With Breast Cancer Risk Among Postmenopausal Women. <b>2020</b> , 3, e203645   | 12 |
| 319 | Association of Nongenetic Factors With Breast Cancer Risk in Genetically Predisposed Groups of Women in the UK Biobank Cohort. <b>2020</b> , 3, e203760                    | 3  |
| 318 | Progesterone and breast. <b>2020</b> , 69, 85-94   | 3  |
| 317 | Microbiome, bile acids, and obesity: How microbially modified metabolites shape anti-tumor immunity. <b>2020</b> , 295, 220-239  | 17 |
| 316 | Hormone Replacement Therapy, Breast Cancer Risk Factors, and Breast Cancer Risk: A Nationwide Population-Based Cohort. <b>2020</b> , 29, 1341-1347                         | 6  |
| 315 | Obesity and breast cancer risk for pre- and postmenopausal women among over 6 million Korean women. <b>2021</b> , 185, 495-506   | 10 |
| 314 | The efficacy and safety of intravaginal oxytocin on vaginal atrophy: A systematic review. <b>2021</b> , 27, 30-41  | 1  |
| 313 | Osteoporotic fractures among foreign-born individuals: a national Swedish study. <b>2021</b> , 32, 343-352   | 4  |
| 312 | WITHDRAWN - Administrative Duplicate Publication: Risks and benefits of hormone replacement therapy before and after a breast cancer diagnosis. <b>2021</b> , 27, NP2-NP10 |    |
| 311 | Evaluation of a tertiary and district general hospital menopause service. <b>2021</b> , 27, 19-29  | 1  |
| 310 | Examining social capital and online social support links: a study in online health communities facing treatment uncertainty. <b>2021</b> , 18, 57-94                       | 3  |
| 309 | Hormone Replacement Therapy, Synthetic Progestogens, and Breast Cancer Risk.   |    |
| 308 | Behavioural Factors in the Social Gradients in Cancer Incidence. <b>2021</b> , 189-203   |    |
| 307 | Relationship Between Proliferative Breast Lesions and Breast Cancer Risk Factors. <b>2021</b> , 17, 15-20  | 1  |
| 306 | Insights on neuroendocrine regulation of immune mediators in female reproductive aging and cancer. <b>2021</b> , 8, 127-148  |    |



|     |   |    |
|-----|---|----|
| 305 | Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists. <b>2021</b> , 42, 967-984 | 34 |
| 304 | Does Unopposed Peri-menopausal or Post-menopausal Estrogen Protect against Breast Cancer? A Systematic Review. 075-082  |    |
| 303 | Prescribing of menopausal hormone therapy in Germany: Current status and changes between 2004 and 2016. <b>2021</b> , 30, 462-471   | 0  |
| 302 | Large-scale systematic analysis of exposure to multiple cancer risk factors and the associations between exposure patterns and cancer incidence. <b>2021</b> , 11, 2343   | 1  |
| 301 | Raloxifene as a treatment option for viral infections. <b>2021</b> , 59, 124-131  | 17 |
| 300 | Stem Cell Paracrine Signaling for Treatment of Premature Ovarian Insufficiency. <b>2020</b> , 11, 626322  | 0  |
| 299 | Dancing With Health: Quality of Life and Physical Improvements From an EU Collaborative Dance Programme With Women Following Breast Cancer Treatment. <b>2021</b> , 12, 635578  | 3  |
| 298 | Random effects models of lymph node metastases in breast cancer: quantifying the roles of covariates and screening using a continuous growth model. <b>2021</b> ,   | 3  |
| 297 | Preventable fractions of cancer incidence attributable to 7-years weight gain in the Norwegian Women and Cancer (NOWAC) study. <b>2021</b> , 11, 3800   |    |
| 296 | Risks, Benefits, and Treatment Modalities of Menopausal Hormone Therapy: Current Concepts. <b>2021</b> , 12, 564781   | 6  |
| 295 | Biochanin A Attenuates Ovariectomy-Induced Cognition Deficit Antioxidant Effects in Female Rats. <b>2021</b> , 12, 603316   | 2  |
| 294 | Which Hormones and Contraception for Women with APS? Exogenous Hormone Use in Women with APS. <b>2021</b> , 23, 44  | 0  |
| 293 | Evaluation of menopausal hormone therapy use in Korea (2002-2013): A nationwide cohort study. <b>2021</b> , 146, 57-62  | 3  |
| 292 | Quality of Life After Bilateral Risk-Reducing Mastectomy and Simultaneous Reconstruction Using Pre-Pectoral Silicone Implants. <b>2021</b> , 15, 741-750  | 3  |
| 291 | Self-selection for mammography screening according to use of hormone replacement therapy: A systematic literature review. <b>2021</b> , 71, 101812  | 1  |
| 290 | Hormone Therapy in Menopause: Concepts, Controversies, and Approach to Treatment. <b>2021</b> , 42, 720-752   | 6  |
| 289 | [Benefit-risk balance of hormone replacement therapy: Cancers and mortality. Postmenopausal women management - CNGOF and GEMVi clinical practice guidelines]. <b>2021</b> , 49, 462-473                                     | 1  |
| 288 | Conjugated equine estrogen used in postmenopausal women associated with a higher risk of stroke than estradiol. <b>2021</b> , 11, 10801   | 2  |

|     |   |    |
|-----|---|----|
| 287 | Cistanche deserticola polysaccharide inhibits OVX-induced bone loss in mice and RANKL-induced osteoclastogenesis. <b>2021</b> , 81, 104464                                    | 2  |
| 286 | Does it matter for the radiologists' performance whether they read short or long batches in organized mammographic screening?. <b>2021</b> , 31, 9548-9555                    | 1  |
| 285 | Multi-input convolutional neural network for breast cancer detection using thermal images and clinical data. <b>2021</b> , 204, 106045  | 11 |
| 284 | Influence of a new botanical combination on quality of life in menopausal Spanish women: Results of a randomized, placebo-controlled pilot study. <b>2021</b> , 16, e0255015  | 0  |
| 283 | Estrogen Deficiency Induces Mitochondrial Damage Prior to Emergence of Cognitive Deficits in a Postmenopausal Mouse Model. <b>2021</b> , 13, 713819                           | 4  |
| 282 | Fracture recurrence in hip fracture with menopausal hormone therapy versus risedronate: a clinical trial. <b>2021</b> , 24, 408-414   | 1  |
| 281 | Less Carcinogenic Chlorinated Estrogens Applicable to Hormone Replacement Therapy. <b>2021</b> , 22,  |    |
| 280 | Estetrol and Mammary Gland: Friends or Foes?. <b>2021</b> , 26, 297-308   | 1  |
| 279 | Combined Lifestyle Behaviors and the Incidence of Common Cancer Types in the Norwegian Women and Cancer Study (NOWAC). <b>2021</b> , 13, 721-734                              | 1  |
| 278 | Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration. Translation to Russian. <b>2021</b> , 2, 119-169                  | 1  |
| 277 | Hormone replacement therapy and cancer survival: a longitudinal cohort study: protocol paper. <b>2021</b> , 11, e046701   |    |
| 276 | Steroid Receptors in Breast Cancer: Understanding of Molecular Function as a Basis for Effective Therapy Development. <b>2021</b> , 13,                                       | 3  |
| 275 | The Reactivity of Human and Equine Estrogen Quinones towards Purine Nucleosides. <b>2021</b> , 13, 1641   |    |
| 274 | The role of education on Cancer amenable mortality among non-Hispanic blacks & non-Hispanic whites in the United States (1989-2018). <b>2021</b> , 21, 907                    | 3  |
| 273 | Extract Ze 450 Re-Balances Energy Metabolism and Promotes Longevity. <b>2021</b> , 10,  | 3  |
| 272 | Menopause and care of the mature woman: Endocrinology, Consequences of Estrogen Deficiency, Effects of Hormone Therapy, and Other Treatment Options. <b>2022</b> , 255-288.e9 |    |
| 271 | Cancer screening and prevention: Sex and gender evidence in lung, breast, and colorectal cancer. <b>2021</b> , 75-99  |    |
| 270 | Living Longer, Healthier Lives. <b>2007</b> , 53-78   | 1  |

|     |   |    |
|-----|---|----|
| 269 | Risk Factors. <b>2010</b> , 3-22  | 4  |
| 268 | Epidemiology of Overweight/Obesity and Cancer Risk. <b>2011</b> , 5-23  | 4  |
| 267 | Mechanisms Linking Obesity to Cancer Risk. <b>2011</b> , 99-142   | 2  |
| 266 | Practical Approach for the Diagnosis and Management of Insomnia During Menopausal Transition. <b>2013</b> , 293-324   | 1  |
| 265 | Second Malignancy Risk After Treatment of Hodgkin Lymphoma. <b>2015</b> , 375-409   | 1  |
| 264 | Die alternde Bevölkerung: Demographie, gesundheitliche Einschränkungen, Krankheiten und Prävention unter Gender-Fokus. <b>2004</b> , 267-300  | 1  |
| 263 | NHG-Standaard Urineweginfectie. <b>2011</b> , 1441-1459   | 2  |
| 262 | Mortality Affected by Health Care and Public Health Policy Interventions. <b>2011</b> , 583-607   | 5  |
| 261 | Menopause. <b>2007</b> , 1039-1071  | 6  |
| 260 | Interventions for Osteoporosis. <b>2007</b> , 351-375   | 1  |
| 259 | Breast Cancer. <b>2006</b> , 995-1012   | 51 |
| 258 | Study designs which can demonstrate and test causation. <b>2007</b> , 19-52   | 1  |
| 257 | Knowledge of reproductive physiology and hormone therapy in 53- to 54-year-old Swedish women: a population-based study. <b>2007</b> , 14, 1039-46   | 5  |
| 256 | The origin of breast cancer. <b>2007</b> , 14, 1060-8   | 12 |
| 255 | Histologic changes in the breast with menopausal hormone therapy use: correlation with breast density, estrogen receptor, progesterone receptor, and proliferation indices. <b>2008</b> , 15, 67-73 | 45 |
| 254 | Combining genome-wide studies of breast, prostate, ovarian and endometrial cancers maps cross-cancer susceptibility loci and identifies new genetic associations.                                   | 2  |
| 253 | Management of breast cancer--part I. <b>2008</b> , 337, a421  | 7  |
| 252 | Bone protection by estrogens occurs through non-tissue-selective activation of the androgen receptor. <b>2006</b> , 116, 2500-9   | 27 |

|     |  |    |
|-----|--|----|
| 251 | Linkage disequilibrium mapping of CHEK2: common variation and breast cancer risk. <b>2006</b> , 3, e168  | 30 |
| 250 | Duration of Adulthood Overweight, Obesity, and Cancer Risk in the Women's Health Initiative: A Longitudinal Study from the United States. <b>2016</b> , 13, e1002081   | 68 |
| 249 | Estrogen receptor beta-selective agonists stimulate calcium oscillations in human and mouse embryonic stem cell-derived neurons. <b>2010</b> , 5, e11791   | 23 |
| 248 | Increased risk for invasive breast cancer associated with hormonal therapy: a nation-wide random sample of 65,723 women followed from 1997 to 2008. <b>2011</b> , 6, e25183  | 12 |
| 247 | Raloxifene and desmethylarrozifene block estrogen-induced malignant transformation of human breast epithelial cells. <b>2011</b> , 6, e27876   | 8  |
| 246 | Generation of breast cancer stem cells by steroid hormones in irradiated human mammary cell lines. <b>2013</b> , 8, e77124   | 22 |
| 245 | Hormonal therapy and risk of breast cancer in mexican women. <b>2013</b> , 8, e79695   | 10 |
| 244 | Inferring gene dependency network specific to phenotypic alteration based on gene expression data and clinical information of breast cancer. <b>2014</b> , 9, e92023   | 7  |
| 243 | Elevation of SIPL1 (SHARPIN) Increases Breast Cancer Risk. <b>2015</b> , 10, e0127546  | 27 |
| 242 | Low Osteoporosis Treatment Initiation Rate in Women after Distal Forearm or Proximal Humerus Fracture: A Healthcare Database Nested Cohort Study. <b>2015</b> , 10, e0143842   | 15 |
| 241 | 90 YEARS OF PROGESTERONE: Steroid receptors as MAPK signaling sensors in breast cancer: let the fates decide. <b>2020</b> , 65, T35-T48  | 8  |
| 240 | [The influence of estrogen and progesterone replacement on growth hormone activity in women with hypopituitarism]. <b>2008</b> , 52, 901-16  | 3  |
| 239 | Long-time qingyan formula extract treatment exerts estrogenic activities on reproductive tissues without side effects in ovariectomized rats and via active ER to ERE-independent gene regulation. <b>2019</b> , 11, 4032-4049 | 1  |
| 238 | Increased breast tissue receptor activator of nuclear factor- $\kappa$ ligand (RANKL) gene expression is associated with higher mammographic density in premenopausal women. <b>2017</b> , 8, 73787-73792                      | 8  |
| 237 | Progesterone receptor membrane component 1 is phosphorylated upon progestin treatment in breast cancer cells. <b>2017</b> , 8, 72480-72493   | 20 |
| 236 | Progesterone receptor isoforms, agonists and antagonists differentially reprogram estrogen signaling. <b>2018</b> , 9, 4282-4300   | 33 |
| 235 | Framing Effects of Risk Communication in Health-Related Decision Making; Learning from a Discrete Choice Experiment.   | 1  |
| 234 | Skin treatments and dermatological procedures to promote youthful skin. <b>2006</b> , 1, 51-6  | 15 |

|     |  |    |
|-----|--|----|
| 233 | Comparative effects of antiresorptive agents on bone mineral density and bone turnover in postmenopausal women. <b>2006</b> , 1, 377-87  | 7  |
| 232 | Hormones and dementia - a comparative study of hormonal impairment in post-menopausal women, with and without dementia. <b>2006</b> , 2, 199-206   | 7  |
| 231 | Are Oxidative Stress and Inflammation Mediators of Bone Loss Due to Estrogen Deficiency? A Review of Current Evidence. <b>2020</b> , 20, 1478-1487   | 15 |
| 230 | PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects. <b>2020</b> , 22,  | 72 |
| 229 | Estrogen, male dominance and esophageal adenocarcinoma: is there a link?. <b>2012</b> , 18, 393-400  | 35 |
| 228 | Validit'hdrique de la Mthode des Choix Discrets: le cas du Traitement Hormonal substitutif de la Mhopause. <b>2008</b> , 26, 259   | 0  |
| 227 | PARP inhibitor reduces proliferation and increases apoptosis in breast cancer cells. <b>2014</b> , 26, 142-7   | 7  |
| 226 | Mitochondrial and caspase pathways are involved in the induction of apoptosis by nardosinen in MCF-7 breast cancer cell line. <b>2018</b> , 13, 12-21  | 13 |
| 225 | Estrogen stimulates adenosine receptor expression subtypes in human breast cancer MCF-7 cell line. <b>2018</b> , 13, 57-64   | 9  |
| 224 | Ecological and Chemotypic Analysis for Improved Growth and Management of Naturally Occurring Black Cohosh (&i&t;Actaea racemosa&/i&t; L.) Populations in Western Maryland. <b>2015</b> , 06, 3272-3281 | 1  |
| 223 | Paroxetine Increased the Serum Estrogen in Postmenopausal Women with Depressive and Anxiety Symptoms. <b>2014</b> , 03, 184-194  | 4  |
| 222 | Phytoestrogens impact on menopausal symptomatology. <b>2013</b> , 25, 98-100   | 5  |
| 221 | The 2020 Menopausal Hormone Therapy Guidelines. <b>2020</b> , 26, 69-98  | 10 |
| 220 | Trends of breast cancer and its management in the last twenty years in Aden and adjacent governorates, Yemen. <b>2012</b> , 13, 4347-51  | 9  |
| 219 | Lifestyle components and primary breast cancer prevention. <b>2014</b> , 15, 10543-55  | 16 |
| 218 | Progesterone Receptor Signaling in the Breast Tumor Microenvironment. <b>2021</b> , 1329, 443-474  | 0  |
| 217 | Verordnungsprofil der Gynkologen. <b>2004</b> , 978-987  |    |
| 216 | Sexualhormone. <b>2004</b> , 835-856   | 1  |



197 Morbidity and Mortality Changes with Hormone Therapy. **2007**, 627-636

196 Balance, falls and osteoporotic fractures. **2007**, 31-44

195 Peri- und Postmenopause. **2008**, 91-117

194 A Personal Account of the Chemoprevention of Breast Cancer: Possible or Not Possible?. **2008**, 391-398

193 Sexualhormone. **2008**, 843-864

192 Decline in hormone replacement prescription and fall in breast cancer incidence: an epidemiological discourse. **2008**, 105, 303-9

6

191 Risk assessment and management. **2009**, 327-337

190 Sexualhormone. **2009**, 835-856

189 Endocrine disease. **2009**, 963-1027

188 HRT and anti-aging. **2009**, 24, 117-126

187 Management of Menopause in the Breast Cancer Patient. **2009**, 1419-1430

186 NHG-Standaard Urineweginfectie. **2009**, 818-836

185 SEX HORMONES AND RELATED DRUGS. **2009**, 135-314

184 Cancer Risk Factors. **2009**, 89-149

183 Lifestyle Factors and Risk of Breast Cancer: A Review of Randomized Trial Findings. **2010**, 23-41

182 Impact of Hormone Replacement Therapy on Breast Cancer. **2010**, 101-108

181 The Effects of Menopausal Hormone Therapy on Breast Cancer: Evidence from the Women's Health Initiative Randomized Placebo-Controlled Trials. **2010**, 197-207

180 Sexualhormone. **2010**, 867-888

- 179 Climacteric. **2010**, 379-385
- 178 Exercise and Quality of Life in Menopause. **2010**, 4103-4117
- 177 The Menopause. **2010**, 576-588
- 176 The menopause and hormone replacement. **2010**, 2010,
- 175 Menopause. **2011**, 405-421
- 174 Les «causes» du cancer du sein. **2011**, 43-77
- 173 Sexualhormone. **2011**, 881-900
- 172 Sexualhormone. **2012**, 903-922
- 171 Sexualhormone. **2012**, 548-575
- 170 La mñopause: physiologie et prise en charge thfapeutique. **2012**, 257-274
- 169 Progesterone Receptor Modulators Induce Apoptosis in Mammary Tumors and Uterine Leiomyomas. **2012**, 205-226
- 168 Public Health - Pages e1-e91. **2012**, e1-e91
- 167 Gynaecology and the Older Patient. 1259-1270
- 166 Epidemiology and Etiology of Breast Cancer. **2013**, 3-12
- 165 Krebs und Hormone. **2013**, 709-719
- 164 Menopause. **2013**, 139-161
- 163 Treating Health Risks or Putting Healthy Women at Risk: Controversies around Chemoprevention of Breast Cancer. **2013**, 206-227
- 162 Sexualhormone. **2013**, 887-907



161 Menopause and Care of the Mature Woman. **2013**, 273-299

160 Effect of Folic Acid Supplementation in Postmenopausal Women. **2013**, 225-239

159 Mammakarzinom. **2013**, 517-555

158 Measuring and Managing Breast Cancer Risk. **2013**, 350-373

157 Hypopituitarism. **2014**, 77-97

156 Breast Cancer Prevention. **2014**, 445-489

155 An Overview of the Breast and Breast Cancer. 1-18

0

154 Risk Assessment in Benign Breast Lesions. **2014**, 269-287

153 What Is the Place of Hormone Replacement Therapy in Ovarian, Endometrial, and Breast Cancer?. **2014**, 237-246

152 Is It Safe to Prevent and Treat Postmenopausal Osteoporosis?. **2014**, 207-214

151 Cancer Prevention, Screening, and Early Detection. **2014**, 322-359.e12

1

150 Sexualhormone. **2014**, 991-1013

149 The role of imaging in breast diagnosis including screening and excision of impalpable lesions. **2014**, 1-19

148 The genetics of breast cancer, risk-reducing surgery and prevention. **2014**, 127-145

147 A Medicines Regulatory Perspective on Women's Medicines. **2015**, 433-458

146 Menopausal Hormone Therapy: A Safety Perspective. **2015**, 331-344

0

145 Medicines for Women: Medicines for Half the World. **2015**, 3-40

1

144 Clinical Implications of Risk and Prognostic Factors in Patients with Breast Carcinomas. **2015**, 2, 1-9

143 Evidenzbasierte Medizin: Vorbild für die Suchtprävention?. **2015**, 57-65

142 Aetiology and Epidemiology of Breast Cancer. **2015**, 17-25

141 Sexualhormone. **2015**, 1007-1028

140 Sex Steroids and Mood in Women. **2015**, 147-169

139 16. Cancer. **2016**,

138 Post-Finasteride Syndrome (PFS) Update: Point/Counterpoint. **2016**, 26, 1-6

137 Sexualhormone. **2016**, 705-718

136 28 De overgangsjaren en de postmenopauze. **2016**, 729-757

135 Rheum rhabarbaricum – Heilpflanzenporträt und anthroposophisch-medizinische Anwendungserfahrungen in der Menopause. **2016**, 69, 42-49

134 Sexualhormone. **2016**, 589-615

133 EVALUATION OF PHYTOESTROGENS AS A THERAPEUTIC ALTERNATIVE TO HORMONE REPLACEMENT THERAPY (HRT) IN POSTMENOPAUSAL WOMEN. **2016**, 5, 7587-7591

132 Peri- und Postmenopause. **2017**, 91-108

131 Lebensqualität im Alter aus der Sicht der Frauenheilkunde. **2017**, 317-326

130 Pharmacological Therapy for Vasomotor Symptoms in Breast Cancer Survivors. **2017**, 255-272

129 Menopause. **2017**, 161-193

128 Sexualhormone. **2017**, 723-737

127 Animal Research Is an Ethical Issue for Humans as Well as for Animals. **2018**, 8, 1

2

126 Sexualhormone. **2018**, 777-791

- 125 Will melatonin change the current attitude towards menopausal hormone replacement therapy?. **2018**, 9,
- 124 Breast Cancer. **2019**, 241-269
- 123 Sexuol hormone. **2019**, 979-996 0
- 122 Hinter den Kulissen. **2019**, 173-189
- 121 La moopause : physiologie et prise en charge thoroapeutique. **2019**, 313-333
- 120 Evaluating Risks, Reported Cases and Screening Recommendations for Breast Cancer in Transgender Patients.
- 119 Estrogen mediates acute elastic fibre homeostasis in skin. 1
- 118 Distinct temporal trends in breast cancer incidence from 1997 to 2016 by molecular subtypes: A population-based study of Scottish cancer registry data. 1
- 117 Royal jelly for genitourinary syndrome of menopause: A randomized controlled trial. **2021**, 0
- 116 Mouse-INtraDuctal (MIND): an in vivo model for studying the underlying mechanisms of DCIS malignancy. **2021**, 1
- 115 Second Malignancy Risk After Treatment of Hodgkin Lymphoma. **2020**, 429-464 1
- 114 Risk of primary brain tumour after breast cancer. **2020**, 9, 28-33 0
- 113 Basisprincipes van  $\alpha$ targeted therapy $\beta$  inclusief hormonale therapie. **2020**, 173-190
- 112 Sexuol hormone. **2020**, 621-648
- 111 Hormone replacement therapy and elevated breast cancer risk: An artifact of growth acceleration?. 0
- 110 Transcriptome Sequencing Reveals Sex Differences in Human Meniscal Cell Response to Estrogen Based on Dosing Kinetics.
- 109 Progesterone addition with low-dose levonorgestrel intrauterine system in menopausal hormone treatment gives less normal breast tissue proliferation than oral norethisterone acetate or medroxyprogesterone acetate. **2020**, 41, 1
- 108 90 Years of progesterone: Ninety years of progesterone: the 'other' ovarian hormone. **2020**, 65, E1-E4 1

- 107 Traitement hormonal substitutif et cancer du sein. **2006**, 1-13
- 106 Erkrankungen der Ovarien. **2005**, 1010-1024
- 105 Sexualhormone. 888-911
- 104 Krebs und Hormone. **2006**, 537-547
- 103 The Role of SERMs in the Treatment of Osteoporosis. 187-206
- 102 Die alternde Bevölkerung: Demographie, gesundheitliche Einschränkungen, Krankheiten und Prävention unter Sex- und Gender-Fokus. **2008**, 467-505
- 101 Pegvisomant: current and possible future indications. **2005**, 2, 525-532
- 100 Sexualhormone. **2007**, 893-917
- 99 The Million Women Study. **2006**, 121-126
- 98 Paradigm Shift in Causal Thinking in Epidemiology. **2006**, 127-133
- 97 Workshop Consensus: The State of the Evidence. **2006**, 167-173
- 96 Sexualhormone. **2008**, 845-867
- 95 Endokrinologische Aspekte der Hautalterung. **2008**, 37-57
- 94 Effect of yoga with and without elastic band resistance training on visfatin, liver enzymes and body composition in postmenopausal women. **2020**, 16, 347-355 1
- 93 Transcriptome and interactome analyses identify the TP53 interacting gene RCCD1 as a candidate susceptibility gene at the 15p26.1 breast and ovarian cancer risk locus.
- 92 Hormone replacement therapy after the menopause--where are we now?. **2005**, 55, 172-4 3
- 91 Clinical opinion: the biologic and pharmacologic principles for age-adjusted long-term estrogen therapy. **2006**, 8, 84 1
- 90 Postmenopausal tibolone therapy: biologic principles and applied clinical practice. **2007**, 9, 2 5

|    |   |    |
|----|---|----|
| 89 | Exercise participation, body mass index, and health-related quality of life in women of menopausal age. <b>2007</b> , 57, 130-5   | 55 |
| 88 | . <b>2003</b> , 11, 433   |    |
| 87 | Editor'S comment. <b>2010</b> , 1, 62   |    |
| 86 | AKT1/BRCA1 in the control of homologous recombination and genetic stability: the missing link between hereditary and sporadic breast cancers. <b>2010</b> , 1, 691-9                          | 20 |
| 85 | Fracture prevention in postmenopausal women. <b>2011</b> , 2011,  | 3  |
| 84 | Soy consumption during menopause. <b>2012</b> , 4, 30-7   | 1  |
| 83 | Knowledge of reproductive physiology and hormone therapy in 40-60 year old women: a population-based study in Yazd, Iran. <b>2012</b> , 10, 383-90  | 1  |
| 82 | Menopause care for obese and diabetic women. <b>2009</b> , 1, 142-52  | 1  |
| 81 | The importance of BRCA1 and BRCA2 genes mutations in breast cancer development. <b>2016</b> , 30, 369   | 41 |
| 80 | Expression of PGRMC1 in paraffin-embedded tissues of breast cancer. <b>2017</b> , 10, 9639-9643   | 2  |
| 79 | Biomedical Research Cohort Membership Disclosure on Social Media. <b>2019</b> , 2019, 607-616   | 1  |
| 78 | Osteogenic induction of menstrual blood mesenchymal stem cell by different species extracts. <b>2021</b> , 11, 281-291  |    |
| 77 | Clinical Impact of Hormone Replacement Therapy on Atrial Fibrillation in Postmenopausal Women: A Nationwide Cohort Study. <b>2021</b> , 10,   | 1  |
| 76 | Review of menopause advice given to patients undergoing bilateral oophorectomy. <b>2021</b> , 20533691211058518   |    |
| 75 | Genistein Regulates Lipid Metabolism via Estrogen Receptor and Its Downstream Signal Akt/mTOR in HepG2 Cells. <b>2021</b> , 13,   | 2  |
| 74 | Long-Term Nightshift Work and Breast Cancer Risk: An Updated Systematic Review and Meta-Analysis with Special Attention to Menopausal Status and to Recent Nightshift Work. <b>2021</b> , 13, |    |
| 73 | The effect of menopausal hormone therapy on gastrointestinal cancer risk and mortality in South Korea: a population-based cohort study. <b>2021</b> , 21, 440                                 | 0  |
| 72 | Electrochemical Biosensors for the Analysis of Breast Cancer Biomarkers: From Design to Application. <b>2021</b> ,  | 12 |

- 71 Effects and mechanisms of natural plant active compounds for the treatment of osteoclast-mediated bone destructive diseases. **2021**, 1-79 0
- 70 International trends in cancer incidence in middle-aged and older adults in 44 countries. **2021**, 2
- 69 Burden of cancer attributable to exogenous hormone use in Japan in 2015. **2021**, 1
- 68 Burden of cancer attributable to modifiable factors in Japan in 2015.. **2022**, 4, 26-36 1
- 67 Risk Factors of Synchronous Breast and Thyroid Cancer: a Controlled Multicenter Study and Review of the Literature.. **2021**, 33, 298-303 1
- 66 Menopausal Hormonal Therapy and Breast Cancer. **2021**, 11, 382-390
- 65 Could Perimenopausal Estrogen Prevent Breast Cancer? Exploring the Differential Effects of Estrogen-Only Versus Combined Hormone Replacement Therapy.. **2022**, 14, 1-7 0
- 64 Night shift work, chemical coexposures and risk of female breast cancer in the Norwegian Offshore Petroleum Workers (NOPW) cohort: a prospectively recruited case-cohort study.. **2022**, 12, e056396
- 63 Risk Factors for Female Breast Cancer: A Population Cohort Study.. **2022**, 14, 0
- 62 Menopausal hormone therapy: why we should no longer be afraid of the breast cancer risk.. **2022**, 1-7 1
- 61 Hypopituitarism. **2022**, 61-78
- 60 The peri-menopause is a critical period for women. **2022**, 13, 19-24
- 59 What is the association between estrogen and breast cancer?. **2022**, 13, 50-56
- 58 Premarin Reduces Neurodegeneration and Promotes Improvement of Function in an Animal Model of Spinal Cord Injury.. **2022**, 23, 0
- 57 Breast cancer. **2022**, 1196-1207
- 56 Breast Density and Estradiol Are Major Determinants for Soluble TNF-TNF-R Proteins in Human Breast Tissue.. **2022**, 13, 850240 0
- 55 Accurate categorisation of menopausal status for research studies: a step-by-step guide and detailed algorithm considering age, self-reported menopause and factors potentially masking the occurrence of menopause.. **2022**, 15, 88 0
- 54 Multivariate analysis of independent roles of socioeconomic status, occupational physical activity, reproductive factors, and postmenopausal hormonal therapy in risk of breast cancer.. **2022**, 1 0

- 53 Differential off-target glucocorticoid activity of progestins used in endocrine therapy.. **2022**, 108998 ○
- 52 Hormone replacement therapy - Current recommendations.. **2021**, ○
- 51 Effect of Ethyl Acetate Fraction of *Marsilea crenata* Presl. Leaf Extract on Major Histocompatibility Complex Class II Expression in Microglial HMC3 Cell Lines. **2021**, 6374-6378
- 50 Dose-Dependent Effects of the *Cimicifuga Racemosa* Extract Ze 450 (Drug Simidona) in the Treatment of Climacteric Complaints: a Randomized Placebo-Controlled Study. **2020**, 220-230
- 49 Female infertility and the evaluation of an infertile couple. 865-883
- 48 Menopause. 985-1003
- 47 Obesity and breast cancer risk: the oncogenic implications of metabolic dysregulation.. **2022**, ○
- 46 Estrogens, Cancer and Immunity.. **2022**, 14, 1
- 45 The promotion of menopausal hormone therapy might be determined by the attitude of health-care professionals.. **2022**, 25, 213-214
- 44 Exercise and menopause. **2022**, 175-192
- 43 Epidemiology and Risk Factors of Breast Cancer. **2022**, 3-29
- 42 Introduction. **2022**, 28, 157-162 ○
- 41 Effects of Hormone Therapy on survival, cancer, cardiovascular and dementia risks in 7 million menopausal women over age 65: a retrospective observational study. ○
- 40 Neuronal GPER Participates in Genistein-Mediated Neuroprotection in Ischemic Stroke by Inhibiting NLRP3 Inflammasome Activation in Ovariectomized Female Mice. ○
- 39 Mechanistic Effects of Estrogens on Breast Cancer. **2022**, 28, 224-240 ○
- 38 Estrogen for the Treatment and Prevention of Breast Cancer. **2022**, 28, 163-168 ○
- 37 Menopausal Hormone Therapy and Breast Cancer. **2022**, 28, 169-175 ○
- 36 Influence of the levonorgestrel-releasing intrauterine system on the risk of breast cancer: a systematic review. 1

|    |   |    |
|----|---|----|
| 35 | Effects of transdermal versus oral hormone replacement therapy in postmenopause: a systematic review.   | 2  |
| 34 | Breast Density: Current Knowledge, Assessment Methods, and Clinical Implications.   | 0  |
| 33 | Global Burden of Female Breast Cancer: Age-Period-Cohort Analysis of Incidence Trends From 1990 to 2019 and Forecasts for 2035. 12,   | 0  |
| 32 | Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration. <b>2022</b> , 21, 173-208   | 1  |
| 31 | The role of obesity and bariatric surgery-induced weight loss in breast cancer.   | 0  |
| 30 | Estrogen, Estrogen Plus Progestin Therapy, and Risk of Breast Cancer. <b>2005</b> , 11, 909s-917s   | 10 |
| 29 | Incidence of Invasive Breast Cancer and Ductal Carcinoma In situ in a Screening Program by Age: Should Older Women Continue Screening?. <b>2004</b> , 13, 1569-1573                     | 5  |
| 28 | Chemical Effects on Breast Development, Function, and Cancer Risk: Existing Knowledge and New Opportunities.  | 1  |
| 27 | Reassuring data regarding the use of hormone therapy at menopause and risk of breast cancer. Publish Ahead of Print,  |    |
| 26 | Lipid-Based Nanomaterials for Drug Delivery Systems in Breast Cancer Therapy. <b>2022</b> , 12, 2948  | 0  |
| 25 | Low frequency pulsed electromagnetic fields exposure alleviate the abnormal subchondral bone remodeling at the early stage of temporomandibular joint osteoarthritis.                   | 0  |
| 24 | A vicious circle in breast cancer: The interplay between inflammation, reactive oxygen species, and microRNAs. 12,  | 0  |
| 23 | Upregulation of an estrogen receptor-regulated gene by first generation progestins requires both the progesterone receptor and estrogen receptor alpha. 13,                             | 0  |
| 22 | Sexually dimorphic estrogen sensing in skeletal stem cells controls skeletal regeneration. <b>2022</b> , 13,  | 0  |
| 21 | Low frequency pulsed electromagnetic fields exposure alleviate the abnormal subchondral bone remodeling at the early stage of temporomandibular joint osteoarthritis. <b>2022</b> , 23, | 0  |
| 20 | Population-based survey on menopausal symptoms and treatment use. 1-8   | 0  |
| 19 | Risk for osteoporosis and fracture with glucocorticoids. <b>2022</b> , 101793   | 1  |
| 18 | Mammographic Breast Density: Current Assessment Methods, Clinical Implications, and Future Directions. <b>2022</b> ,  | 0  |



|    |  |   |
|----|--|---|
| 17 | Estimated cardiorespiratory fitness in relation to overall, breast and prostate cancer incidence: the Norwegian HUNT study. <b>2023</b> , 77, 103-109  | 0 |
| 16 | RANKL and RANK in Cancer Therapy.  | 1 |
| 15 | The importance of long-term follow up of participants in clinical trials.  | 0 |
| 14 | Use of exogenous hormones in those at increased risk for breast cancer: contraceptive and menopausal hormones in gene carriers and other high-risk patients. Publish Ahead of Print,                           | 0 |
| 13 | Hormone replacement therapy in BRCA mutation carriers: how shall we do no harm?.   | 2 |
| 12 | Overview of Gender-Affirming Therapy. <b>2023</b> , 9-32   | 0 |
| 11 | The Women's Health Initiative randomized trials of menopausal hormone therapy and breast cancer: findings in context. Publish Ahead of Print,  | 0 |
| 10 | Breast Cancer Disease Exploitation to Recure a Healthy Lifestyle. <b>2022</b> , 2617-2635  | 0 |
| 9  | Vasomotor Symptoms During Menopause: A Practical Guide on Current Treatments and Future Perspectives. Volume 15, 273-287   | 0 |
| 8  | Oral estradiol/micronized progesterone may be associated with lower risk of venous thromboembolism compared with conjugated equine estrogens/medroxyprogesterone acetate in real-world practice. <b>2023</b> , | 0 |
| 7  | Yeast Hydrolysate and Postmenopausal Osteoporosis. <b>2023</b> , 13, 322   | 0 |
| 6  | Modulation of vulvovaginal atrophy (VVA) by Gelam honey in bilateral oophorectomized rats. 14,   | 0 |
| 5  | BRCA carriers after risk-reducing bilateral salpingo-oophorectomy: menopausal hormone therapy knowledge gaps, and the impact of physicians's recommendations. <b>2023</b> , 26, 154-160                        | 0 |
| 4  | The Efficacy of Oxytocin Gel in Postmenopausal Women with Vaginal Atrophy: An Updated Systematic Review and Meta-Analysis.   | 0 |
| 3  | New advances in menopause symptom management. <b>2023</b> , 101774   | 0 |
| 2  | The WHO claims estrogens are "carcinogenic" is this true?. 1-8   | 0 |
| 1  | Therapeutic management of hormone-dependent cancers in transgender patients. <b>2023</b> , 399-416   | 0 |